Document:

System and Lead Development and Transfer Agreement

 Exhibit 10.12 

SYSTEM AND LEAD DEVELOPMENT AND TRANSFER AGREEMENT 

THIS SYSTEM AND LEAD DEVELOPMENT AND TRANSFER 

AGREEMENT (this “Agreement”) is made effective as of December 30, 2005 between Surgi-Vision, Inc., a Delaware corporation
(the “Company”), and Advanced Bionics Corporation, with its principal place of business at 25129 Rye Canyon Loop, Valencia, California 91355 (“Bionics”). The Company and Bionics are referred to collectively as the
“Parties” and individually as a “Party”. 
 BACKGROUND 

A.        The Company desires to borrow from Bionics and Bionics desires to lend to the
Company an aggregate principal amount of up to $1,500,000 (the “Loan”) to be evidenced by a secured convertible promissory note (the “Note”) of even date herewith, substantially in the form attached as Exhibit
A and bearing interest at a rate of 0% per annum. 
 B.        The Company is
the sole owner or exclusive licensee of Intellectual Property (defined below) relating to MR-compatible, MR-safe, and MR-optimized technology. 

C.        The Company desires to develop for Bionics certain technology (the
“Technology”) solely within the field of neuromodulation including without limitation an MR- compatible, MR-safe, and MR-optimized Deep Brain Stimulation (“DBS”) implant system (the “System”) and
MR-compatible, MR-safe, and MR-optimized DBS lead (the “Lead”). 

D.        Bionics desires to acquire an initial exclusive license to all Intellectual
Property (defined below) relating to the System, a right of first negotiation and a right of first refusal for a subsequent license to the System, and an exclusive perpetual license to the Intellectual Property relating to the Lead as embodied in
the Technology License Agreement (the “License Agreement”). 

E.        Concurrently herewith, the Company and Bionics have entered into a Security
Agreement (the “Security Agreement”, and together with the Note and the License Agreement, the “Concurrent Agreements”), pursuant to which the Company has granted Bionics a security interest in the Collateral (as
defined in the Security Agreement). 
 AGREEMENT 

The Parties agree as follows: 

Section 1. ISSUANCE OF NOTE. Bionics will disburse to the Company the Loan amounts by certified or bank check made payable to
the Company, or by wire transfer of funds, in six quarterly installments of $250,000 each. The first quarterly installment of $250,000 is to be loaned contemporaneously with the execution and delivery of the Note evidencing such Loan. Bionics hereby
authorizes and directs the Company to deliver the Note to Bionics’ address set forth at the beginning of this Agreement. The remaining five quarterly installments of $250,000 are payable, subject to the terms of this Agreement including without

 
limitation Section 7.4(a), one installment on or before March 31, 2006; one installment on or before June 30, 2006; one installment on or before September 30, 2006; one
installment on or before December 31, 2006; and one installment on or before March 31, 2007. 
 Section 2.
DESCRIPTION OF THE NOTE. The Note has the terms and provisions set forth in the Note. 
 Section 3. CLOSING.
Bionics’ disbursement of the initial installment under the Loan and the issuance of the Note by the Company (“Closing”) will take place on the date (the “Closing Date”) when all of the following conditions
precedent are met: 
 3.1 The Parties will execute and deliver each of the Concurrent Agreements. 

3.2 The Company will deliver to Bionics the following, each, unless otherwise noted dated as of the date first written above:

 (a) A good standing certificate of the Company from the Secretary of State of the State of Delaware, dated a recent
date prior to the Closing Date; 
 (b) Copy of the certificate of incorporation of the Company, certified by the
Secretary of State of the State of Delaware; 
 (c) Copy of the bylaws of the Company, certified by its corporate
secretary or an assistant secretary; 
 (d) Resolutions of its Board approving and authorizing the execution, delivery,
and performance of each of the Concurrent Documents, certified by its corporate secretary or an assistant secretary, as being in full force and effect without modification or amendment; and 

(e) Signature and incumbency certificates of the officers of the Company executing each of the Concurrent Agreements. 

3.3 [Intentionally Omitted] 

3.4 UCC Financing Statements. The Company will have authorized Bionics to prepare and file such UCC financing statements and other
instruments as Bionics will require in order to perfect and maintain the continued perfection of the first priority security interest in the Collateral created by the Security Agreement. 

3.5 Cover Sheets, etc. The Company will deliver to Bionics all cover sheets or other documents required to by filed with the
United States Patent and Trademark Officer, the United States Copyright Officer or any successor or substitute office in which filings are necessary in order to create or perfect Bionic’s security interest in respect of the Collateral.

 3.6 The representations and warranties contained in each of the Concurrent Agreements will be true, correct and
complete in all material respects. 
  

 2 

 Section 4. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 

The Company hereby represents and warrants to Bionics as of the Closing Date as follows: 

4.1 Organization and Power. The Company is a corporation duly organized, validly existing and in good standing under the laws of
the state of Delaware, and has all requisite corporate power and authority to execute, deliver and perform all of its obligations under this Agreement and the Concurrent Agreements. The Company is duly qualified and authorized to transact business
and is in good standing in each jurisdiction in which the failure so to qualify would have a material adverse effect on its business, properties, or financial condition. 

4.2 Capitalization; Reserved Stock; Preemptive Rights. Immediately before the Closing, and other than as represented by the Note
and the Conversion Shares, the authorized capital stock of the Company consists of (A) 40,000,000 shares of Common Stock, of which 19,833,269 shares are outstanding, and (B) 10,000,000 shares of preferred stock, par value $0.01 per share,
none of which is outstanding. All of the outstanding shares of Common Stock are duly authorized, are validly issued, fully paid and nonassessable, and were issued in conformity with all applicable state and federal securities laws. The
capitalization of the Company is set forth on Schedule 4.2. Except as reflected on Schedule 4.2, the Company has no other equity securities of any class issued, reserved for issuance, or outstanding. Except as described on Schedule 4.2, there are no
outstanding options, offers, warrants, conversion rights, agreements, or other rights to subscribe for or to purchase from the Company, or commitments by the Company to issue, transfer, or sell (either written or oral, formal or informal, firm or
contingent), shares of or interests in the capital stock or other securities of the Company (whether debt, equity, or a combination thereof) or obligating the Company to grant, extend or enter into any such agreement or commitment. Except as
described on Schedule 4.2, no securities of the Company carry, and no shareholder of the Company has been granted, any preemptive rights other than any that have been waived or are not applicable. The Company is not obligated under any agreement,
arrangement or understanding to redeem or otherwise purchase any of its shares of capital stock. 
 4.3 Authorization.
The execution and delivery by the Company of this Agreement and the Concurrent Agreements, the performance of the Company’s obligations hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby have
been duly authorized by all necessary corporate action and will not, either before or as a result of the consummation of the transactions contemplated by the Concurrent Agreements: (A) violate any provision of the certificate of incorporation
or bylaws of the Company, (B) violate, in any material respect, any provisions of any law or any governmental rule or regulation applicable to the Company, or any contract, indenture, agreement or other instrument to which the Company is a
party, or by which the Company or any of its assets or properties are bound, or (C) be in conflict with, result in a breach of, or constitute (after the giving of notice or lapse of time or both) a default under, or result in the creation or
imposition of any lien of any nature whatsoever upon any of the material property or assets of the Company pursuant to the provisions of any contract, indenture, agreement or other instrument to which the Company is a party or by which it or its
property is bound. Except as set forth in Schedule 4.3, the Company is not required to obtain any approval, consent or authorization from, or to file any declaration or statement with, any governmental instrumentality or agency in connection with or
as a condition 
  

 3 

 
to the execution, delivery or performance of this Agreement or the Concurrent Agreements other than the filing of Form D and any applicable state securities law filings, which filing or filings,
as the case may be, will be made in accordance with applicable laws and regulations. 
 4.4 Binding Obligation. This
Agreement and the Concurrent Agreements have been duly executed and delivered by the Company and are the legally valid and binding obligation of the Company, enforceable against the Company in accordance with their respective terms. 

4.5 Financial Statements. The unaudited balance sheets of the Company as of December 31, 2004 and September 30, 2005,
and the unaudited income statements of the Company for the periods ended December 31, 2004 and September 30, 2005 (collectively the “Financial Statements”), have been prepared from and are in accordance with the books and
records of the Company in conformity with generally accepted accounting principles (“GAAP”) consistently applied throughout the periods indicated on a consistent basis throughout the periods involved. The Financial Statements fairly
present the financial condition and results of operations of the Company as at the dates and for the periods stated or covered thereby. The Financial Statements do not omit or fail to identify material nonrecurring income or other specific items, do
not omit or fail to identify the existence of material transactions not in the ordinary course of business, and contain no excessive write-downs or write-ups of any material assets. Other than those liabilities reflected or reserved against in the
Financial Statements, and except for certain convertible notes in an aggregate principal amount of $50,000, the Company does not have any material liabilities of any nature whatsoever, whether accrued, absolute, contingent, or otherwise, and whether
due or to become due, nor does the Company have actual knowledge of any basis for the assertion against the Company of any material liability of any nature whatsoever, unless such liability has been fully reflected or reserved against in the
Financial Statements. The Financial Statements are attached hereto as Exhibit 4.5. 
 4.6 The Conversion Shares. The
Conversion Shares have been duly authorized and, when issued and delivered upon conversion of the Note, will be duly and validly issued, fully paid and non-assessable, free and clear of any liens or encumbrances created by the Company. 

4.7 Litigation. There is no action, suit, proceeding or investigation pending or, to the Company’s knowledge, currently
threatened against the Company that questions the validity of this Agreement or the Concurrent Agreements or the right of the Company to enter into it, or to consummate the transactions contemplated hereby or thereby, or that would be reasonably
likely to result, either individually or in the aggregate, in any material adverse changes in the assets, business, properties, condition or affairs of the Company, financially or otherwise, or any change in the current equity ownership of the
Company, or change in the ability of the Company to perform, or of Bionics to enforce, this Agreement or the Concurrent Agreements. The Company is not a party or subject to the provisions of any order, writ, injunction, judgment or decree of any
court or government agency or instrumentality. 
 4.8 Intellectual Property. The Company owns, possesses or has legal
rights to use all ideas, inventions, developments and improvements conceived and/or reduced to 
  

 4 

 
practice, patents, trademarks, service marks, trade names, copyrights, know-how, trade secrets, licenses, information and proprietary rights and processes (“Intellectual Property”)
necessary for the Company’s business as now conducted and as proposed to be conducted by the Company by developing the System and Lead for commercial manufacture, use, lease, importation, and sale, including without limitation the
intellectual property licensed to the Company under the License Agreement by and between the Company and the Johns Hopkins University (“JHU”) on or around July 1, 1998 and all other appendices, addenda, amendments, and
agreements related thereto (the “JHU Agreement”) (the owned and licensed rights of the Company, collectively, the “Existing Intellectual Property”), without any conflict with, or infringement of, the rights of
others. Except as set forth in Schedule 4.8 attached hereto, there are no outstanding options, licenses or agreements of any kind relating to the foregoing, nor is the Company bound by or a party to any options, licenses or agreements of any kind
with respect to the Existing Intellectual Property. The Company has not received any communications alleging that the Company has violated or, by conducting its business or developing the System or Lead, would violate the Intellectual Property of
any other person or entity. The Company knows of no prior art or other information material to patentability that would invalidate or render unenforceable the Existing Intellectual Property. The Company further represents and warrants that any
information it gives to Bionics as part of its duties and obligations under this Agreement and the Concurrent Agreements comprises information which it has the right to freely disclose without incurring legal liability to or violating the rights of
others. 
 4.9 Private Placement. On the assumption that the representations and warranties of Bionics are true and
correct, the issuance of the Note as contemplated by this Agreement is exempt from the registration and qualification requirements of the Securities Act of 1933, as amended (the “Securities Act”), and neither the Company nor any
authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemption. 

4.10        Title to Property and Assets. All assets, tangible and intangible, owned by
the Company are owned free and clear of all mortgages, liens, loans, encumbrances and adverse claims, and the security interest of Bionics in the Company’s tangible or intangible property will be a first lien thereon. 

4.11        Leases. Any property and asset leases entered into by the Company have been
made subject to valid and legally binding contracts and are in full force and effect. 

4.12        Tax Returns and Payments. The Company has timely filed all required tax
returns and reports (federal, state and local) as required by law. These returns and reports are true and correct in all material respects. The Company has paid all taxes and other assessments due. The Company has never had any tax deficiency
proposed or assessed against it and has not executed any waiver of any statute of limitations on the assessment or collection of any tax or governmental charge. 

4.13        Permits. The Company has all franchises, permits, licenses, and any similar
authority necessary for and material to the conduct of its business as currently conducted, the lack of which could have a material adverse effect on the Company’s business, 

 

 5 

 
properties or financial condition. The Company is not in default in any material respect under any of such franchises, permits, licenses or other similar authority. 

4.14        Material Contracts. 

(a) The following types of contracts and agreements to which the Company is a party are required to be set forth in Schedule
4.14, being the “Material Contracts”: 
 (i)        each contract and
agreement, whether or not made in the ordinary course of business, that contemplates an exchange of consideration with a value of more than $25,000, in the aggregate, over the term of such contract or agreement; 

(ii)      all contracts, arrangements and agreements evidencing indebtedness over $2,500 in borrowed money
or other value; 
 (iii)     all joint venture, partnership, strategic alliance and business
acquisition or divestiture agreements (and all letters of intent, term sheets and draft agreements relating to any such pending transactions); 

(iv)     all agreements relating to issuances of securities of the Company; 

(v)      all exclusive distribution contracts to which any of the Company; 

(vi)     all leases of real property leased for the use or benefit of the Company; 

(vii)    all contracts relating in whole or in part to Intellectual Property pursuant to which the Company obtains
from any third party any Intellectual Property rights; 
 (viii)   all contracts relating in whole or in part to
Intellectual Property pursuant to which the Company grants to any third party any Intellectual Property rights or the right to manufacture, distribute or sell any product of the Company, such subsidiary or such third party; 

(ix)     all management contracts (excluding contracts for employment) and contracts with other consultants,
including any contracts involving the payment of royalties or other amounts calculated based upon the revenues or income of the Company or income or revenues related to any product of the Company to which the Company is a party; 

(x)      all contracts and agreements with any governmental authority to which the Company; 

 

 6 

 (xi)     all contracts and agreements that limit, or purport to
limit, the ability of the Company to compete in any line of business or with any person or entity or in any geographic area or during any period of time; 

(xii)    all other contracts and agreements, whether or not made in the ordinary course of business, which are
material to the Company, or the absence of which would have a material adverse effect on the Company’s business, properties, or financial condition. 

(b) (i) Each Material Contract is a legal, valid and binding agreement of the Company; (ii) the Company has not
received any claim of default under or cancellation of any Material Contract and the Company is not in breach or violation of, or default under, any Material Contract; (iii) to the knowledge of the Company, no other party is in breach or
violation of, or default under, any Material Contract; and (iv) neither the execution and delivery of this Agreement or the Concurrent Agreements nor the consummation of any transaction contemplated hereby or thereby will constitute a default
under, give rise to cancellation rights under, or otherwise adversely affect any of the material rights of the Company under any Material Contract. The Company has furnished or made available to Bionics true and complete copies of all Material
Contracts. 
 4.15        No Broker. There is no firm, corporation, agency or
other entity or person that is entitled to a finder’s fee or any type of commission in relation to or in connection with the transactions contemplated by this Agreement or the Concurrent Agreements as a result of any agreement or understanding
with the Company or any of its directors, officers, employees or agents. 

4.16        Representations and Warranties. The representations and warranties of
the Company contained in this Agreement and each of the Concurrent Agreements do not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
representations, warranties and other statements and information contained in the Concurrent Agreements not misleading. 

4.17        Principal Business Address. The principal business address of the Company is
200 N. Cobb Parkway, Suite 140, Marietta, GA 30062-3585. 
 Section 5. REPRESENTATIONS AND WARRANTIES OF LENDER.

 Bionics hereby represents and warrants to the Company as of the Closing Date as follows: 

5.1 Authorization of Concurrent Agreements. Bionics is a corporation duly organized, validly existing and in good standing under
the laws of the state of Delaware, and has all requisite corporate power to execute, deliver and perform all of its obligations under this Agreement and the Concurrent Agreements to which it is a party. The execution and delivery by the Bionics of
this Agreement and the Concurrent Agreements to which it is a party, the performance of Bionics’ obligations hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby, have been duly authorized by all
necessary corporate action on the part of Bionics. This Agreement and the Concurrent Agreements to 
  

 7 

 
which it is a party have been duly executed and delivered by Bionics and are the legally valid and binding obligation of Bionics, enforceable against Bionics in accordance with their respective
terms. 
 5.2 Non-contravention. The execution and delivery by Bionics of this Agreement and the Concurrent Agreements to
which it is a party, the performance of Bionics’ obligations hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby will not, either before or as a result of the consummation of the transactions
contemplated by this Agreement or the Concurrent Agreements to which it is a party: (A) violate any provision of the certificate of incorporation or bylaws of Bionics, (B) violate, in any material respect, any provisions of any law or any
governmental rule or regulation applicable to Bionics, or any contract, indenture, agreement or other instrument to which Bionics is a party, or by which Bionics or any of its assets or properties are bound, or (C) be in conflict with, result
in a breach of, or constitute (after the giving of notice or lapse of time or both) a default under, or result in the creation or imposition of any lien of any nature whatsoever upon any of the material property or assets of Bionics pursuant to the
provisions of any contract, indenture, agreement or other instrument to which Bionics is a party or by which it or its property is bound. Bionics is not required to obtain any approval, consent or authorization from, or to file any declaration or
statement with, any governmental instrumentality or agency in connection with or as a condition to the execution, delivery or performance of this Agreement or the Concurrent Agreements to which it is a party. 

5.3 Accredited Investor. Bionics is an “accredited investor” as that term is defined in Rule 501(a) promulgated under
the Securities Act, a copy of which definition is attached hereto as Exhibit B. 
 5.4 Investment. The Note is
being purchased for Bionics’ own account, for investment and not for distribution or resale to others. Bionics agrees that Bionics will not sell or otherwise transfer the Note or any Conversion Shares unless such securities, as the case may be,
are registered under the Securities Act or unless an exemption from such registration is available, except under circumstances where neither such registration nor such exemption is required by law. Bionics understands that neither the Note nor the
Conversion Shares has been registered under the Securities Act and they are or will be issued pursuant to a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the
investment intent as expressed herein. 
 5.5 Speculative Nature of Investment. Bionics acknowledges that the purchase of
the Note involves a high degree of risk and that (a) an investment in the Company is highly speculative and only investors who can afford the loss of their entire investment should consider investing in the Company and purchasing Note;
(b) Bionics may not be able to liquidate its investment; (c) transferability of the Note and the Conversion Shares is extremely limited; and (d) Bionics could sustain the loss of its entire investment. 

5.6 Experience. Bionics acknowledges that it has prior investment experience, including investment in non-listed and
non-registered securities, or has employed the services of an investment advisor, attorney or accountant to review all of the documents furnished or made available by the Company and to evaluate the merits and risks of such an investment on
Bionics’ behalf. 
  

 8 

 5.7 Financial Resources. Bionics hereby represents that it has adequate means of
providing for its current financial needs and contingencies, is able to bear the substantial economic risks of an investment in the Company for an indefinite period of time, has no need for liquidity in such investment, and, at the present time,
could afford a complete loss of such investment. 
 5.8 Lack of Liquidity. Bionics understands that there is no public
market for the Note or the Conversion Shares. Bionics further understands that even if a public market were to develop for any of the Company’s securities, Rule 144 (the “Rule”) promulgated under the Securities Act limits
Bionics’ ability to sell any of the Company’s securities owned by Bionics. Bionics acknowledges that the Company may, if it desires, permit the transfer of the Note or Conversion Shares out of its name only when its request for transfer is
accompanied by an opinion of counsel reasonably satisfactory to the Company that neither the sale nor the proposed transfer results in a violation of the Securities Act or any applicable state “blue sky” laws (collectively
“Securities Laws”). Bionics agrees to hold the Company and its directors, officers and controlling persons and their respective heirs, representatives, successors and assigns harmless and to indemnify them against all liabilities,
costs and expenses incurred by them as a result of any misrepresentation made by Bionics contained herein or any sale or distribution by Bionics in violation of any Securities Laws. Bionics acknowledges that at such time, if ever, as the Note or the
Conversion Shares are registered, sales of such securities will be subject to state securities laws, including those of states which may require any securities sold therein to be sold through a registered broker-dealer or in reliance upon an
exemption from registration. 
 5.9 Address. Bionics hereby represents that the address of such Bionics furnished at the
beginning of this Agreement is such Bionics’ principal business address. 

5.10        Purpose. If Bionics is a partnership, corporation, trust or other entity, it
was not formed for the purpose of investing in the Company. 
 5.11        No
Broker. There is no firm, corporation, agency or other entity or person that is entitled to a finder’s fee or any type of commission in relation to or in connection with the transactions contemplated by this Agreement or the Concurrent
Agreements as a result of any agreement or understanding with Bionics or any of its directors, officers, employees or agents. 

Section 6. LEGENDS. This Section intentionally omitted. 

Section 7. COMPANY COVENANTS 

7.1 Information to Bionics. For so long as the Note or any Conversion Shares are outstanding, the Company covenants to provide
Bionics with the same financial information that the Company provides to its stockholders. In addition, for so long as the Note and any Conversion Shares are outstanding, the Company will provide Bionics with true, correct and

  

 9 

 
complete copies of a quarterly balance sheet, income statement and statement of cash flow not later than 45 calendar days following the end of each calendar quarter; provided, however, that the
Company will not be obligated to provide such financial statements to Bionics if the Board of Directors of the Company (the “Board”) reasonably and, with exception of any Board member designated by Bionics under Section 7.4(a),
unanimously determines that Bionics is a competitor of the Company. 
 7.2 Books and Records. The Company will keep
complete and accurate books and records in conformity with GAAP. 
 7.3 Taxes. The Company will pay all material taxes
imposed upon it or any of its properties or assets or in respect of any of its income, businesses or franchises, and all material claims (including, without limitation, claims for labor, services, materials and supplies) for sums that have become
due and payable before the same will become a lien upon any of its properties or assets. 
 7.4
(a)        Board Representation. The Company will cause that certain First Amended and Restated Stockholders Agreement dated April 30, 2004 among the Company and certain of its stockholders (the
“Stockholders Agreement”) to be amended to allow Bionics the right to designate in writing to the Company a nominee acceptable to the Company (which acceptance will not be unreasonably withheld) for membership to the Board. Such
amendment to the Stockholders Agreement must be in form and substance reasonably satisfactory to the Parties. If the Stockholders Agreement is not satisfactorily amended before 60 days after the Closing Date, Bionics may withhold all remaining Loan
installments payable to the Company until the Stockholders Agreement is satisfactorily amended. The Company acknowledges that both Todd K. Whitehurst and Jeffrey D. Goldberg are acceptable candidates for designation by Bionics as nominees for Board
membership in the event that Bionics elects to designate either of such individuals as a nominee to the Board. The Parties acknowledge and agree that any amendment to the Stockholder’s Agreement will provide that Bionics’ right to
designate a nominee to the Board will continue (I) only as long as the Note is outstanding or (II) if Bionics elects to exercise its Conversion Right, only so long as Bionics (A) converts at least $1,000,000 of the Note Balance into
Conversion Shares and (B) continues to own at least that number of Conversion Shares. 
 (a) Observer. Effective as
of the Closing and continuing during any time before the designation by Bionics of a nominee to the Board as provided herein, Bionics will have the right to designate one representative of Bionics to receive notice of and attend and observe all
meetings of the Board in a nonvoting observer capacity and, in this respect, the Company will give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided however, that such
representative will agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and, provided further, that the Company reserves the right to withhold any information and to exclude such
representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel, or result in a conflict of interest.
Bionics’ rights under this Section 7.4(b) will continue (I) only as long as the Note is outstanding or (II) 
  

 10 

 
if Bionics elects to exercise its Conversion Right, only so long as Bionics (A) converts at least $1,000,000 of the Note Balance into Conversion Shares and (B) continues to own at least
that number of Conversion Shares. 
 Nothing in this Section 7.4 will imply any fiduciary or other duty owed by Bionics to
the Company or its stockholders. 
 7.5 Existence; Liens and Encumbrances; Mergers. Except as otherwise permitted
pursuant to the terms of this Agreement, the Company will at all times preserve and keep in full force and effect its corporate existence. .So long as the Note is outstanding, without the prior written consent of Bionics, Company will not
(a) pledge or otherwise encumber or permit the encumbrance of any of its assets, including the Collateral (as defined in the Security Agreement); (b) merge or consolidate with any entity, or dissolve; (c) declare, make or pay any
distribution or dividend to its stockholders; (d) sell, lease or otherwise dispose of all or any substantial portion of its assets; or (e) engage in any business other than that in which it is presently engaged. Bionics may grant or
withhold its consent in its sole discretion. 
 7.6 Maintenance of Properties. The Company will maintain or cause to be
maintained in good repair, working order and condition, ordinary wear and tear excepted, all material properties used or useful in the business of the Company (including all Existing Intellectual Property and all Intellectual Property developed
after the Closing (i) resulting from communication between the Parties or (ii) relating to the System or Lead for commercial manufacture, use, lease, importation, and sale, including without limitation the intellectual property licensed to
the Company under the JHU Agreement (collectively, “Future Intellectual Property”) and from time to time will make or cause to be made all appropriate repairs, renewals and replacements thereof. 

7.7 Insurance. The Company will maintain or cause to be maintained, with financially sound and reputable insurers, insurance with
respect to liabilities, losses or damage in respect of the assets, properties and businesses of the Company as may customarily be carried or maintained under similar circumstances by corporations of established reputation engaged in similar
businesses, in each case in such amounts (giving effect to self-insurance), with such deductibles, covering such risks and otherwise on such terms and conditions as will be customary for corporations similarly situated in the industry. On or prior
to 45 days after the Closing Date, the Company will deliver to Bionics a certificate from the Company’s insurance broker or other evidence satisfactory to it that all insurance required to be maintained pursuant to this Section 7.7 is in
full force and effect and that Bionics has been named as additional insured and/or loss payee thereunder. 
 7.8
Waiver of Stay, Extension or Usury Laws. The Company covenants (to the extent that it may lawfully do so) that it will not at any time insist upon, or plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay or
extension law or any usury law or other law which prohibit or forgive the Company from satisfying any obligations owed to Bionics under this Agreement, any of the Concurrent Agreements or other documents executed pursuant hereto or thereto, wherever
enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this Agreement, the Note, the License 

 

 11 

 
Agreement, the Security Agreement and the other documents executed pursuant hereto or thereto; and (to the extent that it may lawfully do so) the Company hereby expressly waives all benefit or
advantage of any such law, and covenants that it will not hinder, delay or impede the execution of any power herein granted to Bionics, but will suffer and permit the execution of every such power as though no such law had been enacted. 

7.9 OFAC. 

The Company: (i) will not become a person whose property or interests in property are blocked or subject to blocking pursuant to
Section 1 of Executive Order 13224 of September 23, 2001 Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit or Support Terrorism (66 Fed. Reg. 49079(2001)), (ii) will not engage in any dealings
or transactions prohibited by Section 2 of such executive order, or be otherwise associated with any such person in any manner violative of Section 2, or (iii) will not otherwise become a person on the list of Specially Designated
Nationals and Blocked Persons or subject to the limitations or prohibitions under any other OFAC regulation or executive order. 

Section 8. GENERAL PROVISIONS. 

8.1 Survival of Representations, Warranties and Agreements. The representations, warranties and agreements contained in this
Agreement will survive the execution of this Agreement. 
 8.2 Notices. All notices, requests,
demands and other communications which are required to be or may be given under this Agreement a Party by the other Party must be in writing and will be deemed to have been duly given (a) immediately if delivered in person, (b) the day
following dispatch by a nationally recognized overnight courier service (such as Federal Express or UPS, etc.) for next day delivery, (c) five days after dispatch by certified or registered first class mail, postage prepaid, return receipt
requested, to the Party to whom the same is so given or made, or (d) upon confirmation of receipt, if by facsimile. Any notice or other communication given hereunder will be addressed to the Company, at 200 N. Cobb Parkway, Suite 140, Marietta,
GA 30062-3585, Attention: John C. Thomas, Jr., Fax (770) 424-8236, with a copy to Kimble L. Jenkins, 50 North Front St.,
19th Floor, Memphis, TN 38103, Fax (901) 579-4979, or
to Bionics at the address indicated at the beginning of this document, Attention: General Counsel, Fax (661) 362-4712. 

8.3 Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an original and all of
which together will constitute one and the same instrument. 
 8.4 Headings. All headings are inserted for convenience of
reference only and will not affect the meaning or interpretation of any such provisions or of this Agreement, taken as an entirety. 
  

 12 

 8.5 Severability. If and to the extent that any court of competent jurisdiction holds
any provision (or any part thereof) of this Agreement to be invalid or unenforceable, such holding will in no way affect the validity of the remainder of this Agreement. 

8.6 Changes, Waivers, Etc. Neither this Agreement nor any provision of this Agreement may be changed, waived, discharged or
terminated orally, but rather may only be changed by a statement in writing signed by the Party against which enforcement of the change, waiver, discharge or termination is sought. It is agreed that a waiver by either Party of a breach of any
provision of this Agreement will not operate, or be construed, as a waiver of any subsequent breach by that same Party. 

8.7 Reimbursement of Legal Expenses. Promptly upon the consummation of an equity financing which results in gross proceeds to the
Company of at least $2,500,000, the Company will reimburse Bionics for its legal expenses actually incurred, up to a maximum of $25,000, in connection with the (A) negotiation and documentation of this Agreement and the Concurrent Agreements or
(B) Bionics’ investment in the Company to such date. 
 8.8 Governing Law. This Agreement will be governed by
and construed in accordance with the laws of the State of California. The Parties hereby agree that any dispute which may arise between them arising out of or in connection with this Agreement will be adjudicated before a court located in Los
Angeles, California and they hereby submit to the exclusive jurisdiction of the courts of the State of California located in Los Angeles, California and of the federal courts in the Central District of California with respect to any action or legal
proceeding commenced by any party, and irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is an inconvenient forum,
relating to or arising out of this Agreement or any acts or omissions relating to the sale of the securities hereunder, and consent to the service of process in any such action or legal proceeding by means of registered or certified mail, return
receipt requested, in care of the address set forth below or such other address as the undersigned will furnish in writing to the other. 

8.9 Entire Agreement This Agreement, the Note, the Security Agreement, and the Other Agreements set forth the entire agreement and
understanding between the Parties as to this subject matter and incorporates and supersedes all prior discussions, agreements and understandings of any and every nature among them. 

8.10        Further Assurances. The Parties agree to execute and deliver all such further
documents, agreements and instruments and take such other and further action as may be necessary or appropriate to carry out the purposes and intent of this Agreement. 

8.11        Successors and Assigns. The terms and conditions of this Loan Agreement will
inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the Parties or their respective successors and
assigns any rights, remedies, obligations, or liabilities under or by reason of this Loan Agreement, except as 
  

 13 

 
expressly provided in this Loan Agreement. This Agreement may not be assigned by either of the Parties without the prior written consent of the other Party. 

8.12        Relationship of Parties. In all matters relating to this Agreement, no Party
will have any right, power or authority to create any obligation, express or implied, on behalf of any other Party. Nothing in this Agreement is intended to create or constitute a joint venture or a partnership between the parties hereto.

 Section 9. SYSTEM DEVELOPMENT, LICENSE, AND RIGHT OF FIRST REFUSAL. 

9.1 System Development. The System prototypes must meet each milestone stated on Exhibit C (“System Milestone”)
and [***] (“System Requirements”). 
 (a) Collaboration. To assist the Company in the
development of the System prototype, Bionics will provide the Company with Bionics’ proprietary DBS system and component prototypes if and as developed and available. 

(b) Design Specifications. The Company will document the design specifications and changes necessary to build the System, and all
test results of the System, and will provide such documentation to Bionics along with any other System design modifications necessary for Bionics to manufacture, use, and sell the System. Bionics’ employees and consultants may directly assist
with the development of the System and the Company will reasonably cooperate with, and reasonably accept the design suggestions of, Bionics’ personnel. 

(c) Validation. Upon the due date of each System Milestone, Bionics may test or have the prototype of the System tested to verify
compliance with the requirements of the Systems Milestones and Section 9.1. 
 9.2 Exclusive License. The Company hereby
grants to Bionics, upon and subject to all the terms and conditions of this Agreement, an exclusive, fully paid, worldwide license under the Existing Intellectual Property and all Future Intellectual Property, limited to the field of
neuromodulation, to make, use, import, lease, and sell the System (the “System License”) until the later of (i) the full payment of the Note Balance or (ii) the full conversion of the Note Balance. For the avoidance of
doubt, the System License includes without limitation a sublicense, limited to the field of neuromodulation, of all Existing Intellectual Property and Future Intellectual Property (if any) licensed to the Company under the JHU Agreement, which
sublicense Bionics acknowledges and agrees is subject to the terms of the JHU Agreement. Bionics may grant sublicenses, limited to the duration of the System License, under the Existing Intellectual Property and Future Intellectual Property of the
System License. 
 [***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment. 
  

 14 

 9.3 Exclusive Negotiation of Subsequent System License. Within five days after the
final System Milestone is achieved, the Parties will enter into exclusive negotiations for a license agreement for all or part of the System (the “Subsequent System License”) for a period not to exceed 90 days from the date the
Parties enter into negotiations (the “Exclusivity Period”). This right of first negotiation will not obligate either Party to enter into any future agreement or agree upon any particular terms. 

9.4 Right of First Refusal. In the event the Parties do not execute and deliver the Subsequent System License within the
Exclusivity Period, then, upon the expiration of the Exclusivity Period, the Company may negotiate with other parties. However, for a period of 90 days following the expiration of the Exclusivity Period (the “ROFR Period,” and
together with the Exclusivity Period, the “Negotiation Period”), Bionics will have a right of first refusal with respect to any commercial license of the System within the field of neuromodulation. Bionics will have no further
rights to obtain a license for or relating to the System upon the expiration of the ROFR Period. 
 Section 10. LEAD
DEVELOPMENT AND LICENSE. 
 10.1        Lead Development. Working together
with Bionics and subject to Section 10.1(c), the Company will provide Bionics with a fully functional prototype of the Lead and demonstrate the proper functionality of the prototype of the Lead to Bionics in an animal or cadaver placed within
an MRI machine. The Lead prototype must meet the following objectives (the “Lead Requirements”): [***]. 

(a) Development Expenses. Bionics will reimburse the Company for all reasonable expenses directly associated with the development
of the Lead for Bionics (including, without limitation, costs associated with animal studies and human trials), when the Company submits a request to Bionics for approval prior to incurring such expenses and such expenses are incurred with
Bionics’ written approval, provided receipts for such expenses are submitted to Bionics within 30 days after such expenses are incurred. Upon receiving a request for expense authorization from the Company, Bionics will indicate to the Company
whether the requested expense is authorized within 15 days for expenses up to $1,000 and within 30 days for expenses over $1,000. Bionics will reimburse the Company within 30 days of receiving reasonably detailed invoices describing the
Company’s authorized expenses under this Agreement. The Company will provide those invoices to Bionics within 15 days after the end of each month in which the Company incurs any authorized expense. 

(b) Lead Milestones.  

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. 
  

 15 

	 	(i)	 Bionics will pay the Company $100,000 after the Company has successfully created the Lead meeting the Lead Requirements as demonstrated to
Bionics’ reasonable satisfaction. 

  

	 	(ii)	 Bionics will pay the Company $100,000 after the Company has successfully completed the first live chronic human implantation of the Lead meeting the
Lead Requirements as demonstrated to Bionics’ reasonable satisfaction. 

  

	 	(iii)	 Bionics will pay the Company $1,000,000 after Bionics has successfully received FDA approval of the Lead meeting the Lead Requirements as
demonstrated to Bionics’ reasonable satisfaction. 

 (c) Performance Obligations; Breach; Damages.
In the event that the Company fails to complete each of the milestones of Section 10.1(b) (“Lead Milestones”) by June 30, 2008, and such failure is not the result of Bionics’ failure to reasonably cooperate with
the Company in pursuing the Lead Milestones, the Company will be in breach of this Agreement. Upon receiving written notice of breach under this Section 10.l(c) by Bionics, the Company will have 60 days to cure the breach. If the Company fails
to cure the breach within 60 days after receiving notice of such breach, the Company will immediately pay Bionics a sum of money equal to (i) all Lead Milestone payments disbursed to date, plus (ii) all expense reimbursements previously
paid by Bionics to the Company pursuant to Section 10.1(a), plus (iii) all patent prosecution costs incurred by Bionics under Section 11.2(a) with respect to Patents (defined below) related to the Lead. 

10.2        Exclusive License. Concurrently with this Agreement, the Company has granted
to Bionics in the License Agreement an exclusive, perpetual, transferable, worldwide license, with right of sublicense, under the Existing Intellectual Property and Future Intellectual Property, to make, use, import, lease, and sell any
neuro-related lead, neuro-related lead extension, any other neuro-related lead-type device, or any product related to a neuro-related lead. 

Section 11. INTELLECTUAL PROPERTY OWNERSHIP AND PROTECTION. 

(a) Intellectual Property Transfer and License during Agreement. The Company hereby assigns and transfers to Bionics all right,
title, and interest for all countries in and to all Future Intellectual Property developed before the later of (x) the full payment of the Note Balance or (y) the full conversion of the Note Balance (“Loan Satisfaction
Date”). The Company agrees to (i) promptly and fully disclose in writing to Bionics all Future Intellectual Property, (ii) assign all Future Intellectual Property to Bionics and execute all documents necessary to effect that
assignment, (iii) assist Bionics as set forth in Section 11.2, at Bionics’ expense, in obtaining foreign and domestic intellectual-property protection on all Future Intellectual Property, (iv) execute all documents necessary to
obtain such intellectual-property protection in the name of Bionics, and (v) maintain all information relative to all Future Intellectual Property, as confidential information of Bionics subject to the obligations of confidentiality set forth
in this Agreement. Bionics hereby grants to the 
  

 16 

 
Company an exclusive, fully paid, worldwide license, with right to sublicense, under that transferred Future Intellectual Property outside the field of neuromodulation, to make, use, import,
lease, and sell any system, method, or apparatus. 
 (b) Intellectual Property Re-transfer and Cross-License. Bionics
hereby agrees to assign and transfer to the Company joint ownership for all countries in and to the transferred Future Intellectual Property promptly after the Loan Satisfaction Date (“Re-Transfer”). Upon Re-Transfer, the
transferred Future Intellectual Property will become Intellectual Property that is jointly owned by the Parties (“Joint Intellectual Property”). Effective immediately upon the date of Retransfer, the Company hereby grants to Bionics
an exclusive, fully paid, non-transferable, perpetual worldwide license under the Joint Intellectual Property within the field of neuromodulation, with right to sublicense, to make, use, import, lease, and sell any system, method, or apparatus
thereunder. Bionics hereby grants to the Company an exclusive, fully paid, non-transferable, perpetual worldwide license under the Joint Intellectual Property outside the field of neuromodulation, with right to sublicense, to make, use, import,
lease, and sell any system, method, or apparatus thereunder. 
 11.2        Patent
Prosecution. 
 (a) Costs. Bionics will pay all foreign and domestic Patent (defined below) prosecution costs and
expenses for all patents and applications subject to its sole control as set forth in Section 11.2(b) (“Prosecution Costs”). 

(b) Intellectual Property Protection. Bionics will control the prosecution of all foreign and domestic Patents and applications
thereof and will take such other legal steps as Bionics will determine in its sole discretion to be necessary to protect Bionics’ rights for all Existing Intellectual Property and Future Intellectual Property or Joint Intellectual Property
during the term of any license to Bionics (“Protected Intellectual Property”). The Protected Intellectual Property includes all Existing Intellectual Property and Future Intellectual Property (including all Intellectual Property
licensed under the JHU Agreement to the extent permitted under the JHU Agreement) and Joint Intellectual Property. As used in this Section 11.2, “Patents” means any currently issued U.S. or foreign patent or provisional,
nonprovisional, or foreign patent application, any reissues, reexaminations, extensions, divisionals, continuations, continuations in part, counterparts, and foreign counterparts thereof. For the avoidance of doubt, Bionics will not be obligated to
pay any Prosecution Costs to protect any Intellectual Property if it determines, in its sole discretion, that those Prosecution Costs outweigh the likely benefits to Bionics. 

(c) Company Cooperation. The Company will cooperate with Bionics in filing, prosecuting and maintaining applications and taking
such other legal steps as set forth in this Section 11.2 and will execute and deliver any documents and instruments in connection therewith which Bionics may request at no additional cost or expense to Bionics. 

(d) Company Inspection and Intervention. The Company will have the right upon reasonable notice and reasonable request to
inspect, at the Company’s sole expense and discretion, the prosecution documents and strategy of Bionics with respect to the 

 

 17 

 
Protected Intellectual Property. If the Company desires to file and prosecute any patent application in any country that Bionics determined was not worthwhile to protect Bionics’ rights, the
Company may provide Bionics with a reasonable written request to file and prosecute such patent application (“Prosecution Request”). Bionics will have 30 days to fulfill the Prosecution Request. If Bionics fails to complete the
Prosecution Request after 30 days of receiving the Prosecution Request, the Company may independently file and prosecute the patent application of the Prosecution Request, and the Company will bear all Prosecution Costs and will control the
remainder of the prosecution for the patent application of the Prosecution Request. 
 11.3 Warranty Regarding Third Party
Collaborators. The Parties warrant that all individuals, including without limitation employees and consultants, authorized, invited, or otherwise involved by the Parties, their employees, or consultants, to assist in the development of the
System or Lead, have assigned to the relevant Party or have a legal obligation to assign to the relevant Party all their rights to any Intellectual Property related to, arising from, or based on the development of the System or Lead. 

11.4 Infringement. Both the Company and Bionics will notify the other of any perceived infringement. [***] will defend against
infringement by a third party all Existing Intellectual Property (including all intellectual property licensed under the JHU Agreement to the extent permitted under the JHU Agreement), Future Intellectual Property and Joint Intellectual Property
under which Bionics holds a license from the Company; provided, however, that [***] will have the right, but not the obligation, to participate in the institution and prosecution of any such infringement suit on terms that are fair and equitable to
both Parties. If [***] does not institute an infringement suit within 60 days after [***] written request that it do so, [***] may institute and prosecute such lawsuit. 

(a) Costs. [***] will pay all costs, fees, and expenses associated with an infringement action initiated and prosecuted [***].
[***] will pay all costs, fees, and expenses associated with an infringement action initiated and prosecuted [***]. The costs, fees, and expenses associated with an infringement action initiated and prosecuted by both Parties shall be allocated to,
and paid by, each Party in a fair and equitable manner mutually determined by the Parties. 
 (b) Recovery. Any recovery
obtained in an action initiated and prosecuted [***]. Any recovery obtained in an action initiated and prosecuted [***]. Any recovery obtained in an action initiated and prosecuted by both Parties as contemplated above will be distributed to the
Parties in a fair and equitable manner mutually determined by the Parties. 
 (c) Cooperation. Each Party agrees to
fully cooperate with the other in the prosecution of any such suit at no additional expense to that cooperating Party. 
 [***] Indicates
portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 

 2 

 11.5 Publication and Authorship. The Company will have the right to author, to
publish and to retain or transfer copyright to scientific reports describing the methods and results of any or all Intellectual Property licensed to Bionics, provided that the manuscripts for such reports are made available to Bionics at least
ninety days before publication or submission to a journal so that Bionics can take any steps deemed necessary to protect Intellectual Property disclosed in said manuscripts and articles and provided that such reports include an Acknowledgement
stating that the studies were conducted with the financial and technical support of Bionics. 

11.6        Confidentiality. 

(a) Definition. “Confidential Information”, as used in this Agreement, will include all confidential or proprietary
data or information disclosed by either Party to the other Party in writing, orally, or by drawing or other form pursuant to this Agreement or any of the Concurrent Agreements. 

(b) Non-Disclosure. To the extent that Confidential Information is shared between the Parties, the receiving Party agrees that it
will not disclose any Confidential Information to any third party and, during the term of any license granted to Bionics under this Agreement and for a period of three (3) years thereafter, without the prior written consent of the disclosing
Party, will not use Confidential Information of the disclosing Party for any purpose other than for the performance of the rights and obligations hereunder. The receiving Party further agrees that, except as otherwise expressly provided in this
Agreement, Confidential Information will remain the sole property of the disclosing Party and that it will take all reasonable precautions to prevent any unauthorized disclosure of Confidential Information by its employees, affiliates, and
consultants. No license will be granted by the disclosing Party to the receiving Party with respect to Confidential Information disclosed hereunder unless otherwise expressly provided herein. The non-disclosure obligations of this
Section 11.6(b) will not apply to information that: (i) is known to the receiving Party at the time of disclosure or becomes known to the receiving Party without breach of this Agreement (as shown in the receiving Party’s written
records); (ii) is or becomes publicly known through no wrongful act of the receiving Party or any affiliate of the receiving Party; (iii) is rightfully received from a third party without restriction on disclosure; (iv) is
independently developed by the receiving Party or any of its affiliates; (v) is furnished to any third party by the disclosing Party without restriction on its disclosure; (vi) is approved for release upon a prior written consent of the
disclosing Party; or (vii) is disclosed pursuant to judicial order, requirement of a governmental agency or as otherwise required by law (in which case the receiving Party will notify the disclosing Party before the receiving Party’s
disclosure and cooperate with the disclosing Party in the disclosing Party’s attempts to seek a proper protective order). 

(c) Exchange of Confidential Information. Upon the request of the disclosing Party at any time after the Loan Satisfaction Date,
the receiving Party will promptly return all Confidential Information, in whatever form, furnished hereunder and all copies thereof, excluding any information that the receiving Party needs to retain for purposes of meeting its obligations under
this Agreement or expressly has the right to retain under this 
  

 3 

 
Agreement. With the exception of the prototypes provided to Bionics, in accordance with this Agreement, each Parties will retain custody and ownership of any specimens and original data disclosed
to the other Party and will exercise due care in preserving such specimens and original data in a manner consistent with current standards of scientific conduct. The Company will provide Bionics with complete and timely reports and scientific
analyses of such data and will make specimens and original data available for inspection by representatives of Bionics at Bionics’ request. 

(d) Publicity. The Parties agree that all publicity and public announcements, or other disclosure to any third party, concerning
the formation, existence, and content of this Agreement will be jointly planned and coordinated by and among the Parties. Neither Party will disclose any information concerning the formation, existence, and content, including without limitation the
specific terms, of this Agreement to any third party without the prior written consent of the other Party, which consent will not be withheld unreasonably. Notwithstanding the foregoing, any Party may disclose information concerning this Agreement
as required by the laws, rules, orders, regulations, subpoenas, or directives of a court, government, or governmental agency, after giving prior notice to the other Party. 

(e) Breach. If a Party breaches any of its obligations with respect to confidentiality and unauthorized use of Confidential
Information as set forth in this Agreement, the non-breaching Party will be entitled to equitable relief to protect its interest therein, including but not limited to injunctive relief, as well as money damages notwithstanding anything to the
contrary contained herein. 
 Section 12.        Termination of Licenses. 

 The Parties are entitled to enjoy the benefits of each license granted pursuant to the License Agreement and Sections 9, 10,
and 11, and the termination of any one license is not a termination of any other license even if such licenses grant similar rights. 

Section 13.        Consent by JHU. 

Pursuant to a letter dated as of December 27, 2005, a copy of which has been received by Bionics, JHU consented to the collateral
assignment to Bionics, and the grant to Bionics of a security interest in, all of the Company’s right, title and interest in and to the JHU Agreement. 

[The remainder of this page has been left intentionally blank] 

 

 4 

 In Witness Whereof, the undersigned have executed this Agreement as of the
date first written above. 
 BIONICS: 

ADVANCED BIONICS CORPORATION 
  

			
	 By:
	 	 /s/ Jeffrey H. Greiner

		 	 Jeffrey H. Greiner

		 	 Its: President and Co-Chief Executive Officer

COMPANY: 
 SURGI- VISION, INC.

  

			
		 	 /s/ Kimble L. Jenkins

	 By:
	 	 Kimble L. Jenkins

		 	 Its: President

[Signature Page to System and Lead Development and Transfer Agreement] 

 

 Schedule 4.2-1 

 SCHEDULE 4.2 

CAPITALIZATION 

A capitalization table is set forth on the following page. 

As of the date of this Agreement, options to purchase an aggregate of 1,375,000 shares of the Company’s Common Stock are
outstanding. 
 The Company has issued convertible promissory notes in the aggregate principal amount of $300,000. Such
promissory notes are convertible into, among other things, shares of the Company’s equity securities (of the type, kind and character sold by the Company in a minimum equity financing) and warrants to purchase shares of the Company’s
Common Stock. 
 Pursuant to that certain First Amended and Restated Stockholders’ Agreement dated April 30, 2004,
among the Company, Dara BioSciences, Inc. (“Dara”), JHU and the other stockholders party thereto, Dara has the right to maintain its then current ownership percentage of the Company (determined on a fully diluted basis) upon the issuance
of new securities, subject to customary exceptions. Dara has waived its percentage maintenance right with respect to the Note and any Conversion Shares issued upon conversion thereof. 

 

 Schedule 4.2-1 

 SCHEDULE 4.3 

AUTHORIZATION 

JHU’s consent is required for the Company to collaterally assign, and to grant a security interest in, the Company’s right,
title and interest in and to the JHU Agreement. However, the Company has obtained JHU’s consent. 
  

 Exhibit 4.3-1 

 SCHEDULE 4.8 

INTELLECTUAL PROPERTY 

The Company is not a party to any license agreement other than the JHU Agreement. 

Pursuant to the JHU Agreement, JHU has the retained right to make, have made, provide and use for its and The Johns Hopkins Health
Systems’ internal, non-commercial research purposes “Licensed Products” and “Licensed Services” (as such terms are defined in the JHU Agreement). 

Patents supported by federal funding are subject to the rights, conditions and limitations imposed by U.S. law (see U.S.C. § 202 et
seq.). 
  

 Exhibit 4.8-1 

 SCHEDULE 4.14 

MATERIAL CONTRACTS 

(a)(i) 

Consulting Agreement dated January 22, 2004 between the Company and Neuromodulation Specialists, LLC 

Employment Agreement dated September 1, 2004 between the Company and Kimble Jenkins 

Consulting Agreement dated April 19, 2004 between the Company and Charles P. Steiner 

Consulting and Finder’s Agreement dated October 14, 2005 between the Company and James Terwilliger 

Consulting Agreement dated November 1, 2005 between the Company and Paul Bottomley 

Consulting Agreement dated November 1, 2005 between the Company and Parag Karmarkar 

Consulting Agreement dated November 1, 2005 between the Company and Ergin Atalar 

The JHU Agreement 

The Lead License 

(a)(ii) 

Promissory note made by the Company in favor of Trust One Bank in the principal amount of $690,000. 

The Company has issued convertible promissory notes in the aggregate principal amount of $300,000 (the “Convertible Notes”).

 (a)(iii) 

None 

(a)(iv) 

The Convertible Notes 

The Company’s Stock Option Plan 
  

 Exhibit 4.14-1 

 As of the date of this Agreement, options to purchase an aggregate of 1,375,000 shares of
the Company’s Common Stock are outstanding. Such options were awarded pursuant to individual grant agreements. 

Consulting Agreement dated January 22, 2004 between the Company and Neuromodulation Specialists, LLC 

Employment Agreement dated September 1, 2004 between the Company and Kimble Jenkins 

The First Amended and Restated Stockholders’ Agreement dated April 30, 2004, among the Company, Dara BioSciences, Inc., JHU and
the other stockholders party thereto. 
 (a)(v) 

None 

(a)(vi) 

None 

(a)(vii) 

The JHU Agreement 

(a)(viii) 

None 

(a)(ix) 

Consulting Agreement dated January 22, 2004 between the Company and Neuromodulation Specialists, LLC 

Employment Agreement dated September 1, 2004 between the Company and Kimble Jenkins 

Consulting Agreement dated April 19, 2004 between the Company and Charles P. Steiner 

Consulting and Finder’s Agreement dated October 14, 2005 between the Company and James Terwilliger 

Consulting Agreement dated November 1, 2005 between the Company and Paul Bottomley 

Consulting Agreement dated November 1, 2005 between the Company and Parag Karmarkar 

Consulting Agreement dated November 1, 2005 between the Company and Ergin Atalar 

 

 Exhibit 4.14-2 

 (a)(x) 

None 
 (a)(xi)

 None 

(a)(xii) 
 Second Amended
and Restated Investor Rights’ Agreement dated April 30, 2004, by and among the Company and certain of its stockholders 
  

 Exhibit 4.14-3 

 EXHIBIT A 

FORM OF CONVERTIBLE NOTE 

Begins on the following page 
  

 A-1 

 THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL
(I) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) HAS BECOME EFFECTIVE WITH RESPECT THERETO OR (II) RECEIPT BY THE COMPANY AT LENDER’S SOLE COST AND EXPENSE OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY
TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER AND THAT SUCH ISSUANCE IS NOT IN VIOLATION OF ANY APPLICABLE STATE SECURITIES LAWS. THIS LEGEND WILL BE ENDORSED UPON ANY NOTE
ISSUED IN EXCHANGE FOR THIS NOTE. 
 MULTIPLE ADVANCE 

SECURED CONVERTIBLE PROMISSORY NOTE 
  

			
	Up to $1,500,000	 	December 30, 2005            

1.        Principal. For value received, SURGI-VISION, INC., a
Delaware corporation (“Company”), promises to pay to ADVANCED BIONICS CORPORATION, a Delaware corporation (“Lender”), at its office at 25129 Rye Canyon Loop, Valencia, California 91355, or at such other place
as Lender may from time to time designate in writing, the principal sum specified on the Schedule of Advances attached to this Note, together with accrued interest from the date of disbursement on the unpaid principal of this Note at the rate
set forth in Section 3 hereof. Lender hereby authorizes and directs Company to deliver this Note to Lender’s address set forth at the beginning of this Note. Initially capitalized terms used herein without definition are defined in
that certain System and Lead Development and Transfer Agreement (the “Development Agreement”) of even date herewith between Company and Lender. 

2.        Maturity Date. Unless Lender has previously exercised its
Conversion Right (as defined below), the unpaid principal balance of this Note (plus any interest, fees, and other amounts owing under this Note) (collectively, the “Note Balance”) is due and payable in full on the Maturity Date.
The “Maturity Date” is the earliest of (A) the last day of the Negotiation Period or (B) December 31, 2007, regardless of any extensions of the Negotiation Period that Company and Lender may mutually agree on, or
(C) the date of an occurrence of an Event of Default. If the Maturity Date falls on a day that is not a business day, payment of the unpaid principal of this Note must be made on the next succeeding business day and such extension of time will
be included in computing any interest in respect of such payment. 

3.        Interest Rate. 

      (a)            This Note
bears simple interest at the rate of 0% per annum on its unpaid principal amount from the Closing Date to five days after the Maturity Date. This Note bears simple interest at the rate of 20% per annum (or the highest rate permitted by law,
whichever is less) (the “Default Rate”) on any unpaid principal balance of this Note from five 

 
business days after the Maturity Date until the actual date that the entire Note Balance is satisfied (either by (i) Company paying the entire Note Balance in cash, (ii) Lender electing
in its sole discretion to convert the entire Note Balance into Conversion Shares (as defined below), or (iii) Lender electing in its sole discretion to convert part of the Note Balance into Conversion Shares and Company paying the entire
remaining Note Balance in cash). 

      (b)            All
payments of principal and interest due under this Note must be made without deduction of any present and future taxes, levies, imposts, deductions, charges or withholdings, which amounts must be paid by Company. Company will pay the amounts
necessary such that the gross amount of the principal and interest received by Lender is not less than that required by this Note. If Company is required by law to deduct any such amounts from or in respect of any principal or interest payment under
this Note, then (i) the sum payable to Lender will be increased as may be necessary so that after making all required deductions (including deductions applicable to additional sums payable under this provision) Lender receives an amount equal
to the sum it would have received had no deductions been made, (ii) Company will make such deductions, and (iii) Company will pay the full amount deducted to the relevant taxation authority or other authority in accordance with applicable
law. Company will pay all stamp and documentary taxes. If, notwithstanding the foregoing, Lender pays such taxes, Company will reimburse Lender for the amount paid. Company will furnish Lender official tax receipts or other evidence of payment of
all taxes. 

      (c)            Throughout
the term of this Note, interest will be calculated on the basis of a 360-day year and will be computed for the actual number of days elapsed in the period for which interest is charged. If any payment of interest to be made by Company under this
Note becomes due on a day which is not a business day, such payment must be made on the next succeeding business day and such extension of time will be included in computing the interest due in respect of such payment. 

4.        Conversion. 

      (a)            
Conversion at Lender’s Option. At any time beginning on the Maturity Date and ending five business days after Company’s payment in full of the Note Balance, Lender will have the right, in Lender’s sole discretion, to convert
this Note, in whole or in part (the “Conversion Right”) into the number of Conversion Shares obtained by the calculations of Section 4(b)(i) or Section 4(b)(ii), as applicable. If Lender exercises the Conversion Right
after Company’s payment in full of the Note Balance, Lender will return to Company that part of the Note Balance that Lender is electing to convert to Conversion Shares within five business days of Lender’s receipt of Company’s
payment in full of the Note Balance. 
 “Conversion Shares” means the aggregate number of fully paid and
nonassessable shares of the Common Stock of Company, par value $0.001 per share (“Common Stock”) into which Lender has elected to convert all or part of the Note Balance. 

 

 2 

       (b) Pricing Terms. 

 

	 	(i)	 Conversion Calculation without Subsequent System License. If Company and Lender have not executed and delivered the Subsequent System
License, the number of Conversion Shares will be determined by dividing (A) the amount of the Note Balance to be converted by (B) the lesser of (I) the 10% Conversion Price (as defined below) or (II) if Company consummates a sale of
any of its equity securities after the Closing Date (for the avoidance of doubt, a “sale” of equity securities will not include equity securities issued pursuant to the acquisition of another entity by Company by merger, purchase of all or
substantially all of the assets, or other reorganization whereby Company becomes the owner of more than 50% of the voting power of such entity, equity securities issued pursuant to the conversion or exercise of any convertible securities, options or
warrants, or equity securities (including derivatives) granted, issued or issuable to employees, officers, directors or consultants pursuant to plans or agreements approved by Company’s board of directors), whether in a single or multiple
closings or financings, the average price per share paid for such securities by the purchasers thereof. The term “10% Conversion Price” means, as of a given date, the price per share determined by dividing $1,500,000 by 10% of
Company’s Fully Diluted Shares (as defined below). The term “Fully Diluted Shares” means, as of a given date, the total number of shares of Common Stock (a) issued and outstanding, (b) issuable upon the exercise of
any and all outstanding options, warrants and rights to acquire shares of Common Stock, or upon the conversion of any and all outstanding securities convertible into shares of Common Stock, whether then vested, exercisable or convertible, and
(c) authorized and issuable by the Company under any stock option or other equity compensation plan approved by the Company’s board of directors other than those shares subject to outstanding options, warrants or other similar rights
described in the preceding clause (b). 

  

	 	(ii)	 Conversion Calculation with Subsequent System License. If Company and Lender have executed and delivered the Subsequent System License, the
number of Conversion Shares will be determined by dividing (A) the amount of the Note Balance to be converted by (B) the lesser of (I) the 5% Conversion Price (as defined below) or (II) if Company consummates a sale of any of its
equity securities after the Closing Date (for the avoidance of doubt, a “sale” of equity securities will not include equity securities issued pursuant to the acquisition of another entity by Company by merger, purchase of all or
substantially all of the assets, or other reorganization whereby Company becomes the owner of more than 50% of the voting power of such entity, equity securities issued pursuant to the conversion or exercise of any convertible securities, options or

  

 3 

	 	
warrants, or equity securities (including derivatives) granted, issued or issuable to employees, officers, directors or consultants pursuant to plans or agreements approved by Company’s
board of directors), whether in a single or multiple closings or financings, the average price per share paid for such securities by the purchasers thereof. The term “5% Conversion Price” means, as of a given date, the price per
share determined by dividing $1,500,000 by 5% of Company’s Fully Diluted Shares. 

      (c)            
Conversion Procedure. 
  

	 	(i)	 In order to convert all or any part of the Note Balance, Lender will deliver to Company a written notice stating (A) that Lender has elected to
convert all or part of the Note Balance and (B) the amount of the Note Balance to be converted (the “Conversion Notice”). 

  

	 	(ii)	 Within five business days after receipt of the Conversion Notice, Company will deliver to Lender a certificate for the number of Conversion Shares
issuable upon the conversion; provided that Company will not issue any fractional Conversion Shares. In lieu of Company issuing any fractional shares to Lender or its designees upon conversion, Company will pay to Lender the unconverted
amount of the Note Balance specified in the Conversion Notice, such payment to be in the form of a wire transfer or check payable to Lender. Each conversion will be deemed to have been effected immediately before the close of business on the date on
which this Note is given to the Company pursuant to Section 14 of this Note. Upon conversion of the entire Note Balance, Company will be forever released from all its obligations and liabilities under this Note. 

      (d)            Changes
in Common Stock. If, and as often as, there are any changes in the Common Stock by way of stock split, stock dividend, combination or reclassification, or by any other means, appropriate adjustment will be made by Company and Lender to the price
at which Conversion Shares are issued and the other provisions of this Note, as may be required, so that the rights and privileges granted hereby will continue with respect to the Conversion Shares as so changed. 

      (e)            Access
and Information. Subject to the confidentiality provisions in the Development Agreement, Company will afford to Lender and its accountants, counsel and other representatives full access, upon reasonable request, upon reasonable prior notice and
during normal business hours, to all of Company’s properties, books, accounts, records, contracts, and personnel and, Company will, and will cause its accountants, counsel and other representatives to furnish promptly to Lender and its
representatives all information concerning Company’s business, properties and personnel, in each case as Lender or its representatives reasonably requests for the purpose of evaluating the merits and risks of an

  

 4 

 
investment in Conversion Shares in the event Lender may desire to exercise its Conversion Right; provided, however, that Company reserves the right to withhold any information if access to such
information could adversely affect the attorney-client privilege between Company and its counsel. 

      (f)            
Conversion Shares. Until such time as the Conversion Shares are registered under the Securities Act of 1933, Company will instruct its transfer agent to enter stop transfer orders with respect to such shares and the certificates representing
such shares will be endorsed with the following legend: 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE “BLUE SKY” OR SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, HYPOTHECATED, DISTRIBUTED OR OTHERWISE DISPOSED OF UNLESS THERE IS AN
EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SALE OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT IS AVAILABLE, AND IF AN EXEMPTION IS AVAILABLE, THE COMPANY RECEIVES AN OPINION OF COUNSEL AT THE HOLDER’S SOLE COST AND
EXPENSE STATING THAT SUCH OFFER, SALE, TRANSFER, ASSIGNMENT, PLEDGE, HYPOTHECATION, DISTRIBUTION OR OTHER DISPOSITION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT AND OTHER LAWS. THE RESTRICTIONS CONTAINED HEREIN
ARE BINDING ON THE HOLDER HEREOF AND HIS SUCCESSORS AND ASSIGNS.” 

5.        Schedule of Advances. Lender will, and is hereby authorized by
Company to, note on the Schedule of Advances annexed to this Note and constituting a part of this Note, the date and amount of each advance, payment or prepayment of all or any portion of the principal sum. Absent manifest error, such
notations are conclusive and binding as to the aggregate unpaid principal sum and all other information; provided, however, the failure of Lender to make such a notation will not limit or otherwise affect the obligation of Company to repay the
outstanding principal amount or any interest accrued or accruing thereon or any other amount payable by Company to Lender hereunder. 

6.        Prepayment. Prior to the Maturity Date, Company, in its sole
discretion, may prepay all or any portion of the Note Balance at any time, provided that (i) Company will give Lender not less than a 30-day prior written notice of its intention to prepay an amount specified in such notice on the date
set forth in the notice, and (ii) notwithstanding any provision hereof to the contrary, Lender will have the right before the anticipated prepayment date set forth in the notice to exercise its Conversion Right, under the pricing terms
contained in Section 4(b)(i) of this Note, to convert all or part of the amount to be prepaid into Conversion Shares, in which case the prepayment notice will have no further force or effect regarding the amount to be converted. 

7.        Lawful Money. Principal and interest are payable in lawful money
of the United States of America. 
  

 5 

 8.        Applications of
Payments; Late Charges. 

      (a)            Payments
received by Lender hereunder will be applied first to costs and expenses, then to interest and finally to principal unless Lender elects otherwise in its sole discretion. 

      (b)            If any
payment of principal or interest is not paid when due, such late payment will bear interest at the Default Rate from the day such payment was due until it is paid. In addition, if any payment is five or more days overdue, Lender will have the option
to assess a late charge of $0.03 cents for each dollar so overdue. In connection therewith, Company and Lender agree as follows: 
  

	 	(i)	 Because of such late payment, Lender will incur certain costs and expenses including, without limitation, administrative costs, collection costs,
loss of interest, and other direct and indirect costs in an uncertain amount; 

  

	 	(ii)	 It would be impractical or extremely difficult to fix the exact amount of such costs in such event; 

 

	 	(iii)	 The late charge is a reasonable and good faith estimate of such costs; and 

 

	 	(iv)	 Such late charge will constitute liquidated damages caused by such failure to make a payment of interest or principal when due but only to the
extent such late charge is assessed by Lender, paid by Company and accepted by Lender and only upon the condition that such failure is completely cured concurrently with such payment. 

The application of the Default Rate or the assessment of a late charge to any such late payment as described in this
Section 8(b) will not be interpreted or deemed to extend the period for payment or otherwise limit any of Lender’s remedies under this Note, the Security Agreement, the Development Agreement, or the License Agreement. 

9.        Security. This Note is a secured obligation of Company as set
forth in the Security Agreement of even date herewith between Company and Lender (the “Security Agreement”). 

10.        Covenants of Company. 

      (a)            Use of
Loan Proceeds. Company covenants and agrees that it will use the proceeds of this Note only (i) to pay the second installment in the amount of $124,052.60 (including accrued interest, fees, and related amounts) due on December 1, 2005,
and the third installment in the amount of $120,355.03 (including accrued interest, fees, and related amounts) due on March 1, 2006, under that certain promissory note made by the Company in favor of Trust

  

 6 

 
One Bank of 1715 Aaron Brenner Dr., Memphis, Tennessee 38120 in the principal amount of $690,000 due December 1, 2006 (the “Trust One Bank Note”), (ii) to pay direct
costs and expenses associated with the development of the System and/or the Lead and (iii) to pay to Bass, Berry & Sims, PLC and Myers Bigel Sibley & Sajovec an aggregate amount no greater than $40,000 to cover Company’s
actual costs and expenses associated with the negotiation and documentation of this Note, the Security Agreement, the Development Agreement, the License Agreement and the Other Agreements. Company acknowledges that some costs and expenses incurred
by Company, such as salaries and consulting fees, may relate both to the development of the System and/or the Lead and to other activities of Company. With respect to such costs and expenses, Company will determine, subject to Lender’s
approval, which will not be unreasonably withheld, which percentage of the cost or expense is associated with the development of the System and/or the Lead, for which Company will be permitted to use proceeds of this Note, and which percentage is
associated with other activities of Company, for which Company will not be permitted to use proceeds of this Note. 

      (b)            No
Senior Debt. So long as this Note is outstanding, Company will not incur on or after the Closing Date any indebtedness for borrowed money that is not expressly subordinated to this Note, without the prior written consent of Lender. For the
avoidance of doubt, the phrase “indebtedness for borrowed money” will not include ordinary-course obligations to trade creditors. 

      (c)            No
Liens or Encumbrances. So long as this Note is outstanding, without the prior written consent of Lender, Company will not (a) pledge or otherwise encumber or permit the encumbrance of any of its assets, including the Collateral (as defined
in the Security Agreement); (b) merge or consolidate with any entity, or dissolve; (c) declare, make or pay any distribution or dividend to its stockholders; (d) sell, lease or otherwise dispose of all or any substantial portion of
its assets; or (e) engage in any business other than that in which it is presently engaged. Lender may grant or withhold its consent in its sole discretion. Any grant of that consent will give the Lender the right to exercise the Conversion
Right for all or any part of the Note Balance under the pricing terms contained in Section 4(b)(i). 

11.        Defaults and Remedies. 

      (a)            Events
of Default. Each of the following events constitutes an event of default (“Event of Default”): 
  

	 	(i)	 if any representation or warranty made by Company in this Note, the Security Agreement, the Development Agreement, the License Agreement or in any
report, certificate, financial statement or other instrument furnished in connection with this Note, is false, inaccurate or misleading in any material respect when made or when deemed made hereunder. 

 

	 	(ii)	 any default in the payment of any principal or interest under this Note within five days after date when due hereunder, whether upon the Maturity
Date or by acceleration or otherwise; 

  

 7 

	 	(iii)	 any default by Company in the prompt and complete fulfillment of any of its covenants and obligations under this Note, the Security Agreement, the
Development Agreement, the License Agreement, or any and all other agreements and documents executed and delivered in connection herewith or therewith (the “Other Agreements”) (other than those covenants and obligations referred to
in clause (ii) above or clause (vi) below), if such default is not remedied within 15 days after an officer of Company becomes aware of the factual circumstances giving rise to such default; 

 

	 	(iv)	 if Company: (A) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of it or any of its properties,
(B) admits in writing its inability to pay its debts as they mature, (C) makes a general assignment for the benefit of creditors, (D) is adjudicated as bankrupt or insolvent or is the subject of an order for relief under Title 11 of
the United States Code, or any successor thereto, or (E) files a voluntary petition in bankruptcy, or a petition or an answer seeking reorganization or an arrangement with creditors or to take advantage of any bankruptcy, moratorium,
reorganization, insolvency, readjustment of debt, dissolution or liquidation law or statute, or an answer admitting the material allegations of a petition filed against it in any proceeding under any such law, or (F) takes or permits to be
taken any action in furtherance of or for purpose of effecting any of the foregoing; 

  

	 	(v)	 if any order, judgment or decree will be entered, without the application, approval or consent of Company, by any court of competent jurisdiction,
approving a petition seeking reorganization of Company, or appointing a receiver, trustee, custodian or liquidator of Company, or of all or any substantial part of its assets, and such order, judgment or decree will continue unstayed and in effect
for any period of 60 days; 

  

	 	(vi)	 if the Company fails to meet, by the required date, any System Milestone or Lead Milestone, which failure is not remedied within 15 days following
Lender’s written notice to Company; or 

  

	 	(vii)	 in the event Lender reasonably believes that Company will be unable to perform its obligations under this Note, Lender may request in writing
reasonable assurances of further performance from Company. If, within 15 days from such written request, Company fails to give such assurances reasonably showing its ability to perform, Lender may declare an Event of Default. For avoidance of doubt,
Lender’s reasonable belief of Company’s inability to perform its obligations under this Note must be based on a fact or circumstance that occurs or changes after the date of this Note and results in a material adverse effect upon

  

 8 

	 	
the Company’s financial condition. The foregoing is without any derogation of rights under applicable law to demand further assurances and address anticipatory breaches.

      (b)            
Remedies. 
  

	 	(i)	 Upon the occurrence of any Event of Default, and at all times thereafter during the continuance of an Event of Default: (a) this Note will, in
Lender’s sole discretion and upon Lender’s written notice to Company, become immediately due and payable, as to principal and interest, without presentment, demand, protest, notice or other requirement of any kind, all of which are hereby
expressly waived, anything contained herein or in this Note to the contrary notwithstanding (except in the case of any event described in Sections ll(a)(iv) and (v) of this Note, the occurrence of which will automatically effect acceleration,
regardless of any action or forbearance in respect of any prior or ongoing default or Event of Default which may be inconsistent with such automatic acceleration), (b) Lender may file suit against Company on this Note and/or seek specific
performance or injunctive relief thereunder (whether or not a remedy exists at law or in equity); and (c) Lender will have the right to seek to exercise any and all remedies as it may determine in its discretion (without any requirement of
marshalling of assets, or other such requirement) that may be available at law or in equity. 

  

	 	(ii)	 Lender’s rights, remedies and powers, as provided in this Note and the Security Agreement are cumulative and concurrent and may be pursued
singly, successively or together against this Company, the Collateral (as defined in the Security Agreement) and any other security given at any time to secure the payment of this Note, all at the sole discretion of Lender. Additionally, Lender may
resort to every other right or remedy available at law or in equity without first exhausting the rights and remedies contained herein, all in Lender’s sole discretion. Failure of Lender at any one time, for a period of time or on more than one
occasion, to exercise any of its rights or remedies hereunder or at law or in equity will not constitute a waiver of the right to exercise the same right or remedy at any time thereafter. Any and all waivers must be in writing to be effective.

  

	 	(iii)	 If any suit or action is instituted or attorneys are employed to enforce any of the obligations of this Note, the non-prevailing party hereby
promises and agrees to pay all reasonable costs, including reasonable attorneys’ fees and court costs incurred by the prevailing party. 

  

 9 

 12.        Subordination.
Lender and Company agree and acknowledge that the indebtedness evidenced by this Note is neither subordinate nor subject in right of payment to any other indebtedness issued to third parties. 

13.        Interest Rate Limitation. It is the intent of Company and
Lender in the execution of this Note and all other instruments securing this Note that the loan evidenced hereby be exempt from the restrictions of the usury laws of the State of California. In the event that, for any reason, it should be determined
that the California usury law is applicable to the Loan, Lender and Company stipulate and agree that none of the terms and provisions contained herein or in any of the other Credit Documents will ever be construed to create a contract for the use,
forbearance or detention of money requiring payment of interest at a rate in excess of the maximum interest rate permitted to be charged by the laws of the State of California. In such event, if any holder of this Note collects monies which are
deemed to constitute interest which would otherwise increase the effective interest rate on this Note to a rate in excess of the maximum rate permitted to be charged by the laws of the State of California, all such sums deemed to constitute interest
in excess of such maximum rate will, at the option of Lender, be credit. 

14.        Notices. All notices, requests, demands and
other communications which are required to be or may be given under this Note to a party by the other party must be in writing and will be deemed to have been duly given (a) immediately if delivered in person, (b) the day following
dispatch by a nationally recognized overnight courier service (such as Federal Express or UPS, etc.) for next day delivery, (c) five days after dispatch by certified or registered first class mail, postage prepaid, return receipt requested, to
the Party to whom the same is so given or made, or (d) upon confirmation of receipt, if by facsimile. Any notice or other communication given hereunder will be addressed to the Company, at 200 N. Cobb Parkway, Suite 140, Marietta, Georgia
30062-3585, Attention: John C. Thomas, Jr., Fax (770) 424-8236, with a copy to Kimble L. Jenkins, 50 North Front St.,
19th Floor, Memphis, Tennessee 38103, Fax (901) 579-
4979, , or to Lender at the address indicated at the beginning of this document, Attention: General Counsel, Fax (661) 362-4712. 

15.        Counterparts. This Note may be executed in two or more
counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument. 

16.        Headings. All headings are inserted for convenience of
reference only and will not affect the meaning or interpretation of any such provisions or of this Note, taken as an entirety. 

17.        Severability. If and to the extent that any court of competent
jurisdiction holds any provision (or any part thereof) of this Note to be invalid or unenforceable, such holding will in no way affect the validity of the remainder of this Note. 

18.        Changes, Waivers, Etc. Neither this Note nor any provision of
this Note may be changed, waived, discharged or terminated orally, but rather may only be changed by a statement in writing signed by the Party against which enforcement of the change, waiver, discharge or

  

 10 

 
termination is sought. It is agreed that a waiver by either Lender or Company of a breach of any provision of this Note will not operate, or be construed, as a waiver of any subsequent breach by
that same party. 
 19.        Governing Law. This Note will be
governed by and construed in accordance with the laws of the State of California. The parties hereby agree that any dispute which may arise between them arising out of or in connection with this Note will be adjudicated before a court located in Los
Angeles, California and they hereby submit to the exclusive jurisdiction of the courts of the State of California located in Los Angeles, California and of the federal courts in the Central District of California with respect to any action or legal
proceeding commenced by any party, and irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is an inconvenient forum,
relating to or arising out of this Note or any acts or omissions relating to the sale of the securities hereunder, and consent to the service of process in any such action or legal proceeding by means of registered or certified mail, return receipt
requested, in care of the address set forth below or such other address as the undersigned will furnish in writing to the other. 

20.        Entire Agreement. This Note, the Security Agreement, the
Development Agreement, the License Agreement and the Other Agreements set forth the entire agreement and understanding between Lender and Company as to this subject matter and incorporates and supersedes all prior discussions, agreements and
understandings of any and every nature among them. 

21.        Further Assurances. Lender and Company agree to execute and
deliver all such further documents, agreements and instruments and take such other and further action as may be necessary or appropriate to carry out the purposes and intent of this Note. 

22.        Successors and Assigns. The terms and conditions of this Note
will inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties. Nothing in this Note, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Note, except as expressly provided in this Note. This Note is non-negotiable. Neither Company nor Lender may assign or otherwise transfer this Note
without the prior written consent of the other party. 

23.        Relationship of Parties. In all matters relating to this Note,
no party will have any right, power or authority to create any obligation, express or implied, on behalf of any other party. Nothing in this Note is intended to create or constitute a joint venture or a partnership between the parties hereto.

 [SIGNATURES APPEAR ON NEXT PAGE] 
  

 11 

 IN WITNESS WHEREOF, Company has signed this Note and delivered this
Note to Lender as of the date first written above. 
  

							
	COMPANY:	 		 	SURGI- VISION, INC.,
		 		 	a Delaware corporation
				
		 		 	 By:
	 	  

		 		 	 Name:

		 		 	 Title:

  

 S-1 

 SCHEDULE OF ADVANCES 

 

									
	        Date        
	 	
Amount of Principal
        Advanced      
  
	 	Unpaid
       
 Principal        
Balance	 	        Amount        

Paid	 	        Notation        

Made By
	01/04/06	 	$250,000	 	$250,000	 	–	 	Initial Advance

  

 Appendix A 

 EXHIBIT B 

DEFINITION OF ACCREDITED INVESTOR 

Pursuant to Rule 501(a) of the Securities Act of 1933, as amended, the term “accredited investor” will have the meaning
indicated below: 
  

	 	a.	 Accredited investor. “Accredited investor” will mean any person who comes within any of the following categories, or who the issuer
reasonably believes comes within any of the following categories, at the time of the sale of the securities to that person: 

  

	 	1.	 Any bank as defined in section 3(a)(2) of the Act, or any savings and loan association or other institution as defined in section 3(a)(5)(A) of the
Act whether acting in its individual or fiduciary capacity; any broker or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934; any insurance company as defined in section 2(13) of the Act; any investment company
registered under the Investment Company Act of 1940 or a business development company as defined in section 2(a)(48) of that Act; any Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c) or
(d) of the Small Business Investment Act of 1958; any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such
plan has total assets in excess of $5,000,000; any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974 if the investment decision is made by a plan fiduciary, as defined in section 3(21) of such act, which
is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by
persons that are accredited investors; 

  

	 	2.	 Any private business development company as defined in section 202(a)22 of the Investment Advisers Act of 1940; 

 

	 	3.	 Any organization described in section 501(c)3 of the Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership,
not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000; 

  

	 	4.	 Any director, executive officer, or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or
general partner of a general partner of that issuer; 

  

 B-1 

	 	5.	 Any natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase exceeds $1,000,000;

  

	 	6.	 Any natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person’s
spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year; 

  

	 	7.	 Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is
directed by a sophisticated person as described in Rule 506(b)(2)(ii) and 

  

	 	8.	 Any entity in which all of the equity owners are accredited investors. 

 

 B-2 

 EXHIBIT C 

SYSTEM MILESTONES 

The Systems Milestones are as follows: 
  

	1.	 The Company will successfully develop and demonstrate, in the brain of an animal or cadaver placed within an MRI machine, a fully functional probe
meeting the System Requirements as demonstrated to Bionics’ reasonable satisfaction by [***]. 

  

	2.	 The Company will successfully acquire or develop, and demonstrate, in an MRI machine, a fully functional prototype of a frameless head mount meeting
the System Requirements as demonstrated to Bionics’ reasonable satisfaction by [***]. If the Company acquires the prototype from a third party, Bionics must have reached a manufacturing supply agreement with the third party by [***] in order
for this System Milestone to be considered achieved. Alternatively, Bionics may provide written notice to the Company that this System Milestone is achieved even without a manufacturing supply agreement with the third party.

  

	3.	 The Company will successfully develop and demonstrate in an MRI machine a fully functional cannula that is compatible and integrated with the
frameless head mount and the probe and that meets the System Requirements as demonstrated to Bionics’ reasonable satisfaction by [***]. 

  

	4.	 The Company will successfully develop and demonstrate the entire System in a sterile environment within an MRI machine meeting the System
Requirements as demonstrated to Bionics’ reasonable satisfaction and in accordance with all applicable laws, regulations, and industry standards relevant to a sterile MRI DBS environment by [***]. 

 

	5.	 The Company will successfully develop and demonstrate, in the brain of an animal or cadaver placed within an MRI machine, a fully functional
prototype of the entire System meeting the System Requirements as demonstrated to Bionics’ reasonable satisfaction by [***]. 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 
  

 C-1 

 EXHIBIT D 

TECHNOLOGY LICENSE AGREEMENT 

Begins on the following page 
  

 D-1 

 TECHNOLOGY LICENSE AGREEMENT 

THIS AGREEMENT (“Agreement”) is made effective as of December 30, 2005 (the “Effective Date”) and entered into
by and between Surgi-Vision, Inc., a Delaware corporation (“Licensor”) and Advanced Bionics Corporation (“Licensee”) (individually, a “Party” and collectively, the “Parties”). 

BACKGROUND 

The Parties have entered into a Lead System and Lead Development and Transfer Agreement (the “Development Agreement”) and other
agreements (“Other Agreements”) referenced therein concurrent with this Agreement wherein the Parties have agreed to develop technology relating to a neuromodulation or deep brain stimulation lead that may be safely reside within a patient
who is placed within a magnetic resonance (“MR”) machine (“Lead”). 
 Licensor is the sole owner and
exclusive licensee of certain confidential and proprietary technology relating to the Lead (“Existing Technology”). 

Licensor desires to have the Existing Licensed Technology further developed and commercialized (the “Future Technology”) and is
willing to grant a license to any Future Technology to which Licensor has any right or interest in exchange for the cooperation and other forms of consideration of Licensee set forth in the Other Agreements and set forth as royalty payments in this
Agreement. 
 Licensee desires to acquire an exclusive license under the Licensed Technology (defined below). 

AGREEMENT 

The Parties agree as follows: 

1.  DEFINITIONS. 

A.        “Affiliate” of a person or entity is a person or entity controlling,
controlled by or under common control with the person or entity specified, directly or indirectly by any means whatsoever. “Controlling”, “controlled” or “control” means owning greater than 50% of the voting equity
interests of a person or entity, either directly or indirectly through other entities in which it has such an interest, or otherwise having the power to direct the management of that person or entity. 

B.        The “Existing Technology” and the “Future Technology” are referred
to collectively as the “Licensed Technology” and include without limitation all intellectual property such as patents, trademarks, service marks, trade names, copyrights, know-how, trade secrets, licenses, information and proprietary
rights and processes owned by or licensed to Licensor relating in any way to a neuro-related lead, neuro-related lead extension, neuro-related lead-type device, or the “Lead”, “Lead Requirements”, or “Lead Milestones”
defined in the Development Agreement, including without limitation the intellectual property licensed to the Licensor under 
  

 Page 1 of 6 

 
the License Agreement by and between the Licensor and the Johns Hopkins University (“JHU”) on or around June 30, 1998 and all other appendices, addenda, amendments, and agreements
related thereto (the “JHU Agreement”). 
 C.        “Licensed
Product” means any neuro-related lead, neuro-related lead extension, any other neuro-related lead-type device, or any product related to a neuro-related lead, in each case which incorporates the Licensed Technology. 

D.        “Net Sales” means the total monetary consideration actually received by
Licensee for Licensed Products sold, less any sales person’s commissions payable in good faith to non-related third parties, royalties and other similar fees payable in good faith to non-related third parties, trade discounts allowances for
conversions and exchanges, returns, freight, insurance and taxes (other than income taxes). For purposes of this definition, Licensed Products will be considered “sold” when Licensee receives payment either from the purchaser or, in the
case of Licensed Products sold by a sublicensee, from such sublicensee. 

E.        “Sublicensee” means any sublicensee(s) of the rights granted to Licensee
under this Agreement. 
 2.     LICENSE. Licensor hereby grants to Licensee and its Affiliates, upon and
subject to all the terms and conditions of this Agreement, an exclusive, transferable (including without limitation sublicensable), worldwide, perpetual license under the Licensed Technology, to make, use, import, lease, and sell the Licensed
Products for the term of this Agreement. For the avoidance of doubt, the license grant of this Agreement includes without limitation an exclusive, transferable (including without limitation sublicensable), worldwide sublicense of all intellectual
property licensed to Licensor under the JHU Agreement (to the extent it is Licensed Technology) to make, use, import, lease, and sell the Licensed Products, which sublicense Licensee acknowledges and agrees is subject to the terms of the JHU
Agreement. Licensor grants Licensee the right to adapt the Licensed Technology to a commercial form suitable for incorporation into Licensee’s product(s). 

3.        COMPENSATION AND AUDIT. 

A.        In consideration for the license granted hereunder, Licensee agrees to pay to Licensor
the royalty payments recited in Exhibit A based on Licensee’s Net Sales of Licensed Products (less accessories or other components or products used in combination with the Licensed Products). 

B.        Only one royalty will be paid hereunder for each Licensed Product whether such Licensed
Product is covered by more than one (1) claim of a licensed patent, by the claims of more than one (1) of the licensed patents, or by the claims of patent of more than one country. 

C.        The royalty owed Licensor will be calculated on an annual calendar basis and will be
payable as indicated in Exhibit A. 
 D.        Licensor will have the right, upon
reasonable notice and reasonable request at Licensor’s sole expense, to inspect Licensee’s relevant books and records and all other documents and material in Licensee’s possession or control with respect to ascertaining the royalty
payments due. 
  

 Page 2 of 6 

 4.    INDEMNITY. Licensor agrees to defend, indemnity and hold Licensee
and its officers, directors, agents, Sublicensees, employees, and customers, harmless against all costs, expenses, and losses (including reasonable attorney fees and costs) incurred as a result of any claim that the Licensed Technology infringes or
misappropriates any third party’s intellectual property. Licensee will deliver written notice of a claim for indemnification with reasonable promptness to Licensor, which notice will describe in reasonable detail the nature of the claim.
However, any failure to timely give that notice will not relieve Licensor of any of its indemnification obligations under this Agreement. Licensor has the right, subject t Licensee’s consent (“Approval”), to participate in and control
the defense of the claim with counsel of its choice. Licensee will have the right to employ separate counsel in any action and to participate in the defense of that action, but the fees and expenses of that counsel will be at the sole expense of the
Licensee unless (i) Licensor, upon or after Approval, failed to assume the defense and diligently prosecute or settle the claim, or (ii) in the reasonable judgment of counsel retained by Licensor to represent Licensor, there exists or
develops a conflict that would ethically prohibit counsel to Licensor from representing Licensee. If requested by Licensor upon or after Approval, Licensee will cooperate with Licensor and its counsel in contesting any claim that Licensor elects to
contest, including, without limitation, by making any counterclaim against the person or entity asserting the claim or any cross-complaint against any person or entity, in each case only to the extent that any counterclaim or cross-complaint arises
from the same actions or facts giving rise to the claim. Licensee will be the sole judge of the acceptability of any compromise or settlement of any claim, litigation, or proceeding in respect of which indemnity may be sought under this Agreement.
Licensor will not enter into any settlement or compromise of any claim without Licensee’s consent. 

5.        COOPERATION. Both Parties will further cooperate to ensure that both Parties enjoy the
benefits of all licenses granted under this Agreement. 
 6.    NOTICE AND PAYMENT. All
notices, requests, demands, payments, and other communications which are required to be or may be given under this Agreement to a Party by the other Party must be in writing and will be deemed to have been duly given (a) immediately if
delivered in person, (b) the day following dispatch by a nationally recognized overnight courier service (such as Federal Express or UPS, etc.) for next day delivery, (c) five days after dispatch by certified or registered first class
mail, postage prepaid, return receipt requested, to the Party to whom the same is so given or made, or (d) upon confirmation of receipt, if by facsimile. Any notice or other communication given hereunder will be addressed to the Licensor, at
200 N. Cobb Parkway, Suite 140, Marietta, GA 30062-3585, Attention: John C. Thomas, Jr., Fax (770) 424- 8236, , with a copy to Kimble L. Jenkins, 50 North Front St.,
19th Floor, Memphis, TN 38103, Fax (901) 579-4979, or
to the Licensee, at 25129 Rye Canyon Loop, Valencia, CA 91355, Attention: General Counsel, Fax (661) 362-4712. 

7.    GOVERNING LAW. This Agreement will be governed by and construed in accordance with the laws of the State of
California. The Parties hereby agree that any dispute which may arise between them arising out of or in connection with this Agreement will be adjudicated before a court 

 

 Page 3 of 6 

 
located in Los Angeles, California and they hereby submit to the exclusive jurisdiction of the courts of the State of California located in Los Angeles, California and of the federal courts in
the Central District of California with respect to any action or legal proceeding commenced by any Party, and irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding brought in such a
court or respecting the fact that such court is an inconvenient forum, relating to or arising out of this Agreement or any acts or omissions relating to the sale of the securities hereunder, and consent to the service of process in any such action
or legal proceeding by means of registered or certified mail, return receipt requested, in care of the address set forth below or such other address as the undersigned will furnish in writing to the other. 

8.    AGREEMENT BINDING ON SUCCESSORS. The provisions of this Agreement will be binding upon and will inure to
the benefit of the Parties, their heirs, administrators, successors, and assigns. 
 9.    ASSIGNABILITY.
Neither Party may assign this Agreement or the rights and obligations thereunder to any third party without prior express written approval of the other Party, which consent will not be unreasonably withheld. 

10.    WAIVER. No waiver by either Party of any default will be deemed as a waiver of any prior or subsequent default
of the same of other provisions of this Agreement. 
 11.    SEVERABILITY. If any term, clause, or provision
herein is held invalid or unenforceable by a court of competent jurisdiction, such invalidity will not affect the validity or operation of any other term, clause or provision, and such invalid term, clause or provision will be deemed to be severed
from this Agreement. 
 12.    INTEGRATION; AMENDMENT. Aside from the Development Agreement and the Other
Agreements, this Agreement constitutes the entire understanding of the Parties, and revokes and supersedes all prior agreements between the Parties and is intended as a final expression of their agreement. It will not be modified or amended except
in writing signed by the Parties and specifically referring to this Agreement. 
 13. COUNTERPARTS. This Agreement may be executed
and delivered in one or more counterparts each of which when executed will be deemed an original, but all of which taken together will constitute one and the same agreement. 

 

 Page 4 of 6 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound
hereby, have each caused to be affixed hereto its or his/her hand the day indicated. 
  

									
	 SURGI-VISON, INC.
	 		 	 ADVANCED BIONICS CORPORATION

					
	 By:
	 		 		 	 By:
	 	
	  
	 		 	  

	 Signature
	 		 		 	 Signature
	 	
	  
	 		 	  

	 Printed Name
	 		 	 Printed Name
	 	
	  
	 		 	  

	 Title
	 		 		 	 Title
	 	

  

 Page 5 of 6 

 EXHIBIT A 

Royalty Rate for Licensed Technology, 

Royalty payments under this Agreement will be as follows: 

(1) If Licensee incorporates Licensed Technology into a deep brain stimulation lead (“Licensed DBS Lead”), Licensee will pay
Licensor an 8% royalty of Net Sales for all Licensed DBS Leads sold commercially after FDA approval, for so long as such Licensed DBS Leads incorporate technology that is claimed by at least one non-expired, non-abandoned, valid and enforceable
Patent included in the Licensed Technology, with a minimum royalty payment of [***] per year in each of the first three years in which Licensee sells the Licensed DBS Leads. 

(2) Alternatively, if Licensee incorporates Licensed Technology into a DBS implantable pulse generator (“Licensed DBS IPG”) in
order to have a system that is MR safe along with the Licensed DBS Lead, Licensee will pay Licensor a 2% royalty of Net Sales for all Licensed DBS Leads and all Licensed DBS IPGs sold commercially after FDA approval, for so long as such Licensed DBS
Leads and Licensed DBS IPGs incorporate technology that is claimed by at least one non-expired, non-abandoned, valid and enforceable Patent included in the Licensed Technology, with a minimum royalty payment of [***] per year in each of the first
three years in which Licensee sells the Licensed DBS Leads and Licensed DBS IPGs. 
 (3) If Licensee incorporates Licensed
Technology into any lead-related, non-IPG, product other than a Licensed DBS Lead or Licensed DBS IPG (“Other Licensed Products”), Licensee will pay Licensor a 4% royalty of Net Sales for all Other Licensed Products sold commercially after
FDA approval, for so long as such Other Licensed Products incorporate technology that is claimed by at least one non- expired, non-abandoned, valid and enforceable Patent included in the Licensed Technology. 

(4) If Licensee incorporates Licensed Technology into a non-DBS implantable pulse generator (“Licensed Non-DBS IPG”) in order
to have a system to sell along with Other Licensed Products, Licensee will pay Licensor a 2% royalty of Net Sales for all Licensed Non-DBS IPGs and all associated Other Licensed Products sold commercially after FDA approval, for so long as such
Licensed Non-DBS Leads and Other Licensed Products incorporate technology that is claimed by at least one non-expired, non-abandoned, valid and enforceable Patent included in the Licensed Technology. 

For purposes of this EXHIBIT A, the term “Patent” includes existing and future patents with any and all issued and non-expired
reissuances, continuations, continuations-in-part, revisions, extensions and re-examinations thereof, but does not include trade secrets or other proprietary technologies that are not expressly claimed by any patent included within the definition of
“Patent”. 
 [***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment. 
  

 Page 6 of 6 

 EXHIBIT 4.5 

FINANCIAL STATEMENTS 

Begins on the following page 
  

 Exhibit 4.5 -1 

 Surgi-Vision, Inc. 

Balance Sheet 

As of September 30, 2005 
  

			
	 ASSETS
	  	
	 Current Assets
	  	
	 Cash
	  	73,185.57   
	 Inventory
	  	24,780.00   
	 Total Current Assets
	  	97,965.57   
	 Property, net of depreciation
	  	13,750.00   
	 Other Assets
	  	
	 Prepaid Consulting Fees
	  	74,913.34   
		  	 
	 Total Other Assets
	  	74,913.34   
		  	 
	 TOTAL ASSETS
	  	186,628.91   
		  	 
	 LIABILITIES & EQUITY
	  	
	 Liabilities
	  	
	 Accounts Payable
	  	24,569.85   
	 Payables to Affiliates and Accrued Salaries
	  	728,891.48   
	 Payable to Attorneys
	  	250,772.34   
	 Note Payable and Accrued Interest - 2 Yr Note to Trust One Bank
	  	578,888.89   
	 Convertible Notes
	  	250,000.00   
		  	 
	 Total Liabilities
	  	1,833,122.56   
		  	 
	 Equity
	  	
	 Additional Paid in Capital
	  	22,427,782.29   
	 Common Stock
	  	178,332.75   
	 Retained Earnings
	  	        (24,252,608.69)  
		  	 
	 Total Equity
	  	(1,646,493.65)  
		  	 
	 TOTAL LIABILITIES & EQUITY
	  	186,628.91   
		  	 

 (Unaudited – For Management Purposes Only)

 Surgi-Vision, Inc. 

Statement of Operations 

For the Nine Months Ended September 30, 2005 
  

			
	 Ordinary Income/Expense
	  	
	 Expense
	  	
	 Corporate Personnel Costs
	  	181,905.95 
	 Depreciation
	  	3,750.00 
	 Interest Expense
	  	44,546.56 
	 Other General & Administrative
	  	198,790.01 
	 Research & Development
	  	191,671.01 
	 Sales, Marketing & Promotion
	  	995.00 
	 Travel & Entertainment
	  	                        77,474.74 

		  	 
	 Total Expense
	  	699,133.27 
		  	 
	 Net Loss
	  	(699,133.27)
		  	 

 (Unaudited – for Management Purposes Only)

 Surgi-Vision, Inc. 

Balance Sheet 

December 31, 2004 
  

				
	 ASSETS
	  		
	 Current Assets
	  		
	 Cash
	  	$	155,541,26 
		  	 	 
	 Total Current Assets
	  	 	155,541.26 
	 Fixed Assets
	  		
	 Machinery & Equipment
	  	 	25,000.00 
	 Accumulated Depreciation
	  	 	-7,500.00 
		  	 	 
	 Total Fixed Assets
	  	 	17,500.00 
	 Other Assets
	  		
	 Prepaid Consulting Fees
	  	 	117,052.08 
		  	 	 
	 Total Other Assets
	  	 	117,052.08 
		  	 	 
	 TOTAL ASSETS
	  	$	290,093.34 
		  	 	 
	 LIABILITIES & EQUITY
	  		
	 Liabilities
	  		
	 Current Liabilities
	  		
	 Accounts Payable
	  	$	197,098.51 
	 Accrued Liabilities
	  	 	67,977.13 
	 Note Payable to ARE
	  	 	301,308.71 
	 Current Portion of Note Payable to GE
	  	 	444,444.44 
	 Payroll Liabilities
	  	 	245.00 
		  	 	 
	 Total Current Liabilities
	  	 	1,011,073.79 
	 Long Term Liabilities
	  		
	 Note Payable to GE
	  	 	222,222.34 
		  	 	 
	 Total Long Term Liabilities
	  	 	222,222.34 
		  	 	 
	 Total Liabilities
	  	 	1,233,296.13 
	 Equity
	  		
	 Additional Paid in Capital
	  	 	22,427,782.29 
	 Common Stock
	  	 	178,332.75 
	 Retained Earnings
	  	 	    -23,549,317.83 
		  	 	 
	 Total Equity
	  	 	-943,202.79 
		  	 	 
	 TOTAL LIABILITIES & EQUITY
	  	$	290.093.34 
		  	 	 

Confidential                    (Unaudited)

 Surgi-Vision, Inc. 

Statement of Operations 

For the Year Ended December 31, 2004 
  

				
	 Ordinary Income/Expense
	  		
	 Income
	  		
	 Sales of Coils
	  	  $	27,050.00 
		  	 	 
	 Total Income
	  	 	27,050.00 
		  	 	 
	 Gross Profit
	  	 	27,050.00 
	    Expense
	  		
	 Corporate Personnel Costs
	  	 	9,926.50 
	 Depreciation
	  	 	5,000.00 
	 Interest Expense
	  	 	37,235.92 
	 Occupancy Costs
	  	 	3,472.12 
	 Other General & Administrative
	  	 	138,125.82 
	 Payroll Expenses
	  	 	75,056.00 
	 Professional Fees
	  	 	268,422.58 
	 Research & Development
	  	 	554,943.61 
	 Sales, Marketing & Promotion
	  	 	336.80 
	 Settlement Costs - Sokolov
	  	 	36,300.00 
	 Travel & Entertainment
	  	 	97,666.86 
		  	 	 
	 Total Expense
	  	 	1,226,486.21 
		  	 	 
	 Net Ordinary Income
	  	 	-1,199,436.21 
	 Other Income/Expense
	  		
	   Other Expense
	  		
	 Allocated Corp Overhead
	  	 	196,139.79 
		  	 	 
	 Total Other Expense
	  	 	196,139.79 
		  	 	 
	 Net Other Income
	  	 	-196,139.79 
		  	 	 
	 Net Income
	  	  $	    (1,395,576.00)
		  	 	 

Confidential                       
                         (Unaudited) 

 Execution Version 

AMENDMENT #1 TO THE SYSTEM AND LEAD 

DEVELOPMENT AND TRANSFER AGREEMENT BETWEEN 

SURGI-VISION, INC. 

AND 

ADVANCED BIONICS® CORPORATION 

This is an amendment (“Amendment”) to the System and Lead Development and Transfer Agreement (“Agreement”), which Agreement has an
Effective Date of December 30, 2005 (“Agreement”), between SURGI-VISON, INC (“Company”) and ADVANCED BIONICS® CORPORATION. This Amendment #1 is effective on May 31, 2006. 

The parties mutually agree as follows: 
 The
first system milestone in Exhibit C System Milestones in the Agreement shall be stricken: 
 “1. The Company will
successfully develop and demonstrate, in the brain of an animal or cadaver placed within an MRI machine, a fully functional probe meeting the System Requirements as demonstrated to Bionics’ reasonable satisfaction by [***]. 

The following system milestone will replace the strickened original, first system milestone in the Agreement: 

“1. By [***], the Company will accomplish the following: The Company will design and create a working prototype of an internal MRI
probe, consistent with the System Requirements, to be utilized in a 1.5T MRI magnet to guide a DBS lead implantation procedure in humans with Parkinson’s Disease. The size and specifications of the internal MRI probe will be designed[***]. The
Company will perform safety and imaging studies on the working prototype in a phantom, consistent with clinical protocols [***]. 
  

					
	 Agreed to and accepted:
	 		 	
			
	 ADVANCED BIONICS® CORPORATION
	 		 	 SURGI-VISION, INC.

			
	       /s/ Todd Whitehurst

 
	 		 	 /s/ Kim Jenkins

 

	 Todd Whitehurst
	 		 	 Kim Jenkins, President

	 Vice President, Emerging Indications
	 		 	

 [***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and
Exchange Commission pursuant to a request for confidential treatment. 

 OMNIBUS AMENDMENT 

TO SYSTEM AND LEAD DEVELOPMENT AND TRANSFER AGREEMENT 

This OMNIBUS AMENDMENT (this “Amendment”) is dated as of June 30, 2007 and entered into by
and between Surgi-Vision, Inc., a Delaware corporation (the “Company”) and Advanced Bionics Corporation, a Delaware corporation (“Bionics”), and is made with reference to (i) that certain System and Lead
Development and Transfer Agreement dated as of December 30, 2005, as amended by that certain Amendment No. 1 dated as of May 31, 2006 (as so amended, supplemented or otherwise modified from time to time, the “Development
Agreement”), by and between the Company and Bionics, (ii) that certain Multiple Advance Secured Convertible Promissory Note dated as of December 30, 2005 made by the Company and payable to Bionics (as amended, restated,
supplemented or otherwise modified from time to time, the “Note”), (iii) that certain License Agreement dated as of December 30, 2005 between the Company and Bionics (as amended, supplemented, or otherwise modified from
time to time, the “License Agreement”), and (iv) that certain Security Agreement dated as of December 30, 2005 by and between the Company and Bionics (as amended, supplemented, or otherwise modified from time to time, the
“Security Agreement”). 
 RECITALS 

WHEREAS, the Company and Bionics desire to (i) amend the Development Agreement to revise the System
Milestones and the Lead Milestones (as those terms are defined in the Development Agreement) and (ii) make certain other amendments as set forth below: 

NOW, THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained,
the parties hereto agree as follows: 
 Section 1.
AMENDMENTS TO THE DEVELOPMENT AGREEMENT 
  

	1.1	 Defined Terms. 

Capitalized terms used in Section 1 of this Amendment without definition shall have the same meanings in
Section 1 as set forth in the Development Agreement. 
  

	1.2	 Amendment to the Background 

The third paragraph of the Background is hereby amended by deleting it therefrom in its entirety and substituting the
following therefor: 
 “The Company desires to develop for Bionics certain technology (the
“Technology”) solely within the field of neuromodulation including, without limitation, a magnetic resonance (“MR”) compatible, MR-safe, and MR-optimized Deep Brain Stimulation (“DBS”) implant
system (the “System”) and MR-compatible, MR-safe, and MR-optimized lead that may safely reside within a patient who is placed within an MR-machine (the “Lead”).” 

	1.3	 Amendment to Section 1: Issuance of Note 

Section 1 of the Development Agreement is hereby amended by deleting the references to “December 31, 2006”
and “March 31, 2007” contained therein and substituting “Amendment Effective Date (as defined in the Omnibus Amendment between the Parties dated as of June 30, 2007)” therefor. 

 

	1.4	 Amendment to Section : Representations and Warranties of the Company 

Section 4.8 of the Development Agreement is hereby amended by adding the following sentence at the end thereof:

 “From and after June 30, 2007, the definition of the Existing Intellectual Property shall include
that certain License Agreement by and between the Company and JHU entered into on or around December 7, 2006, and all other appendices, addenda, amendments, and agreements related thereto (“Second JHU Agreement”, and together
with the JHU Agreement, the “JHU Agreements”).” 
  

	1.5	 Amendment to Section 7: Company Covenants 

A.          Section 7.6 of the Development Agreement is hereby
amended by deleting a reference to “JHU Agreement” contained therein and substituting “JHU Agreements” therefor. 

B.          Section 7.6 of the Development Agreement is hereby
further amended by adding the following sentences at the end thereof: 
 “Notwithstanding anything to the
contrary contained herein. Future Intellectual Property shall not include any Future Intellectual Property relating to the System (and not relating in any way to the Lead) in development of which Bionics has not contributed to the conception or
design. In case of doubt, Bionics will make a determination in its sole discretion as to whether any Future Intellectual Property should be categorized as relating to the System or the Lead and whether Bionics contributed to the conception or design
of any Future Intellectual Property relating to the System.” 
  

 2 

	1.6	 Amendments to Section 8: General Provisions 

A.          Section 8.9 of the Development Agreement is hereby
amended by deleting the phrase “This Agreement, the Note, the Security Agreement, and the Other Agreements” contained therein and substituting “This Agreement and the Concurrent Agreements” therefor. 

B.          Section 8.11 of the Development Agreement is hereby
amended by deleting all references to “Loan Agreement” contained therein and substituting “Agreement” therefor. 
  

	1.7	 Amendments to Section 9: System Development License, and Right of First Refusal 

Section 9.2 of the Development Agreement is hereby amended by deleting all references to “JHU Agreement”
contained therein and substituting “JHU Agreements” therefor, 
  

	1.8	 Amendments to Section 10: Lead Development and License 

A.          Section 10.1 of the Development Agreement is hereby
amended by deleting the first paragraph therefrom in its entirety and substituting the following therefor: 

“10.1 Lead Development. Working together with Bionics and subject to Section 10.1(c), the Company will
provide Bionics with a fully functional prototype of the Lead and demonstrate the proper functionality of the prototype of the Lead to Bionics in an MRI phantom, animal or cadaver placed within an MRI machine. The Lead prototype must meet the
following objectives (the “Lead Requirements”): [***] 

B.          Section 10.1 of the Development Agreement is hereby
further amended by deleting subsection (b) therefrom in its entirety and substituting the following therefor: 

“(b)    Lead Milestones: 

 

	 	(i)	 On or before [***], the Company will present to Bionics a prototype Lead body that incorporates the Company’s most promising MR/RF safe Lead
design. Such prototype Lead body will contain[***]. 

  

	 	(ii)	 The Company shall provide consulting and advisory services (including, without limitation, testing and analyzing of the Lead feasibility models and
prototypes) to Bionics, for a period of 12 months from the Amendment Effective Date, in connection with Bionics’ effort to develop a [***] that 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 
  

 3 

 meets the [***] requirements that will be necessary for a final product.
The Company will make one full-time equivalent employee or consultant available to Bionics during the twelve-month period to provide the consulting and advisory services as requested by Bionics. Specifically, such full-time employee, if not
otherwise engaged in other activities for Bionics, shall work on the development of a new generation of a Lead design (as further defined in Section 10.3) in the case the existing Lead designs do not prove to be manufacturable. As compensation for
the consulting services provided pursuant to this clause (ii), Bionics shall pay the Company the amount of $125,000 on the Amendment Effective Date. Any Intellectual Property conceived or developed by the Company pursuant to such consulting
arrangement shall be subject to the terms of this Agreement. The Company also agrees to use its best efforts to make [***] available for such consulting arrangement for up to 20 hours per quarter collectively. Bionics shall reimburse the Company for
all reasonable, documented out-of-pocket expenses incurred by the Company relating to its consulting arrangement with Bionics. The Company shall be deemed to have achieved and completed the milestone set forth in this clause (ii) upon the expiration
of the twelve-month consulting period. 
  

	 	(iii)	 Bionics will pay the Company $100,000 after Bionics has successfully completed the first live chronic human implantation of the Lead meeting the
Lead Requirements as demonstrated to Bionics’ reasonable satisfaction. 

  

	 	(iv)	 Bionics will pay the Company $1,000,000 after Bionics has successfully received FDA approval of MRI-safe labeling of the first Lead meeting the Lead
Requirements as demonstrated to Bionics’ reasonable satisfaction. 

  

	 	(v)	 Bionics will pay the Company $500,000 after Bionics has successfully received FDA approval of MRI-safe labeling of the second Lead meeting the Lead
Requirements as demonstrated to Bionics’ reasonable satisfaction, which $500,000 shall be a prepayment of the future royalty payments by Bionics to the Company solely related to the sale of such second Lead under the License Agreement.

  

	 	(vi)	 The milestones described in the preceding clauses (i) through (v) shall constitute the “Lead Milestones.”

 C. Section 10.1 of the Development Agreement is hereby further amended by deleting the
first sentence contained in subsection (c) thereof and substituting the following in lieu thereof: 

“In the event (i) the Company fails to complete each of the Lead Milestones, other than the Lead Milestone
described in Section 10.1(b)(v) above, by December 31, 2012 and (ii) such failure is not the result of Bionics’ failure to reasonably cooperate with the Company in pursuing such Lead Milestones, the Company will be in breach of
this Agreement.” 
 [***] Indicates portions of this exhibit that have been omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential treatment. 
  

 4 

 D.        Section 10 of the
Development Agreement is hereby amended by adding the following Section 10.3: 
 “10.3 Incentive
Payments. For each new generation of a Lead design, Bionics shall pay the Company incentive payments as indicated below. The determination of whether a change in Lead design represents an incremental change or a new generation of design will be
decided by Bionics in its sole discretion. Minor changes in design are not a new generation. Substantial changes in design represent a new generation. Different numbers of conductors (e.g., 4-conductor versus 8-conductor) represent different
generations. 
  

	 	(i)	 Bionics shall pay the Company the amount of $75,000 when the Company delivers each new generation (as determined by Bionics in its sole discretion)
of a Lead design with at least 3 crude prototypes and supporting test data evaluating heating in a 1.5 Tesla MRI scanner; provided that during the term of this Agreement Bionics shall not pay more than $250,000 in the aggregate pursuant to
this Section 10.3(a). Each payment shall be payable when the Company presents the prototypes and a positive summary report of the testing to Bionics to the reasonable satisfaction of Bionics. [***]. Notwithstanding the foregoing to the contrary, a
$100,000 payment will be made to the Company if and when it presents the first [***] as reasonably specified by Bionics and agreed to by the Company and supporting data evaluating in a 1.5 Tesla MRI scanner. 

 

	 	(ii)	 No later than ninety days after Bionics delivers to the Company at least 10 (or, at Bionics” discretion at least 5) pre-production Lead
prototypes of each new generation [***] to evaluate heating in a 1.5 Tesla MRI scanner, the Company shall complete the testing of such prototypes and present Bionics with a summary report of the testing, in each case to Bionics’ reasonable
satisfaction. [***]. Bionics shall pay the Company the amount of $50,000 when the Company tests and submits a report, pursuant to this subsection, each new generation of a Lead design with at least 10 (or, at Bionics’ discretion at least 5)
pre-production Lead prototypes provided by Bionics to evaluate heating in a 1.5 Tesla MRI scanner. This sum shall be payable when the Company presents a summary report of the testing to Bionics to the reasonable satisfaction of Bionics.
Notwithstanding the foregoing to the contrary, Bionics will pay a sum of $75,000 for completion of the testing of the first [***]. 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 
  

 5 

	 	(iii)	 No later than ninety days after Bionics delivers to the Company at least 10 final product Leads of each new generation, the Company shall complete
the testing of such Leads to evaluate heating in a 1.5 Tesla MRI scanner, present Bionics with a report of testing, and assist Bionics with the preparation of a report for the FDA that includes in-depth discussion of physics underlying principles of
operation of MRI safety of the Lead for the purpose of seeking MRI-safe labeling for the final product Lead, in each case to Bionics’ reasonable satisfaction. Bionics shall pay the Company the amount of $75,000 when the Company presents a
report of the testing to Bionics to the reasonable satisfaction of Bionics. Final product Leads shall meet [***]. 

  

	1.9	 Amendments to Section 11: Intellectual Property Ownership and Protection 

A.          Section 11.1 (a) of the Development Agreement is
hereby amended by deleting clause (v) therein. 

B.          Section 11.2 of the Development Agreement is hereby
amended by deleting paragraph (a) in its entirety and substituting the following therefor: 
 “(a)
Costs. Bionics will pay all foreign and domestic Patent and Application (as such terms are defined below) prosecution costs and expenses for all Patents and Applications subject to its control as set forth in Section 11.2(b)
(“Prosecution Costs”).” 

C.          Section 11.2 of the Development Agreement is hereby
amended by (1) deleting all references to “JHU Agreement” contained in subsection (b) thereof and substituting “JHU Agreements” therefor, and (2) adding the following sentence at the end of subsection (b):

 “The term “Patent” means a currently issued U.S. or foreign patent. The term
“Application” means a U.S., PCT or foreign patent application, including provisionals, utilities, designs, national stage filings and any continuations, divisionals, extensions, reissues, reexaminations, continuations in part
thereof.” 
 D.          Section 11.3 of the
Development Agreement is hereby amended by deleting such Section in its entirety and substituting the following in lieu therefor: 

“11.3 Warranty Regarding Third Party Collaborators. The Parties warrant that all individuals, including
without limitation employees and consultants, authorized, invited, or otherwise involved by the Parties, their employees, or consultants, to assist in the development of the System or Lead, have or will have a legal obligation to assign, license, or
grant an option to license to the relevant Party all their rights to any Intellectual Property related to, arising from, or based on the development of the System or Lead.” 

E.          Section 11.4 of the Development Agreement is hereby
amended by deleting all references to “JHU Agreement” contained therein and substituting “JHU Agreements” therefor. 
 [***]
Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 

 6 

 F. Section 11.6 of the Development Agreement is hereby amended by
adding the following at the end of paragraph (d): 
 “In addition, notwithstanding the foregoing, Bionics
acknowledges and agrees that (i) the Company is permitted to share its Lead information with third parties to develop products for cardiac applications (provided, however, that if such third party is also engaged in the business of developing
products for neurological applications, the Company shall ensure that such third party will use the Lead information only in connection with cardiac applications and will not use the Lead information for or with respect to any neuro-related
products), (ii) the Company is permitted to share its System information with third parties following the expiration of the Exclusivity Period if the Parties do not execute and deliver the Subsequent System License within the Exclusivity
Period, and (iii) in connection with the disclosures contemplated in the preceding clauses (i) and (ii), the Company is permitted to disclose the existence of this Agreement and the scope of any license granted hereunder or pursuant to the
License Agreement.” 
  

	1.10	 Amendments to Exhibit C: System Milestones 

Exhibit C to the Development Agreement is hereby amended by (1) deleting the reference to [***] contained therein and
substituting [***] therefor, and (2) deleting the reference to [***] and substituting [***] therefor. 

Section
2.        AMENDMENTS TO THE NOTE 

Bionics and the Company hereby agree to the amendments to the Note that are reflected in the form of the Amended and
Restated Multiple Advance Secured Convertible Promissory Note attached hereto as Exhibit A (the “Amended Note”). 

Section  3.  AMENDMENT TO THE LICENSE AGREEMENT
 
  

	3.1	 Defined Terms 

Capitalized terms used in Section 3 of this Amendment without definition shall have the same meanings in
Section 3 as set forth in the License Agreement, 
  

	3.2	 Amendment to Section 1: Definitions 

Section 1 of the License Agreement is hereby amended by adding the following phrase at the end of paragraph B:

 “and under the License Agreement by and between the Licensor and JHU entered into on or around
December 7, 2006, and all other appendices, addenda, amendments and agreements related thereto (the “Second JHU Agreement”, and together with the JHU Agreement, the “JHU Agreements”)” 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 
  

 7 

	3.3	 Amendment to Section 2: License 

Section 2 of the License Agreement is hereby amended by deleting all references to “JHU Agreement” and
substituting “JHU Agreements” therefor. 
  

	3.4	 Amendment to Section 3: Compensation and Audit 

Section 3 of the License Agreement is hereby amended by adding the following new paragraph E: 

“E. Licensee agrees that, if required by the JHU Agreements, the packaging containing Licensed Products sold by
Licensee, any of its Affiliates or any of its Sublicensees will be marked with the number of the applicable patent(s) licensed hereunder in accordance with each applicable country’s patent laws.” 

Section 4.        
AMENDMENTS TO THE SECURITY AGREEMENT 
  

	4.1	 Defined Terms 

Capitalized terms used in Section 4 of this Amendment without definition shall have the same meanings in
Section 4 as set forth in the Security Agreement. 
  

	4.2	 Amendments to Section 4: Representations and Warranties 

A.          Section 4 of the Security Agreement is hereby amended
by amending subsection (g) thereof by deleting the second sentence thereof and substituting the following in lieu therefor: 

“Grantor owns, possesses or has legal rights to use all Patents, Trademarks, service marks, trade names, copyrights,
know-how, trade secrets, licenses, information and proprietary rights and processes necessary for the Grantor’s business as now conducted and as proposed to be conducted by the Grantor by developing the System and Lead for commercial
manufacture, use, lease, importation, and sale including, without limitation, the intellectual property licensed to Grantor under the License Agreement by and between Grantor and the Johns Hopkins University (“JHU”) entered into on or
around July 1, 1998 and the License Agreement by and between the Grantor and JHU entered into on or around December 7, 2006, and all other appendices, addenda, amendments, and agreements related thereto (the “JHU Agreements”)
(the owned and licensed rights of Grantor, collectively, the “Intellectual Property”), without any conflict with, or infringement of, the rights of others. 

B.          Section 4 of the Security Agreement is hereby further
amended by amending subsection (g) thereof by adding “Except as set forth on Schedule 10 annexed hereto,” before the fifth sentence. 
  

 8 

	4.3	 Amendments to Section 18: Continuing Security Interest; Termination and Release; Assignment 

Section 18 of the Security Agreement is hereby amended by deleting paragraph (b) thereof in its entirety and
substituting the following therefor: 
 “Provided an Event of Default has not occurred and is continuing,
Secured Party will terminate and release its liens and security interests in all Collateral at the later of (i) payment in full and in cash or conversion in full of the Note Balance on or before July 15, 2008 or (ii) after the Grantor
has achieved the first two Lead Milestones (as defined in the Development Agreement) as stated in Sections 10.1(b)(i) and (ii) of the Development Agreement (the “Collateral Release”). For the avoidance of doubt, if both
conditions (i) and (ii) above have not occurred on or before August 31, 2008, the foregoing termination and release provision and this Section 18(b) shall be null and void and of no force and effect. 

 

	4.4	 Amendment to Schedules to Security Agreement 

Schedule 10 to Security Agreement is hereby deleted in its entirety and replaced with the new Schedule 10 attached as
Exhibit B hereto. 

Section 5.        
CONDITIONS TO EFFECTIVENESS 

Sections 1 through 4 of this Amendment shall become effective only upon the satisfaction of all of the following
conditions precedent (the date of satisfaction of such conditions being referred to herein as the “Amendment Effective Date”): 

A. On or before the Amendment Effective Date, the Company shall deliver to Bionics the following, each, unless otherwise
noted, dated the Amendment Effective Date: 

1.          Executed copy of this Amendment;

 2.          Executed copy of the Amended
Note; 
 3.          Executed consent from JHU
to sublicense to Bionics under the JHU Agreement dated December 7, 2006; 

4.          Certified copies of its Certificate of
Incorporation, together with a good standing certificate from the Secretary of State of the State of Delaware, each dated a recent date prior to the Amendment Effective Date; 

5.          A certificate, dated as of the Amendment
Effective Date, of its corporate secretary or an assistant secretary, certifying that there have been no changes in its Bylaws from the form of Bylaws previously delivered to Bionics; 

6.          Resolutions of its Board of Directors
approving and authorizing the execution, delivery, and performance of this Amendment and the Amended Note, 
  

 9 

 
certified as of the Amendment Effective Date by its corporate secretary or an assistant secretary as being in full force and effect without modification or amendment; 

7.          Signature and incumbency certificates of
its officers executing this Amendment and the Amended Note; and 

8.          All documents necessary to assign to
Bionics all Future Intellectual Property developed from December 30, 2005 and execute all documents necessary to effect that assignment. 

B.          On or before the Amendment Effective Date,
all corporate and other proceedings taken or to be taken in connection with the transactions contemplated hereby and all documents incidental thereto not previously found acceptable by Bionics shall be satisfactory in form and substance to Bionics,
and Bionics shall have received all such counterpart originals or certified copies of such documents Bionics may reasonably request. 

Section 6.    COMPANY’S
REPRESENTATIONS AND WARRANTIES 
 In order
to induce Bionics to enter into this Amendment and effect the amendment in the manner provided herein, the Company represents and warrants to Bionics that the following statements are true, correct and complete as of the Amendment Effective Date:

 A.          Corporate Power and
Authority.      The Company has all requisite corporate power and authority to enter into this Amendment and to carry out the transactions contemplated by, and perform its obligations under, the Development
Agreement, the License Agreement and the Security Agreement, each as amended by this Amendment, and the Amended Note (collectively, the “Amended Documents”). 

B.          Authorization of
Agreements.    The execution and delivery of this Amendment and the Amended Note and the performance of the Amended Documents have been duly authorized by all necessary corporate action on the part of the Company. 

C.          No Conflict.      The
execution and delivery by the Company of this Amendment and the Amended Note and the performance by the Company of the Amended Documents do not and will not (i) violate any provision of the Certificate of Incorporation or Bylaws of the Company,
(ii) violate any provisions of any law or any governmental rule or regulation applicable to the Company or any order, judgment or decree of any court or other agency of government binding on the Company, (iii) conflict with, result in a
breach of or constitute (with due notice or lapse of time or both) a default under any contractual obligation of the Company, (iv) result in or require the creation or imposition of any lien upon any of the properties or assets of the Company
(other than Liens created under any of the Amended Documents in favor of Bionics), or (v) require any approval of the stockholders of the Company, or any approval or consent of any person under any contractual obligation of the Company, which
has not already been obtained. 
 D.          Governmental
Consents.    The Company is not required to obtain any approval, consent or authorization from, or provide any notice to, any federal, state or other 

 

 10 

 
governmental authority or regulatory body as a condition to the execution and delivery of this Amendment and the Amended Note or the performance by the Company of the Amended Documents.

 E.          Binding Obligation. Each of this
Amendment and the Amended Note has been duly executed and delivered by the Company and this Amendment and the Amended Documents are the legally valid and binding obligations of the Company, enforceable against Company in accordance with their
respective terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors’ rights generally or by equitable principles relating to enforceability. 

F.          Incorporation of Representations and Warranties From
Development Agreement.    Except as set forth in Schedule 6.F attached hereto, the representations and warranties contained in Sections 4.7, 4.8 and 4.12 of the Development Agreement are and will be true, correct and complete
in all material respects on and as of the Amendment Effective Date to the same extent as though made on and as of that date, except to the extent such representations and warranties specifically relate to an earlier date, in which case they were
true, correct and complete in all material respects on and as of such earlier date. 
 Section 7.
MISCELLANEOUS 

A.      Reference to and Effect on the Amended Documents. 

(i)           On and after the Amendment Effective Date, each
reference in the Development Agreement to “this Agreement”, “hereunder”, “hereof”, “herein” or words of like import referring to the Development Agreement, and each reference in the Amended Documents to the
“Development Agreement”, “thereunder”, “thereof or words of like import referring to the Development Agreement shall mean and be a reference to the Develop Agreement as amended by this Amendment. 

(ii)          On and after the Amendment Effective Date, each reference
in the Security Agreement to “this Agreement”, “hereunder”, “hereof”, “herein” or words of like import referring to the Security Agreement, and each reference in the Amended Documents to the “Security
Agreement”, “thereunder”, “thereof or words of like import referring to the Security Agreement shall mean and be a reference to the Security Agreement as amended by this Amendment. 

(iii)         On and after the Amendment Effective Date, each reference in
the License Agreement to “this Agreement”, “hereunder”, “hereof”, “herein” or words of like import referring to the License Agreement, and each reference in the Amended Documents to the “License
Agreement”, “thereunder”, “thereof or words of like import referring to the License Agreement shall mean and be a reference to the License Agreement as amended by this Amendment. 

(iv)         On and after the Amendment Effective Date, each reference in
the Amended Documents to the “Note”, “thereunder”, “thereof or words of like import referring to the Note shall mean and be a reference to the Amended Note. 

 

 11 

 (ii)          Except as
specifically amended by this Amendment, the Amended Documents shall remain in full force and effect and are hereby ratified and confirmed. 

(iii)         The execution, delivery and performance of this Amendment
shall not, except as expressly provided herein, constitute a waiver of any provision of, or operate as a waiver of any right, power or remedy of Bionics or the Company under, any of the Amended Documents. 

B.          Headings.    Section and
subsection headings in this Amendment are included herein for convenience of reference only and shall not constitute a part of this Amendment for any other purpose or be given any substantive effect. 

C.          Applicable
Law.      THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF CALIFORNIA (INCLUDING
WITHOUT LIMITATION SECTION 1646.5 OF THE CIVIL CODE OF THE STATE OF CALIFORNIA), WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES. 

D.          Clarification of
Scope.      For the avoidance of any doubt whatsoever, Bionics and the Company acknowledge and agree that the terms “neuromodulation” and “neuro- related” (as used in any of the Amended
Documents) do not include, and in no event does any license granted to Bionics under the Development Agreement or the License Agreement relate to, cardiac applications. 

E.          Counterparts; Effectiveness.  This
Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one
and the same instrument; signature pages may be detached from multiple separate counterparts and attached to a single counterpart so that all signature pages are physically attached to the same document. This Amendment (other than the provisions of
Sections 1 through 4 hereof, the effectiveness of which is governed by Section 5 hereof) shall become effective upon the execution of a counterpart hereof by the Company and Bionics and receipt by the Company and Bionics of written or
telephonic notification of such execution and authorization of delivery thereof. 

F.          Return of Original Note.    On
the Amendment Effective Date, Bionics shall deliver to the Company the original Note for cancellation. 
 [The remainder of page
intentionally left blank.] 
  

 12 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to
be duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above. 
  

			
	BIONICS:
	
	 ADVANCED BIONICS CORPORATION

		
	 By:
	 	  /s/ Jeffrey H. Greiner

 

		 	 Jeffrey H. Greiner
  

Its: President and Co-Chief Executive Officer

	
	COMPANY:
	
	 SURGI-VISION, INC.

		
	 By:
	 	 /s/ Kimble Jenkins

 

		 	 Kimble L. Jenkins
  

Its: President

  

 S-1 

 EXHIBIT A 

TO OMNIBUS AMENDMENT 

[FORM OF AMENDED NOTE] 

THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL (I) A REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OF 1933 (THE “ACT”) HAS BECOME EFFECTIVE WITH RESPECT THERETO OR (II) RECEIPT BY THE COMPANY AT LENDER’S SOLE COST AND EXPENSE OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT
REGISTRATION UNDER THE ACT IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER AND THAT SUCH ISSUANCE IS NOT IN VIOLATION OF ANY APPLICABLE STATE SECURITIES LAWS. THIS LEGEND WILL BE ENDORSED UPON ANY NOTE ISSUED IN EXCHANGE FOR THIS NOTE.

 AMENDED AND RESTATED MULTIPLE ADVANCE 

SECURED CONVERTIBLE PROMISSORY NOTE 
  

			
	Up to $1,500,000	  	June 30, 2007

1.          Principal. For value received, SURGI-VISION,
INC., a Delaware corporation (“Company”), promises to pay to ADVANCED BIONICS CORPORATION, a Delaware corporation (“Lender”), at its office at 25129 Rye Canyon Loop, Valencia, California 91355, or at such
other place as Lender may from time to time designate in writing, the principal sum specified on the Schedule of Advances attached to this Note, together with accrued interest from the date of disbursement on the unpaid principal of this Note
at the rate set forth in Section 3 hereof. Lender hereby authorizes and directs Company to deliver this Note to Lender’s address set forth at the beginning of this Note. Initially capitalized terms used herein without definition are
defined in that certain System and Lead Development and Transfer Agreement dated as of December 30, 2005, as amended by that certain Amendment No. 1 dated as of May 31, 2006 and by that certain Omnibus Amendment dated as of
June 30, 2007 (as so amended, and as further amended, supplemented or otherwise modified from time to time, the “Development Agreement”), by and between Company and Lender. 

2.          Maturity Date. Unless Lender has previously
exercised its Conversion Right (as defined below), the unpaid principal balance of this Note (plus any interest, fees, and other amounts owing under this Note) (collectively, the “Note Balance”) is due and payable in full on the
Maturity Date. The “Maturity Date” is the earliest of (A) the last day of the Negotiation Period or (B) June 30, 2008, regardless of any extensions of the Negotiation Period that Company and Lender may mutually agree
on, or (C) the date of an occurrence of an Event of Default. If the Maturity Date falls on a day that is not a business day, payment of the unpaid 

 

 1 

 
principal of this Note must be made on the next succeeding business day and such extension of time will be included in computing any interest in respect of such payment. 

3.          Interest Rate. 

(a)                This Note bears simple
interest at the rate of 0% per annum on its unpaid principal amount from the Closing Date to five days after the Maturity Date. This Note bears simple interest at the rate of 20% per annum (or the highest rate permitted by law, whichever is
less) (the “Default Rate”) on any unpaid principal balance of this Note from five business days after the Maturity Date until the actual date that the entire Note Balance is satisfied (either by (i) Company paying the entire
Note Balance in cash, (ii) Lender electing in its sole discretion to convert the entire Note Balance into Conversion Shares (as defined below), or (iii) Lender electing in its sole discretion to convert part of the Note Balance into
Conversion Shares and Company paying the entire remaining Note Balance in cash). 

(b)                All payments of
principal and interest due under this Note must be made without deduction of any present and future taxes, levies, imposts, deductions, charges or withholdings, which amounts must be paid by Company. Company will pay the amounts necessary such that
the gross amount of the principal and interest received by Lender is not less than that required by this Note. If Company is required by law to deduct any such amounts from or in respect of any principal or interest payment under this Note, then
(i) the sum payable to Lender will be increased as may be necessary so that after making all required deductions (including deductions applicable to additional sums payable under this provision) Lender receives an amount equal to the sum it
would have received had no deductions been made, (ii) Company will make such deductions, and (iii) Company will pay the full amount deducted to the relevant taxation authority or other authority in accordance with applicable law. Company
will pay all stamp and documentary taxes. If, notwithstanding the foregoing, Lender pays such taxes, Company will reimburse Lender for the amount paid. Company will furnish Lender official tax receipts or other evidence of payment of all taxes.

 (c)                Throughout
the term of this Note, interest will be calculated on the basis of a 360-day year and will be computed for the actual number of days elapsed in the period for which interest is charged. If any payment of interest to be made by Company under this
Note becomes due on a day which is not a business day, such payment must be made on the next succeeding business day and such extension of time will be included in computing the interest due in respect of such payment. 

4.          Conversion. 

(a)               Conversion at
Lender’s Option. At any time beginning on the Maturity Date and ending five business days after Company’s payment in full of the Note Balance, Lender will have the right, in Lender’s sole discretion, to convert this Note, in whole
or in part (the “Conversion Right”) into the number of Conversion Shares obtained by the calculations of Section 4(b)(i) or Section 4(b)(ii), as applicable. If Lender exercises the Conversion Right after Company’s
payment in full of the Note Balance, Lender will return to Company that part of the Note Balance that Lender is electing to convert to Conversion Shares within five business days of Lender’s receipt of Company’s payment in full of the Note
Balance. 
  

 2 

 “Conversion Shares” means the aggregate number of fully
paid and nonassessable shares of the Common Stock of Company, par value $0.01 per share (“Common Stock”) into which Lender has elected to convert all or part of the Note Balance. 

(b)               Pricing Terms.

  

	 	(i)	 Conversion Calculation. Except for the circumstances described in Section 4(b)(ii) below, the number of Conversion Shares will be
determined by dividing (A) the amount of the Note Balance to be converted by (B) the lesser of (1) the 5% Conversion Price (as defined below) or (II) if Company consummates a sale of any of its equity securities after the Closing Date
(for the avoidance of doubt, a “sale” of equity securities will not include equity securities issued pursuant to the acquisition of another entity by Company by merger, purchase of all or substantially all of the assets, or other
reorganization whereby Company becomes the owner of more than 50% of the voting power of such entity, equity securities issued pursuant to the conversion or exercise of any convertible securities, options or warrants, or equity securities (including
derivatives) granted, issued or issuable to employees, officers, directors or consultants pursuant to plans or agreements approved by Company’s board of directors), whether in a single or multiple closings or financings, the average price per
share paid for such securities by the purchasers thereof. The term “5% Conversion Price” means, as of a given date, the price per share determined by dividing $1,500,000 by 5% of Company’s Fully Diluted Shares (as defined
below). The term “Fully Diluted Shares” means, as of a given date, the total number of shares of Common Stock (a) issued and outstanding, (b) issuable upon the exercise of any and all outstanding options, warrants and
rights to acquire shares of Common Stock, or upon the conversion of any and all outstanding securities convertible into shares of Common Stock, whether then vested, exercisable or convertible, and (c) authorized and issuable by the Company
under any stock option or other equity compensation plan approved by the Company’s board of directors other than those shares subject to outstanding options, warrants or other similar rights described in the preceding clause (b).

  

	 	(ii)	 If (a) an Event of Default has occurred and is continuing or (b) the Company, in its sole discretion, prepays all or any portion of the
Note Balance prior to the Maturity Date pursuant to Section 6 hereof or (c) the Company grants the consent pursuant to Section 10(c) hereof, the number of Conversion Shares will be determined by dividing (A) the amount of the
Note Balance to be converted by (B) the lesser of (I) the 10% Conversion Price (as defined below) or (II) if Company consummates a sale of any of its equity securities after the Closing Date (for the avoidance of doubt, a “sale”
of equity securities will not include equity securities issued pursuant to the acquisition of another entity by Company by merger, purchase of all or substantially all of the assets, or other

  

 3 

	 	
reorganization whereby Company becomes the owner of more than 50% of the voting power of such entity, equity securities issued pursuant to the conversion or exercise of any convertible
securities, options or warrants, or equity securities (including derivatives) granted, issued or issuable to employees, officers, directors or consultants pursuant to plans or agreements approved by Company’s board of directors), whether in a
single or multiple closings or financings, the average price per share paid for such securities by the purchasers thereof. The term “10% Conversion Price” means, as of a given date, the price per share determined by dividing
$1,500,000 by 10% of Company’s Fully Diluted Shares. 

  

	 	(iii)	 Warrant. If, upon Lender’s exercise of its Conversion Right pursuant to Section 4(b)(i), Company and Lender have not executed and
delivered the Subsequent System License, in addition to the number of Conversion Shares obtained by the calculation set forth in Section 4(b)(i) above, Lender will receive from the Company a warrant, in substantially the form attached hereto as
Exhibit.A (the “Warrant”), to purchase the number of shares of Common Stock equal to the difference, if positive, between (A) the amount determined by dividing (I) the amount of the Note Balance converted pursuant
to Section 4(b)(i) by (II) the 10% Conversion Price, minus (B) the number of Conversion Shares obtained by the calculation set forth in Section 4(b)(i) above. Such Warrant shall become exercisable if (A) Company and Lender have
not executed and delivered the Subsequent System License on or before the last day of the Negotiation Period or (B) an Event of Default has occurred and is continuing prior to the last day of the Negotiation Period.

  

	 	(iv)	 Full Conversion. Reference in the Development Agreement, this Note and/or any of the other Concurrent Documents to the “conversion of
the Note Balance” or words of like import shall mean and be a reference to Lender’s receipt of (A) the number of Conversion Shares obtained by the calculation set forth in Sections 4(b)(i) or 4(b)(ii), as applicable, and (B) if
applicable, the Warrant, For the avoidance of doubt, reference in the Development Agreement, this Note and/or any of the other Concurrent Documents to the “conversion of the Note Balance” or words of like import shall not mean or include
Lender’s exercise of all or any portion of the Warrant. 

(c)               Conversion Procedure.

  

	 	(i)	 In order to convert all or any part of the Note Balance, Lender will deliver to Company a written notice stating (A) that Lender has elected to
convert all or part of the Note Balance and (B) the amount of the Note Balance to be converted (the “Conversion Notice”). 

  

	 	(ii)	 Within five business days after receipt of the Conversion Notice, Company will deliver to Lender a certificate for the number of Conversion

  

 4 

	 	
Shares issuable upon the conversion; provided that Company will not issue any fractional Conversion Shares. In lieu of Company issuing any fractional shares to Lender or its designees upon
conversion, Company will pay to Lender the unconverted amount of the Note Balance specified in the Conversion Notice, such payment to be in the form of a wire transfer or check payable to Lender. Each conversion will be deemed to have been effected
immediately before the close of business on the date on which this Note is given to the Company pursuant to Section 14 of this Note. Upon conversion of the entire Note Balance, Company will be forever released from all its obligations and
liabilities under this Note. 

(d)               Changes in Common
Stock. If, and as often as, there are any changes in the Common Stock by way of stock split, stock dividend, combination or reclassification, or by any other means, appropriate adjustment will be made by Company and Lender to the price at which
Conversion Shares are issued and the other provisions of this Note, as may be required, so that the rights and privileges granted hereby will continue with respect to the Conversion Shares as so changed. 

(e)               Access and
Information. Subject to the confidentiality provisions in the Development Agreement, Company will afford to Lender and its accountants, counsel and other representatives full access, upon reasonable request, upon reasonable prior notice and
during normal business hours, to all of Company’s properties, books, accounts, records, contracts, and personnel and, Company will, and will cause its accountants, counsel and other representatives to furnish promptly to Lender and its
representatives all information concerning Company’s business, properties and personnel, in each case as Lender or its representatives reasonably requests for the purpose of evaluating the merits and risks of an investment in Conversion Shares
in the event Lender may desire to exercise its Conversion Right; provided, however, that Company reserves the right to withhold any information if access to such information could adversely affect the attorney-client privilege between Company and
its counsel. 

(f)               Conversion Shares.
Until such time as the Conversion Shares are registered under the Securities Act of 1933, Company will instruct its transfer agent to enter stop transfer orders with respect to such shares and the certificates representing such shares will be
endorsed with the following legend: 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE “BLUE SKY” OR SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, HYPOTHECATED, DISTRIBUTED OR OTHERWISE DISPOSED OF UNLESS THERE IS AN EFFECTIVE
REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SALE OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT IS AVAILABLE, AND IF AN EXEMPTION IS AVAILABLE, THE COMPANY RECEIVES AN OPINION OF COUNSEL AT THE HOLDER’S SOLE COST AND EXPENSE STATING
THAT SUCH OFFER, SALE, TRANSFER, ASSIGNMENT, PLEDGE, 
  

 5 

 
HYPOTHECATION, DISTRIBUTION OR OTHER DISPOSITION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT AND OTHER LAWS. THE RESTRICTIONS CONTAINED HEREIN ARE BINDING ON
THE HOLDER HEREOF AND HIS SUCCESSORS AND ASSIGNS,” 

5.          Schedule of Advances. Lender will, and is hereby
authorized by Company to, note on the Schedule of Advances annexed to this Note and constituting a part of this Note, the date and amount of each advance, payment or prepayment of all or any portion of the principal sum. Absent manifest
error, such notations are conclusive and binding as to the aggregate unpaid principal sum and all other information; provided, however, the failure of Lender to make such a notation will not limit or otherwise affect the obligation of Company to
repay the outstanding principal amount or any interest accrued or accruing thereon or any other amount payable by Company to Lender hereunder. 

6.          Prepayment Prior to the Maturity Date, Company, in
its sole discretion, may prepay all or any portion of the Note Balance at any time, provided that (i) Company will give Lender not less than a 30-day prior written notice of its intention to prepay an amount specified in such notice on
the date set forth in the notice, and (ii) notwithstanding any provision hereof to the contrary, Lender will have the right before the anticipated prepayment date set forth in the notice to exercise its Conversion Right, under the
pricing terms contained in Section 4(b)(ii) of the Note, to convert all or part of the amount to be prepaid into Conversion Shares, in which case the prepayment notice will have no further force or effect regarding the amount to be
converted. 
 7.          Lawful Money.
Principal and interest are payable in lawful money of the United States of America, 

8.          Applications of Payments; Late Charges. 

(a)               Payments received by Lender
hereunder will be applied first to costs and expenses, then to interest and finally to principal unless Lender elects otherwise in its sole discretion. 

(b)               If any payment of principal
or interest is not paid when due, such late payment will bear interest at the Default Rate from the day such payment was due until it is paid. In addition, if any payment is five or more days overdue, Lender will have the option to assess a late
charge of $0.03 cents for each dollar so overdue. In connection therewith, Company and Lender agree as follows: 
  

	 	(i)	 Because of such late payment, Lender will incur certain costs and expenses including, without limitation, administrative costs, collection costs,
loss of interest, and other direct and indirect costs in an uncertain amount; 

  

	 	(ii)	 It would be impractical or extremely difficult to fix the exact amount of such costs in such event; 

 

 6 

	 	(iii)	 The late charge is a reasonable and good faith estimate of such costs; and 

 

	 	(iv)	 Such late charge will constitute liquidated damages caused by such failure to make a payment of interest or principal when due but only to the
extent such late charge is assessed by Lender, paid by Company and accepted by Lender and only upon the condition that such failure is completely cured concurrently with such payment. 

The application of the Default Rate or the assessment of a late charge to any such late payment as described in this
Section 8(b) will not be interpreted or deemed to extend the period for payment or otherwise limit any of Lender’s remedies under this Note, the Security Agreement, the Development Agreement, or the License Agreement. 

9.          Security. This Note is a secured obligation of
Company as set forth in the Security Agreement dated as of December 30, 2005, as amended by that certain Omnibus Amendment dated as of June 30, 2007 (as so amended, and as further amended, supplemented or otherwise modified from time to
time, the “Security Agreement”), by and between Company and Lender. 

10.        Covenants of Company. 

(a)               Use of Loan Proceeds.
Company covenants and agrees that it will use the proceeds of this Note only (i) to pay the second installment in the amount of $124,052.60 (including accrued interest, fees, and related amounts) due on December 1, 2005, and the third
installment in the amount of $120,355.03 (including accrued interest, fees, and related amounts) due on March 1, 2006, under that certain promissory note made by the Company in favor of Trust One Bank of 1715 Aaron Brenner Dr., Memphis,
Tennessee 38120 in the principal amount of $690,000 due December 1, 2006 (the “Trust One Bank Note”), (ii) to pay direct costs and expenses associated with the development of the System and/or the Lead and (iii) to
pay to Bass, Berry & Sims, PLC and Myers Bigel Sibley & Sajovec an aggregate amount no greater than $40,000 to cover Company’s actual costs and expenses associated with the negotiation and documentation of this Note, the
Security Agreement, the Development Agreement, the License Agreement and the Other Agreements. Company acknowledges that some costs and expenses incurred by Company, such as salaries and consulting fees, may relate both to the development of the
System and/or the Lead and to other activities of Company. With respect to such costs and expenses, Company will determine, subject to Lender’s approval, which will not be unreasonably withheld, which percentage of the cost or expense is
associated with the development of the System and/or the Lead, for which Company will be permitted to use proceeds of this Note, and which percentage is associated with other activities of Company, for which Company will not be permitted to use
proceeds of this Note. 

(b)               No Senior Debt. So
long as this Note is outstanding, Company will not incur on or after the Closing Date any indebtedness for borrowed money that is not expressly subordinated to this Note, without the prior written consent of Lender. For the avoidance of doubt, the
phrase “indebtedness for borrowed money” will not include ordinary-course obligations to trade creditors. 
  

 7 

(c)               No Liens or
Encumbrances. So long as this Note is outstanding, without the prior written consent of Lender, Company will not (a) pledge or otherwise encumber or permit the encumbrance of any of its assets, including the Collateral (as defined in the
Security Agreement); (b) merge or consolidate with any entity, or dissolve; (c) declare, make or pay any distribution or dividend to its stockholders; (d) sell, lease or otherwise dispose of all or any substantial portion of its
assets; or (e) engage in any business other than that in which it is presently engaged. Lender may grant or withhold its consent in its sole discretion. Any grant of that consent will give the Lender the right to exercise the Conversion Right
for all or any part of the Note Balance under the pricing terms contained in Section 4(b)(ii). For the avoidance of doubt, this Section 10(c) shall not apply with respect to any license and/or sublicense to any of the Intellectual Property
Collateral (as defined in the Security Agreement) if such license and/or sublicense is not inconsistent with the terms of the Development Agreement or License Agreement. 

11.       Defaults and Remedies. 

(a)               Events of
Default.  Each of the following events constitutes an event of default (“Event of Default”): 
  

	 	(i)	 if any representation or warranty made by Company in this Note, the Security Agreement, the Development Agreement, the License Agreement or in any
report, certificate, financial statement or other instrument furnished in connection with this Note, is false, inaccurate or misleading in any material respect when made or when deemed made hereunder. 

 

	 	(ii)	 any default in the payment of any principal or interest under this Note within five days after date when due hereunder, whether upon the Maturity
Date or by acceleration or otherwise; 

  

	 	(iii)	 any default by Company in the prompt and complete fulfillment of any of its covenants and obligations under this Note, the Security Agreement, the
Development Agreement, the License Agreement, or any and all other agreements and documents executed and delivered in connection herewith or therewith (the “Other Agreements”) (other than those covenants and obligations referred to
in clause (ii) above or clause (vi) below), if such default is not remedied within 15 days after an officer of Company becomes aware of the factual circumstances giving rise to such default; 

 

	 	(iv)	 if Company: (A) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of it or any of its properties,
(B) admits in writing its inability to pay its debts as they mature, (C) makes a general assignment for the benefit of creditors, (D) is adjudicated as bankrupt or insolvent or is the subject of an order for relief under Title 11 of
the United States Code, or any successor thereto, or (E) files a voluntary petition in bankruptcy, or a petition or an answer seeking reorganization or an arrangement with creditors or to take advantage of any bankruptcy, moratorium,
reorganization, insolvency, readjustment of debt, dissolution 

  

 8 

	 	
or liquidation law or statute, or an answer admitting the material allegations of a petition filed against it in any proceeding under any such law, or (F) takes or permits to be taken any
action in furtherance of or for purpose of effecting any of the foregoing; 

  

	 	(v)	 if any order, judgment or decree will be entered, without the application, approval or consent of Company, by any court of competent jurisdiction,
approving a petition seeking reorganization of Company, or appointing a receiver, trustee, custodian or liquidator of Company, or of all or any substantial part of its assets, and such order, judgment or decree will continue unstayed and in effect
for any period of 60 days; 

  

	 	(vi)	 if the Company fails to meet, by the required date, any System Milestone or Lead Milestone, which failure is not remedied within 15 days following
Lender’s written notice to Company; or 

  

	 	(vii)	 in the event Lender reasonably believes that Company will be unable to perform its obligations under this Note, Lender may request in writing
reasonable assurances of further performance from Company. If, within 15 days from such written request, Company fails to give such assurances reasonably showing its ability to perform, Lender may declare an Event of Default, For avoidance of doubt,
Lender’s reasonable belief of Company’s inability to perform its obligations under this Note must be based on a fact or circumstance that occurs or changes after the date of this Note and results in a material adverse effect upon the
Company’s financial condition. The foregoing is without any derogation of rights under applicable law to demand further assurances and address anticipatory breaches. 

(b)               Remedies. 

 

	 	(i)	 Upon the occurrence of any Event of Default, and at all times thereafter during the continuance of an Event of Default: (a) this Note will, in
Lender’s sole discretion and upon Lender’s written notice to Company, become immediately due and payable, as to principal and interest, without presentment, demand, protest, notice or other requirement of any kind, all of which are hereby
expressly waived, anything contained herein or in this Note to the contrary notwithstanding (except in the case of any event described in Sections ll(a)(iv) and (v) of this Note, the occurrence of which will automatically effect acceleration,
regardless of any action or forbearance in respect of any prior or ongoing default or Event of Default which may be inconsistent with such automatic acceleration), (b) Lender may file suit against Company on this Note and/or seek specific
performance or injunctive relief thereunder (whether or not a remedy exists at law or in equity); and (c) Lender will have the right to seek to exercise any and all remedies as it may determine in its discretion (without any requirement of
marshalling of assets, or other such requirement) that may be available at law or in equity. 

  

 9 

	 	(ii)	 Lender’s rights, remedies and powers, as provided in this Note and the Security Agreement are cumulative and concurrent and may be pursued
singly, successively or together against this Company, the Collateral (as defined in the Security Agreement) and any other security given at any time to secure the payment of this Note, all at the sole discretion of Lender. Additionally, Lender may
resort to every other right or remedy available at law or in equity without first exhausting the rights and remedies contained herein, all in Lender’s sole discretion. Failure of Lender at any one time, for a period of time or on more than one
occasion, to exercise any of its rights or remedies hereunder or at law or in equity will not constitute a waiver of the right to exercise the same right or remedy at any time thereafter. Any and all waivers must be in writing to be effective.

  

	 	(iii)	 If any suit or action is instituted or attorneys are employed to enforce any of the obligations of this Note, the non-prevailing party hereby
promises and agrees to pay all reasonable costs, including reasonable attorneys’ fees and court costs incurred by the prevailing party. 

12.        Subordination.      Lender and
Company agree and acknowledge that the indebtedness evidenced by this Note is neither subordinate nor subject in right of payment to any other indebtedness issued to third parties. 

13.        Interest Rate Limitation.      It
is the intent of Company and Lender in the execution of this Note and all other instruments securing this Note that the loan evidenced hereby be exempt from the restrictions of the usury laws of the State of California. In the event that, for any
reason, it should be determined that the California usury law is applicable to the Loan, Lender and Company stipulate and agree that none of the terms and provisions contained herein or in any of the other Credit Documents will ever be construed to
create a contract for the use, forbearance or detention of money requiring payment of interest at a rate in excess of the maximum interest rate permitted to be charged by the laws of the State of California. In such event, if any holder of this Note
collects monies which are deemed to constitute interest which would otherwise increase the effective interest rate on this Note to a rate in excess of the maximum rate permitted to be charged by the laws of the State of California, all such sums
deemed to constitute interest in excess of such maximum rate will, at the option of Lender, be credit. 

14.        Notices.  All notices, requests, demands and other
communications which are required to be or may be given under this Note to a party by the other party must be in writing and will be deemed to have been duly given (a) immediately if delivered in person, (b) the day following dispatch by a
nationally recognized overnight courier service (such as Federal Express or UPS, etc.) for next day delivery, (c) five days after dispatch by certified or registered first class mail, postage prepaid, return receipt requested, to the Party to
whom the same is so given or made, or (d) upon confirmation of receipt, if by facsimile. Any notice or other communication 

 

 10 

 
given hereunder will be addressed to the Company, at 200 N. Cobb Parkway, Suite 140, Marietta, Georgia 30062-3585, Attention: John C. Thomas, Jr., Fax (770) 424-8236, with a copy to Kimble
L. Jenkins, 50 North Front St., 19th Floor, Memphis,
Tennessee 38103, Fax (901) 579-4979, , or to Lender at the address indicated at the beginning of this document, Attention: General Counsel, Fax (661) 362-4712. 

15.        Counterparts. This Note may be executed in two or more
counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument. 

16.        Headings.    All headings are inserted for
convenience of reference only and will not affect the meaning or interpretation of any such provisions or of this Note, taken as an entirety. 

17.        Severability.    If and to the extent that
any court of competent jurisdiction holds any provision (or any part thereof) of this Note to be invalid or unenforceable, such holding will in no way affect the validity of the remainder of this Note. 

18.        Changes, Waivers, Etc. Neither this Note nor any provision of
this Note may be changed, waived, discharged or terminated orally, but rather may only be changed by a statement in writing signed by the Party against which enforcement of the change, waiver, discharge or termination is sought. It is agreed that a
waiver by either Lender or Company of a breach of any provision of this Note will not operate, or be construed, as a waiver of any subsequent breach by that same party. 

19.        Governing Law.      This Note
will be governed by and construed in accordance with the laws of the State of California. The parties hereby agree that any dispute which may arise between them arising out of or in connection with this Note will be adjudicated before a court
located in Los Angeles, California and they hereby submit to the exclusive jurisdiction of the courts of the State of California located in Los Angeles, California and of the federal courts in the Central District of California with respect to any
action or legal proceeding commenced by any party, and irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is an
inconvenient forum, relating to or arising out of this Note or any acts or omissions relating to the sale of the securities hereunder, and consent to the service of process in any such action or legal proceeding by means of registered or certified
mail, return receipt requested, in care of the address set forth below or such other address as the undersigned will furnish in writing to the other. 

20.        Entire Agreement.      This Note,
the Security Agreement, the Development Agreement, the License Agreement and the Other Agreements set forth the entire agreement and understanding between Lender and Company as to this subject matter and incorporates and supersedes all prior
discussions, agreements and understandings of any and every nature among them. 
  

 11 

 21.        Further Assurances.
Lender and Company agree to execute and deliver all such further documents, agreements and instruments and take such other and further action as may be necessary or appropriate to carry out the purposes and intent of this Note.

 22.        Successors and Assigns. The terms and
conditions of this Note will inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties. Nothing in this Note, express or implied, is intended to confer upon any party other than the parties hereto or
their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Note, except as expressly provided in this Note, This Note is non-negotiable. Neither Company nor Lender may assign or otherwise
transfer this Note without the prior written consent of the other party. 

23.        Relationship of Parties.  In all matters relating to
this Note, no party will have any right, power or authority to create any obligation, express or implied, on behalf of any other party. Nothing in this Note is intended to create or constitute a joint venture or a partnership between the parties
hereto. 
 24.        Amendment and
Restatement.    This Note constitutes an amendment and restatement of that certain Multiple Advance Secured Convertible Promissory Note dated December 30, 2005, made by Company in favor of Lender in the maximum principal
amount of $1,500,000, and replaces and supersedes such promissory note in all respects. 
 [SIGNATURES APPEAR ON NEXT PAGE]

  

 12 

 IN WITNESS WHEREOF,
 Company has signed this Note and delivered this Note to Lender as of the date first written above. 

 

			
	 COMPANY:
	 	 SURGI- VISION,
INC.,
 a Delaware corporation

		
		 	 By:

		 	 Name:

Title:

  

 S-1 

 SCHEDULE OF ADVANCES 

 

															
	
            Date         
   
	  	 Amount of

Principal
 Advanced

	  	 	  	 Unpaid

Principal
 Balance

	  	 	  	 Amount Paid
	  	 	  	 Notation

Made By

	01/04/06	  	$250,000	  		  	$250,000	  		  	—  	  		  	 Initial Advance

								
	01/31/06	  	$250,000	  		  	$500,000	  		  	—  	  		  	
								
	06/30/06	  	$250,000	  		  	$750,000	  		  	—  	  		  	
								
	09/30/06	  	$250,000	  		  	$1,000,000	  		  	—  	  		  	
								
	07/    /07	  	$500,000	  		  	$1,500,000	  		  	—  	  		  	

 EXHIBIT A 

TO AMENDED AND RESTATED MULTIPLE ADVANCE SECURED CONVERTIBLE 

PROMISSORY NOTE 

[FORM OF WARRANT] 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THIS WARRANT HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE. THIS WARRANT, AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF, MAY NOT BE SOLD,
MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR THE AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE
SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. 

                    ,
200   
 SURGI-VISION, INC. 

STOCK PURCHASE WARRANT 

This Warrant is issued as of this              day of
                     200  , by SURGI-VISION, INC., a Delaware corporation (the “Company”), to ADVANCED BIONICS
CORPORATION, a Delaware corporation (the “Holder”). 

1.        Issuance of Warrant; Term; Price. 

      (a)        Issuance.    
This Warrant is issued pursuant to Section 4(b)(iii) of that certain Amended and Restated Multiple Advance Secured Convertible Promissory Note dated as of June 30, 2007, payable to the Holder by the Company (together with any and all
replacements and renewals thereof, the “Note”). Reference also is made to that certain System and Lead Development and Transfer Agreement dated as of December 30, 2005, as amended by that certain Amendment No. 1 dated as
of May 31, 2006 and by that certain Omnibus Amendment dated as of June 30, 2007 (as so amended, and as further amended, supplemented or otherwise modified from time to time, the “Development Agreement”), by and between the
Company and the Holder. Capitalized terms used herein without definition will have the meanings ascribed to such terms in the Development Agreement. 

      (b)        Shares Issuable upon
Exercise. The Company hereby grants to the Holder the right to purchase, upon the terms hereof and at the Warrant Price (as defined below), [            ] shares of common stock
(“Common Stock”) of the Company, subject to adjustment as set forth in Section 2 below (the “Warrant Shares”). [Note: The initial number of Warrant Shares will be determined according to the calculation set
forth in Section 4(b)(iii) of the Note.] 
  

 1 

   (c)        Term.
This Warrant shall not be exercisable by the Holder unless (A) the Company and the Holder have not executed and delivered the Subsequent System License on or before the last day of the Negotiation Period or (B) at any time prior to the
last day of the Negotiation Period, an Event of Default has occurred and is continuing (the ‘Trigger Date”). If the Company and the Holder have executed and delivered the Subsequent System License on or before the Trigger Date, this
Warrant shall expire automatically and become null and void. If the Company and the Holder have not executed and delivered the Subsequent System License on or before the Trigger Date, the Holder may exercise this Warrant at any time after the
Trigger Date until 5:00 p.m. (Eastern Time) on the fifth business day following the Trigger Date, at which time this Warrant shall expire automatically and become null and void. 

  (d)        Exercise Price.    The exercise
price (the “Warrant Price”) per share for which all or any of the Warrant Shares may be purchased pursuant to the terms of this Warrant shall be equal to $0.01. 

2.        Adjustment of Number and Kind of Shares. The number and kind of
securities issuable upon the exercise of this Warrant shall be subject to adjustment from time to time as follows: 

  (a)        Dividends in Stock Adjustment. In case at any time
or from time to time on or after the date hereof the holders of the Common Stock of the Company (or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received, or, on or after the record
date fixed for the determination of eligible stockholders, shall have become entitled to receive, without payment therefore, other or additional securities or other property (other than cash) of the Company by way of dividend or distribution, then
and in each case, the Holder shall, upon the exercise hereof, be entitled to receive, in addition to the number of Warrant Shares receivable thereupon, and without payment of any additional consideration therefore, the amount of such other or
additional securities or other property (other than cash) of the Company which such Holder would hold on the date of such exercise had it been the holder of record of such Common Stock on the date hereof and had thereafter, during the period from
the date hereof to and including the date of such exercise, retained such shares and/or all other additional securities or other property receivable by it as aforesaid during such period, giving effect to all adjustments called for during such
period by this Section 2(a), Section 2(b) and Section 2(c). 

  (b)        Reclassification or Reorganization
Adjustment.      In case of any reclassification or change of the outstanding securities of the Company or of any reorganization of the Company on or after the date hereof, the Holder, upon the exercise hereof at
any time after the consummation of such reclassification, change or reorganization, shall be entitled to receive, in lieu of the stock or other securities and property receivable upon the exercise hereof prior to such consummation, the stock or
other securities or property to which such Holder would have been entitled upon such consummation if such holder had exercised this Warrant immediately prior thereto, all subject to further adjustment as provided in Section 2(a) and
Section 2(c). 
  

 2 

      (c)        Stock Splits and Reverse Stock
Splits. If at any time on or after the date hereof the Company shall subdivide its outstanding shares of Common Stock into a greater number of shares, the number of shares receivable upon exercise of this Warrant shall thereby be proportionately
increased; and, conversely, if at any time on or after the date hereof the outstanding number of shares of Common Stock shall be combined into a smaller number of shares, the number of shares receivable upon exercise of this Warrant shall thereby be
proportionately decreased. 
 3.        No Fractional
Shares.    No fractional shares of Warrant Stock will be issued in connection with any subscription hereunder. 

4.        No Stockholder Rights. This Warrant as such shall not entitle
the Holder to any of the rights of a stockholder of the Company until the Holder has exercised this Warrant in accordance with Section 6 hereof. 

5.        Reservation of Stock.    The Company
covenants that during the term of this Warrant, the Company will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of this Warrant. The Company
agrees that its issuance of this Warrant constitutes full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for Warrant Shares upon the exercise of this Warrant.

 6.        Exercise of Warrant. This Warrant may be exercised
by the Holder, during the term of this Warrant as provided in Section 1(c) above, by the surrender of this Warrant at the principal office of the Company, accompanied by payment in full of the Warrant Price of the shares purchased
thereby. Notwithstanding any provision of the Development Agreement to the contrary, the Holder shall be entitled to offset against any amount owing to the Company under the Development Agreement the Warrant Price of any shares purchased by the
Holder upon the exercise of this Warrant. This Warrant shall be deemed to have been exercised immediately prior to the close of business on the date of its surrender for exercise as provided above, and the Holder shall be treated for all purposes as
the holder of record of the Warrant Shares as of the close of business on such date. As promptly as practicable, the Company shall issue and deliver to the Holder a certificate or certificates for the number of Warrant Shares issuable upon such
exercise. The Warrant Shares issuable upon exercise of this Warrant shall, upon their issuance, be fully paid and nonassessable. 

7.        Certificate of Adjustment.    Whenever the
number or type of securities issuable upon exercise of this Warrant is adjusted as herein provided, the Company shall deliver to the Holder a certificate of an officer of the Company setting forth the nature of such adjustment and a brief statement
of the facts requiring such adjustment. 
 8.        No Limitation on
Corporate Action. No provisions of this Warrant and no right granted or conferred hereunder shall in any way limit, affect or abridge the exercise by the Company of any of its corporate rights or powers to recapitalize, amend its Certificate of
Incorporation, reorganize, consolidate or merge with or into another corporation, to transfer all or any part of its property or assets, or to exercise any other corporate rights and powers. 

 

 3 

 9.          Assignment
of Warrant.    The Holder may not assign or transfer this Warrant without the prior written consent of the Company. Any purported assignment or transfer of this Warrant in violation of this Section 9 shall be void
abs initio. 
 10.        Restrictive Legends. To the extent
applicable, each certificate evidencing any of the Warrant Shares shall be endorsed with the legends set forth below, and Holder covenants that, except to the extent such restrictions are waived by the Company, Holder shall not transfer the Warrant
Shares without complying with the restrictions on transfer described in such legends: 

    (a)   The following legend under the Securities Act: 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE
“BLUE SKY” OR SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, HYPOTHECATED, DISTRIBUTED OR OTHERWISE DISPOSED OF UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH
SALE OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT IS AVAILABLE, AND IF AN EXEMPTION IS AVAILABLE, THE COMPANY RECEIVES AN OPINION OF COUNSEL AT THE HOLDER’S SOLE COST AND EXPENSE STATING THAT SUCH OFFER, SALE, TRANSFER, ASSIGNMENT,
PLEDGE, HYPOTHECATION, DISTRIBUTION OR OTHER DISPOSITION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT AND OTHER LAWS. THE RESTRICTIONS CONTAINED HEREIN ARE BINDING ON THE HOLDER HEREOF AND ITS SUCCESSORS AND
PERMITTED ASSIGNS.” 
     (d)        If
required by the authorities of any state in connection with the issuance or sale of the Warrant Shares, the legend required by such state authority. 

11.        Replacement of Warrant.  Upon receipt by the Company
of evidence reasonably satisfactory to the Company of the loss, theft or destruction of this Warrant, and on delivery of an indemnity agreement or security reasonably satisfactory in form and amount to the Company, the Company will execute and
deliver to the Holder, in lieu thereof, a new Warrant of like tenor. 

12.        Miscellaneous.      This Warrant
shall be governed by the laws of the State of Delaware. The headings in this Warrant are for purposes of convenience of reference only, and shall not be deemed to constitute a part hereof. The invalidity or unenforceability of any provision hereof
shall in no way affect the validity or enforceability of any other provisions. 

13.        Notices.    All notices, requests, demands
and other communications which are required to be or may be given under this Warrant to a party by the other party must be in writing and will be deemed to have been duly given (a) immediately if delivered in person, (b) the day following
dispatch by a nationally recognized overnight courier service (such as Federal Express, UPS, etc.) for next day delivery, (c) five days after dispatch by certified or registered first class

  

 4 

 
mail, postage prepaid, return receipt requested, to the party to whom the same is so given or made, or (d) upon confirmation of receipt if by facsimile. Any notice or other communication
given hereunder will be addressed (x) to the Company at 200 N. Cobb Parkway, Suite 140, Marietta, Georgia 30062-3585, Attention: John C. Thomas, Jr., Fax (770) 424-8236, with a copy to Kimble L. Jenkins, 50 North Front St.,
19th Floor, Memphis, Tennessee 38103, Fax
(901) 579-4979, or (y) to the Holder at 25129 Rye Canyon Loop, Valencia, California 91355, Attention: General Counsel, Fax (661) 362-4712, or at such other address as one party shall have notified the other party hereto by notice
given in conformity with this Section 13. 

14.        Taxes.  The Company shall pay all issue taxes and
other governmental charges (but not including any income taxes of the Holder) that may be imposed in respect of the issuance or delivery of the Warrant Shares or any portion thereof. 

15.        Amendment: Waiver. Any term of this Warrant may be amended or
waived with the written consent of the Company and the Holder. 

16.        Representations by Holder. The Holder represents and warrants
to the Company, as of the date hereof and as of the date of any exercise of this Warrant, that (a) the Holder is acquiring this Warrant and the Warrant Shares for its own account, for investment purposes, and not with a present view either to
sell, distribute or transfer, or to offer for sale, distribution or transfer, this Warrant or the Warrant Shares, (b) the Holder is experienced in evaluating companies such as the Company, has such knowledge and experience in financial and
business matters as to be capable of evaluating the merits and risks of the Holder’s investment and has the ability to suffer the total loss of such investment, and (c) the Holder is an “accredited investor” within the meaning of
Regulation D under the Securities Act. 
  

			
	 SURGI- VISION, INC.

			
		
	 By:
	 	  

			
	 Name:
	 	  

			
	 Title:
	 	  

	
	 AGREED TO AND ACCEPTED BY:

	
	 ADVANCED BIONICS CORPORATION

			
		
	 By:
	 	  

			
	 Name:
	 	  

			
	 Title:
	 	  

 

 5 

 NOTICE OF EXERCISE 

To:    Surgi-Vision, Inc. 

The undersigned hereby elects to purchase
                                        
“Warrant Shares” pursuant to the provisions of Section 6 of the attached Warrant, and tenders herewith payment of the purchase price for such shares in full. In exercising the attached Warrant, the undersigned hereby confirms and
acknowledges its representations and warranties set forth in Section 16 of the attached Warrant. 
  

			
	 ADVANCED BIONICS CORPORATION

		
	 By:
	 	  

			
	 Name:
	 	  

			
	 Title:
	 	  

			
	 Date:
	 	  

 EXHIBIT B 

TO OMNIBUS AMENDMENT 

SCHEDULE 10 

TO THE SECURITY AGREEMENT 

U.S. Copyright Registrations: 
  

			
	 Title
	  	 Registration No.        Date of Issue   Registered
Owner

		
	 None
	  	

 Foreign Copyright Registrations: 

 

			
	 Country
	  	 Title      Registration No.        Date of Issue

		
	 None
	  	

 Pending U.S. Copyright Registration Applications: 

 

			
	
Title    Appl. No.        Date of Application   Copyright
Claimant

		
	 None
	  	

 Pending Foreign Copyright Registration Applications: 

 

			
	 Country
	  	 Title    Appl. No.      Date of Application

		
	 None
	  	

 The Grantor has granted Secured Party certain licenses to the Intellectual Property pursuant to
the Concurrent Agreements. 
 The Grantor is a party to the JHU Agreements. 

Pursuant to the JHU Agreements, JHU has the retained right to make, have made, provide and use for its and The Johns Hopkins Health
Systems’ internal, non-commercial purposes “Licensed Products” and “Licensed Services” (as such terms are defined in the JHU Agreements). 

Patents supported by federal funding are subject to the rights, conditions and limitations imposed by U.S. law. 

 The Grantor is a party to an option agreement with JHU. Pursuant to that option agreement,
the Grantor has notified JHU that the Grantor will exercise its option on a “Microcapsule” patent application that was filed in May 2007. Such patent application is not related to the Lead or the System. 

The Grantor is a party to an assignment agreement with [***] for [***]. 

The Grantor has a pending research collaboration/sponsorship agreement with UCSF. 

The Grantor has a pending sponsorship agreement with the University of Utah and Dr. Marrouche (with an option for an exclusive
license for any intellectual property arising from the sponsored work). Such intellectual property would not be related to the Lead or the System. 

The Grantor has filed on a JHU case (funded by the Grantor) that has not yet been formally licensed from JHU. The case is directed to
embolic procedures and is not related to the Lead or the System. 
 The Grantor is a party to various consulting agreements that
include options/licenses/assignments of or to intellectual property or conceived ideas. 
 The Grantor knows of a third-party
attempt to invoke an interference against U.S. 6,904,307. 
 [***] Indicates portions of this exhibit that have been omitted and
filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 
  

 2 

 SCHEDULE 6.F  

TO OMNIBUS AMENDMENT 

1.        With reference to the second sentence of Section 4.8 of the
Development Agreement, the disclosure set forth in Schedule 4.8 to the Development Agreement is replaced and superseded by the following disclosure: 

The Company has granted Bionics certain licenses to the Existing Intellectual Property pursuant to this Agreement and the
Concurrent Agreements. 
 The Company is a party to the JHU Agreements. 

Pursuant to the JHU Agreements, JHU has the retained right to make, have made, provide and use for its and The Johns
Hopkins Health Systems’ internal, non-commercial purposes “Licensed Products” and “Licensed Services” (as such terms are defined in the JHU Agreements). 

Patents supported by federal funding are subject to the rights, conditions and limitations imposed by U.S. law.

 2.        With reference to the fourth sentence of Section 4.8
of the Development Agreement, the Company knows of a third-party attempt to invoke an interference against U.S. 6,904,307. 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 

 OMNIBUS AMENDMENT #2 

TO SYSTEM AND LEAD DEVELOPMENT AND TRANSFER AGREEMENT 

      This AMENDMENT (this “Amendment”) is dated as of
March 19, 2008 and entered into by and between Surgi-Vision, Inc., a Delaware corporation (the “Company”) and Boston Scientific Neuromodulation Corporation (formerly known as Advanced Bionics Corporation), a Delaware
corporation (“Bionics”), and is made with reference to (i) that certain System and Lead Development and Transfer Agreement dated as of December 30, 2005, as amended by that certain Amendment No. 1 dated as of
May 31, 2006, as further amended by that certain Omnibus Amendment dated as of June 30, 2007 (as so amended, supplemented or otherwise modified from time to time, the “Development Agreement”), by and between the Company
and Bionics, and (ii) that certain Technology License Agreement dated as of December 30, 2005, as amended by that certain Omnibus Amendment dated as of June 30, 2007 (as so amended, supplemented or otherwise modified from time to
time, the “License Agreement”), by and between the Company and Bionics. 
 RECITALS 

      WHEREAS, the Company and Cardiac Pacemakers, Inc. (“CPI”), a
wholly-owned indirect subsidiary of Boston Scientific Corporation and an affiliate of Bionics have, concurrent with this Amendment, entered into a Technology License Agreement (the “CPI License Agreement”) and a Development
Agreement (the “CPI Development Agreement”) (collectively, the CPI License Agreement and the CPI Development Agreement are referred to as the “CPI Agreements”), which contain, among other things, certain provisions
regarding Intellectual Property ownership, patent prosecution, enforcement and confidentiality; 

      WHEREAS, the Company and Bionics desire to amend the Development Agreement to
be consistent with such Intellectual Property ownership, patent prosecution, enforcement and confidentiality provisions contained in the CPI Agreements; and 

      WHEREAS, the Company and Bionics desire to amend the License Agreement to
reconcile the compensation provisions contained therein with those in the CPI License Agreement: 

      NOW, THEREFORE, in consideration of the premises and the agreements,
provisions and covenants herein contained, the parties hereto agree as follows: 

     Section 1.   
     AMENDMENTS TO THE DEVELOPMENT AGREEMENT 

 

	1.1	 Defined Terms. 

      Capitalized terms used in this Amendment without definition shall have the same
meanings as set forth in the Development Agreement. 
  

 1 

	1.2	 Amendments to Section 11: Intellectual Property Ownership and Protection. 

      A.        Section 11.1 (a) of the
Development Agreement is hereby amended by deleting the last sentence of such Section in its entirety and substituting the following in lieu thereof: 

“Notwithstanding any of the foregoing to the contrary, any Shared Future Intellectual Property shall be solely owned
by CPI and Bionics. Bionics hereby grants to the Company an exclusive, fully paid, worldwide license, with right to sublicense, (a) under the Shared Future Intellectual Property for use within the SVI Grant-Back Field (as that term is defined
in the CPI Development Agreement), to make, use, import, lease, and sell any system, method, or apparatus, and (b) under all Non-Shared Future Intellectual Property for use outside the field of neuromodulation, to make, use, import, lease, and
sell any system, method, or apparatus. The term “Shared Future Intellectual Property” means any Future Intellectual Property that constitutes Development IP (as that term is defined in the CPI Development Agreement). The term
“Non-Shared Future Intellectual Property” means any transferred Future Intellectual Property that does not constitute Development IP (as that term is defined in the CPI Development Agreement). 

      B.        Section 11.1 (b) of the
Development Agreement is hereby amended by deleting such Section in its entirety and substituting the following in lieu thereof: 

(b) Intellectual Property Re-transfer and Cross-License. Bionics hereby agrees to assign and transfer to the
Company joint ownership for all countries in and to any transferred Non-Shared Future Intellectual Property promptly after the Loan Satisfaction Date (“Re-Transfer”). Upon Re-Transfer, the Non-Shared Future Intellectual Property
will become Intellectual Property that is jointly owned by the Parties (“Joint Intellectual Property”). Effective immediately upon the date of Re-Transfer, (i) the Company hereby grants to Bionics an exclusive, fully paid,
non-transferable, perpetual worldwide license under the Joint Intellectual Property within the field of neuromodulation, with right to sublicense, to make, use, import, lease, and sell any system, method, or apparatus thereunder, and
(ii) Bionics hereby grants to the Company an exclusive, fully paid, non-transferable, perpetual worldwide license under the Joint Intellectual Property outside the field of neuromodulation (but subject to CPI’s exclusivity as set forth in
the CPI Agreements), with right to sublicense, to make, use, import, lease, and sell any system, method, or apparatus thereunder. 
  

	1.3	 Amendment to Section 11.2: Patent Prosecution. 

      A.        Section 11.2 of the Development
Agreement is hereby amended by deleting such Section in its entirety and substituting the following in lieu thereof: 

             11.2      
Patent Prosecution. 
 (a) Costs. Bionics and its Affiliates will pay all Patent Prosecution costs and
expenses for all Patents subject to their sole control, as set forth in Section 11.2(b) below (“Prosecution Costs”). The term “Patent” means all classes or types of patents, design patents,
utility patents, including issued patents, published and non-published patent applications 
  

 2 

 
(including inventors’ certificates and utility models) in any country or jurisdiction or under any treaty, including all originals, provisionals, substitutions, continuations,
continuations-in-part, divisionals, supplementary protection certificates, renewals, all letters patent granted thereon, and all reissues, reexaminations, extensions, confirmations, revalidations, registrations, patents of addition and foreign
counterparts, as well as industrial design registrations. The term “Prosecution” means prosecution of any proceeding in the United States Patent and Trademark Office or in any other registration authority in any country, including
regarding any application (whether ex parte or inter partes), including interference, reexamination and reissue. The terms “Affiliate” and “Affiliates” have the meanings ascribed thereto in the CPI Agreements. 

(b)        Intellectual Property Protection. Bionics and its Affiliates will jointly
control the Prosecution of all Patents included in the Bionics Controlled IP, each at its own expense and with legal counsel of its own choice, and will take such other legal steps as Bionics and its Affiliates will determine in their sole
discretion to be necessary to protect their rights for all Bionics Controlled IP. For the avoidance of doubt, neither Bionics nor its Affiliates will be obligated to pay any Prosecution Costs to protect any Intellectual Property if they determine,
in their sole discretion, that those Prosecution Costs outweigh the likely benefits to Bionics or such Affiliate. The term “Bionics Controlled IP” means all Existing Intellectual Property, Joint Intellectual Property and Future
Intellectual Property, except any Existing Intellectual Property that relates to the System. 

(c)        Company Cooperation. The Company will cooperate with Bionics and its Affiliates
in filing, Prosecuting and maintaining Patents and taking such other legal steps as set forth in this Section 11.2 and will execute and deliver any documents and instruments in connection therewith which Bionics or its Affiliates may request at
no additional cost or expense to Bionics or such Affiliate. 

(d)        Company Inspection and Intervention. The Company will have the right upon
reasonable notice and reasonable request to inspect, at the Company’s sole expense and discretion, the Prosecution documents and strategy of Bionics and its Affiliates with respect to any Bionics Controlled IP that does not constitute Shared
Future Intellectual Property. The Parties agree that such information constitutes Confidential Information of Bionics and its Affiliates, and that the disclosure of such information is not intended to constitute a waiver of any privilege, including
attorney-client privilege. Bionics (or its applicable Affiliate) will provide written notice to the Company prior to abandoning any patent application or issued Patent that is part of the Bionics Controlled IP. If the Company desires to file and
Prosecute any patent application, or to pay maintenance fees or annuities to maintain any issued Patent, in any country that Bionics or its Affiliates determined was not worthwhile to protect Bionics’ or such Affiliates’ rights, the
Company may provide Bionics with a reasonable written request to file and Prosecute or maintain such Patent (“Prosecution Request”). Bionics will have thirty (30) days to fulfill the Prosecution Request. If Bionics (or one of
its Affiliates) fails to complete the Prosecution Request within thirty (30) days of receiving the Prosecution Request, then (i) the Company may independently file and Prosecute the patent application or maintain the issued Patent that was
the subject of the Prosecution Request, (ii) the Company will bear all Prosecution Costs and will control the remainder of the Prosecution for such patent application or the maintenance of such issued Patent, and (iii) with respect to a
Prosecution involving any Future Intellectual Property or Joint Intellectual Property, Bionics and its Affiliates will have the right 

 

 3 

 
(but not the obligation) to participate in an advisory capacity in such Prosecution. The Parties acknowledge and agree that any action by the Company pursuant to this Section 11.2(d) will
not confer or convey any ownership rights in the subject Patent to the Company, and will not otherwise adversely affect any of Bionics’ or its Affiliates’ rights in same. 

 

	1.4	 Amendment to Section 11.4: Infringement. 

      A.        Section 11.4 of the Development
Agreement is hereby amended by deleting such Section in its entirety and substituting the following in lieu thereof: 

             11.4      
Infringement. 
 (a)        Notice of Infringement. If either Party learns of
any actual, alleged or threatened Infringement of any Bionics Controlled IP by a Third Party, such Party shall promptly notify the other Party and shall provide such other Party with all available evidence of such Infringement. The term
“Infringe” means (as applicable, depending on the context of the subject or object of the word Infringe) to infringe, misappropriate, use or disclose without authorization or otherwise violate Intellectual Property rights (whether
direct, indirect, contributory, inducement or otherwise). The words “Infringement” and “Infringing” have corresponding meanings. The term “Third Party” means one or more persons or entities other
than SVI, Bionics and their respective Affiliates. 
 (b)        Enforcement
of Bionics Controlled IP. As between the Parties, [***] shall have the sole right (but not the obligation), each at its own expense and with legal counsel of its own choice, to bring suit (or take other appropriate legal action) against any
actual, alleged or threatened Infringement of the Bionics Controlled IP; provided, however, that [***] shall have the right (but, subject to Section 11.4(c) below, not the obligation) to participate in an advisory capacity only in
the institution and prosecution of any such Infringement suit, (a) with respect to any Shared Future Intellectual Property only if and to the extent the accused product is related primarily to the [***] and (b) with respect to any other
Bionics Controlled IP only if and to the extent the accused product is related primarily to [***]. 

(c)        Join in Action. If either [***] brings any such action or proceeding hereunder,
[***] agrees to be joined as party plaintiff if necessary to prosecute such action or proceeding, and, at [***] expense, to give [***] reasonable assistance and authority to file and prosecute the suit; provided, however, that neither
Party shall be required to transfer any right, title or interest in or to any property to other Party to confer standing on a Party hereunder. 

(d)        Costs. [***] will pay all costs, fees, and expenses associated with an
Infringement action they have initiated and prosecuted. [***] will pay all costs, fees, and expenses associated with [***] participation in an advisory capacity under Section 11.4(b). 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 
  

 4 

 (e) Recovery. Any recovery obtained in an action initiated and
prosecuted solely by [***], and in which [***] does not participate in an advisory capacity, shall belong to [***]. Any recovery obtained in an action initiated and prosecuted by [***], and in which [***] participates in an advisory capacity, shall
be allocated in a fair and equitable manner mutually determined by the Parties. For purposes of clarity, any recovery pursuant to this section will be net of litigation costs as provided in Section 11.4(d) above. 

(f) Cooperation. [***] agrees to fully cooperate with [***] in the prosecution of any such suit at no additional
expense to [***]. 
 (g) Loss of Exclusive Rights Under CPI License Agreement. [***] acknowledges that,
notwith-standing the foregoing to the contrary, in the event CPI exercises its Termination Option (as such term is defined in the CPI Development Agreement), [***] of the CPI License Agreement. Therefore, in the event of any conflict between the
terms of this Section 11.4 and the terms of [***], the terms of the CPI License Agreement will control. 
  

	1.5	 Amendment to Section 11.5: Publication and Authorship 

      A.        Section 11.5 of the Development
Agreement is hereby amended by deleting such Section in its entirety and substituting the following in lieu thereof: 

                 11.5 Publication
and Authorship. Notwithstanding Section 11.6(e) below, the Company will have the right to author, to publish and to retain or transfer copyright to scientific reports describing the methods and results of any or all Bionics Controlled IP
that does not constitute Shared Future Intellectual Property; provided that, if the studies were conducted with the financial and/or technical support of Bionics or any of its Affiliates, such reports shall include an acknowledgment to that
effect. Prior to publishing any reports or submitting any manuscripts wherein the publication could adversely affect patent rights for any Bionics Controlled IP (i.e., new inventions for which patent applications have not been filed), (i) the
Company shall make the manuscripts for such reports available to Bionics or one of Bionics’ Affiliates, using reasonable efforts to provide Bionics or such Affiliate copies of such manuscripts at least thirty (30) days before submission to
a journal or other publisher so that Bionics can take any steps it deems necessary to protect such Surgi-Vision IP disclosed in such manuscripts, (ii) Bionics will promptly review such manuscripts, and (iii) the Company will delay its
submission to such journal or other publisher for up to one hundred eighty (180) days if Bionics, in its reasonable discretion, determines that it needs additional time to protect such Bionics Controlled IP. 

 

	1.6	 Amendment to Section 11.6: Confidentiality 

      A.        Section 11.6 of the Development
Agreement is hereby amended by deleting such Section in its entirety and substituting the following in lieu thereof: 
 [***]
Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 

 5 

             11.6      
Confidentiality. 
 (a)        Definition. “Confidential Information”
means information which is disclosed or shared by one Party to the other Party, or generated or developed by one or both Parties, that the non-owning Party has a reasonable basis to believe is confidential to the owning Party or has been marked
or orally designated by the owning Party as confidential. 

(b)        Ownership of Confidential Information. The Parties agree that (i) all
Shared Future Intellectual Property and Non-Shared Future Intellectual Property will be deemed to be Confidential Information owned by Bionics (irrespective of which Party generated, developed or first shared or disclosed such information),
(ii) all Joint Intellectual Property will be deemed to be Confidential Information owned by both Parties (irrespective of which Party generated, developed or first shared or disclosed such information), and (iii) the terms and existence of
this Agreement are Confidential Information owned by both Parties. Except as otherwise expressly provided in this Section 11.6, neither Party is subject to the obligations of a “no-owning Party” with respect to Confidential
Information that is owned by both Parties. Except as otherwise expressly provided in this Agreement, for all other Confidential Information, the “owning Party” is deemed to be the disclosing Party. Confidential Information shall remain the
property of the owning Party, and the non-owning Party shall not be deemed by virtue of this Agreement or any access to the owning Party’s Confidential Information to have acquired any right, title or interest in or to any Confidential
Information, except the limited right to use such Confidential Information in accordance with the terms of this Agreement or other agreements between the Parties or their Affiliates. 

(c)        Non-Use and Non-Disclosure. Either Party may make available to the other Party
or otherwise generate or develop Confidential Information. The non-owning Party will maintain the owning Party’s Confidential Information in confidence and will not use such Confidential Information except as reasonably necessary to perform its
obligations and exercise its rights under this Agreement or other agreements between the Parties or their Affiliates. Notwithstanding any provision to the contrary contained in the CPI Agreements, the Company agrees and acknowledges that Bionics and
its Affiliates may share all of the Company’s Confidential Information with and among each of their respective Affiliates for use solely within the Field (as that term is defined in the CPI Agreements), provided that (i) prior to any such
sharing of the Company’s Confidential Information such Affiliates are bound by obligations of confidentiality, non-disclosure and non-use substantially similar in scope to those in this Agreement and (ii) Bionics shall be responsible for
any breach of confidentiality, non disclosure and non-use by any such Affiliate. Neither Party will disclose the other Party’s Confidential Information without the prior written consent of the other Party, except as permissible in
Section 11.6(e) below or in other agreements between the Parties or their Affiliates. All Confidential Information will be treated by the non-owning Party with the same care as it would exercise in the handling of its own Confidential
Information, but not less than reasonable care. The limitations and undertakings specified in this Section 11.6 shall survive termination of this Agreement for a period of five (5) years. 

(d)        Standard Exceptions. The obligations of Sections 11.6(c), (f) and
(g) do not apply to any of the other Party’s Confidential Information: (i) which, other than 
  

 6 

 
Shared Future Intellectual Property and Non-Shared Future Intellectual Property, is already known by the non-owning Party at the time of the disclosure; (ii) following such information
becoming publicly known without the wrongful act or breach of this Agreement by the non-owning Party; (iii) following such information becoming rightfully received by the non-owning Party from a Third Party without breaching any confidentiality
obligation owed by such Third Party to the owning Party; (iv) following such information becoming approved for release by written authorization of the owning Party; or (v) other than Shared Future Intellectual Property and Non-Shared
Future Intellectual Property, following such information becoming subsequently and independently developed by employees or representatives of the non-owning Party without knowledge or use of the owning Party’s Confidential Information. The
burden of proving the existence of facts which would provide an exception under this Section 11.6(d) rests with the non-owning Party. Notwithstanding any provision herein to the contrary, to the extent required under the JHU Agreements, the
Company shall be permitted to disclose the terms of this Agreement to JHU. 

(e)      Permitted Disclosures. Each Party may disclose the other Party’s
Confidential Information: 
 (i)    to the extent reasonably necessary for a
Party to prepare, file and Prosecute a Patent application under this Agreement or other agreements between the Parties or their Affiliates; 

(ii)    to the extent permissible under any other agreements between the Parties or their Affiliates;

 (iii)    to the extent reasonably necessary for a Party to develop or commercialize,
directly or indirectly through one or more licensees, products related to or utilizing Intellectual Property within its allocated (or retained) field of rights pursuant to this Agreement or the License Agreement; provided that: (a) such
disclosure may include the disclosure of this Agreement’s and the License Agreement’s existence and the scope of any license granted hereunder or thereunder; and (b) prior to making any such disclosure pursuant to this subsection,
such Party will, if reasonably practical, take reasonable steps to limit the scope of such disclosure and its effect on confidentiality; 

(iv)      to the extent reasonably necessary for the purposes of this Agreement or other
agreements between the Parties, to its respective Affiliates, consultants, agents, advisors, attorneys, outside contractors and clinical investigators, but only if those persons are bound by obligations of confidentiality, non-disclosure, and
non-use substantially similar in scope to those in this Agreement; provided, such Party shall be responsible for any breaches of confidentiality, non-disclosure and non-use by any such Affiliate, consultant, agent, advisor, attorney, outside
contractor or clinical investigator to whom disclosure is made; 
 (v)    in connection
with communications to such Party’s stockholders and prospective investors; provided that unless otherwise agreed between the Parties: (a) such stockholders and prospective investors are subject to obligations of confidentiality no less
stringent than those contained herein; and (b) such disclosure be expressly limited to the existence of this Agreement and the License Agreement and the scope of any license granted hereunder or thereunder; 

 

 7 

 (vi)    to the extent reasonably necessary to enforce
this Agreement or other agreements between the Parties or their Affiliates; 

(vii)      to the extent reasonably necessary to comply with a subpoena, court order, or
administrative order. Before complying, the Party subject to such subpoena, court order or administrative order will notify the other Party, allow the other Party a reasonable time to oppose the disclosure, and reasonably cooperate with the other
Party’s efforts to do so; or 
 (viii)    to the extent reasonably necessary to comply
with an applicable law, rule, regulation of any governmental authority or securities exchange, including the FDA, the Securities and Exchange Commission and the New York Stock Exchange. Before complying, the Party subject to such law, rule or
regulation will notify the other Party, allow the other Party a reasonable time to seek a protective order (if appropriate), and reasonably cooperate with the other Party’s efforts to do so. 

(f)        Further Limitation on Use and Disclosure of Bionics Controlled IP.
Notwithstanding the foregoing, while Bionics recognizes the Company’s legitimate right (except to the extent limited by the CPI Agreements or the License Agreement) to commercialize the Bionics Controlled IP outside the Field (as that term
is defined in the CPI Agreements), the Parties agree and acknowledge that, in order to give Bionics the full benefit of the exclusive license granted pursuant to the License Agreement, with respect to those portions of the Bionics Controlled IP that
constitute Confidential Information owned by the Company, the Company will, if reasonably practical, take reasonable steps to limit the scope of any disclosure of such Bionics Controlled IP; provided, however, that the foregoing obligation on
the Company will not apply with respect to disclosure of Bionics Controlled IP by the Company to CPI. 

(g)        Return of Information. Upon the request of the owning Party at any time after
the Loan Satisfaction Date, the non-owning Party will promptly return or destroy (at the other Party’s choice) all Confidential Information owned by such other Party then in its possession and, if applicable, provide a certification of such
destruction; provided, however, that the foregoing will not apply to any Confidential Information that the non-owning Party needs to retain for purposes of meeting its obligations and exercising its rights under this Agreement and the License
Agreement or expressly has the right to retain under this Agreement or the License Agreement. With the exception of the prototypes provided to Bionics, in accordance with this Agreement, each Party will retain custody and ownership of any specimens
and original data disclosed to the other Party and will exercise due care in preserving such specimens and original data in a manner consistent with current standards of scientific conduct. The Company will provide Bionics with complete and timely
reports and scientific analyses of such data and will make specimens and original data available for inspection by representatives of Bionics at Bionics’ request. 

 

 8 

 (h) Injunctive Relief. Each Party acknowledges and agrees that the
breach of this Section 11.6 would be likely to cause serious and irreparable harm, the amount of which may be extremely difficult to estimate, thus making any remedy at law or in damages inadequate. Each Party therefore agrees that if the other
Party breaches this Section 11.6 or if such Party has cause to believe that the other Party intends to or is about to breach such provisions, then such Party will be entitled to seek injunctive relief enjoining the breach and will have the
right to specifically enforce this Agreement and the terms and provisions hereof in addition to any other remedy available at law or in equity. 

(i) System Information. For the avoidance of any doubt, Bionics acknowledges and agrees that the Company is
permitted to share its System information with third parties following the expiration of the Exclusivity Period if the Parties do not execute and deliver the Subsequent System License within the Exclusivity Period. 

Section 2.      AMENDMENT TO THE LICENSE AGREEMENT 

Section 3.B of the License Agreement is hereby amended by adding the following sentence at the end thereof:

 “In the event that a product simultaneously falls within the definition of “Licensed Product”
under this Agreement and the definition of “Royalty Product” under the CPI License Agreement: (a) Licensor agrees that any sale of such product will only implicate the payment of fees under one of the two agreements, not both (e.g.,
Licensor will not receive royalty payments both under this Agreement and the CPI License Agreement with respect to the same sale); (b) the Parties will determine which agreement will govern the fees to be paid to Licensor primarily by reference
to the product’s actual intended use, and whether such use falls within the scope of the neuromodulation field of the Development Agreement or the “Implantable Cardiac Field” of the CPI License Agreement; and (c) if the Parties
are unable to determine the governing agreement pursuant to clause (b) above, the Parties shall settle such disagreement pursuant to substantially the same mediation and arbitration provisions set forth in Section 4(E) and (F) of the
CPI License Agreement with respect to a “Royalty Product Dispute” (as such term is defined in the CPI License Agreement) (it being understood and agreed that the scope of the arbitration will be limited to determining which agreement will
govern the fees to be paid to the Company and that in no event will the Arbitrators have the power or authority to terminate this Agreement or the CPI License Agreement). 
  

 9 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to
be duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above. 
  

									
	 SURGI-VISION, INC
	 		 	  BOSTON SCIENTIFIC

		 		 	  NEUROMODULATION CORPORATION

		 		 	  (formerly known as ADVANCED BIONICS

 CORPORATION)

					
	 BY:
	 	  /s/ Kim Jenkins
	 		 	  BY:
	 	 /s/ Michael Onuscheck

									
					
	 NAME:
	 	 Kim Jenkins
	 		 	  NAME:
	 	     Michael Onuscheck

					
	 TITLE:
	 	 Pres
	 		 	  TITLE:
	 	     President

  

 10Technology License Agreement

 Exhibit 10.13 

TECHNOLOGY LICENSE AGREEMENT 

THIS TECHNOLOGY LICENSE AGREEMENT (this “Agreement”) is made effective as of March 19, 2008 (the
“Effective Date”) and entered into by and between Surgi-Vision, Inc., a Delaware corporation (“SVI”), and Cardiac Pacemakers, Inc. (“CPI”) (individually, a “Party” and collectively,
the “Parties”). 
 WHEREAS, the Parties have entered into a Development Agreement (the
“Development Agreement”) concurrent with this Agreement wherein the Parties have agreed to develop technology relating to implantable medical leads for cardiac applications; 

WHEREAS, SVI is the sole owner or exclusive licensee in the Implantable Cardiac Field of the Surgi-Vision IP; 

WHEREAS, SVI has previously entered into the Bionics Agreements with Bionics, pursuant to which Bionics has certain
ownership and other exclusive rights to certain of SVI’s Intellectual Property in the field of neuromodulation; 

WHEREAS, SVI desires to have the Surgi-Vision IP further developed and commercialized and is willing to grant CPI a
field-limited license to the Surgi-Vision IP in exchange for the license fee and royalty payments set forth in this Agreement; and 

WHEREAS, CPI desires to acquire an exclusive license in the Implantable Cardiac Field under the Surgi-Vision IP.

 NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the Parties agree as
follows: 
 1.  Definitions. 
  

	 	A.	 “Affiliate” of a Person is a Person controlling, controlled by or under common control with the Person specified.
“Controlling”, “controlled” or “control” means owning greater than 50% of the voting equity interests of a Person, either directly or indirectly through one or more intermediaries in which it has such an interest, or
otherwise having the power to direct the management of that Person. 

  

	 	B.	 “Arbitrators” has the meaning ascribed thereto in Section 4(F)(iii). 

 

	 	C.	 “Billabong Patents” means (i) the Patents listed on Exhibit A, and (ii) any claims of any future Patent which
claim and are entitled to claim (in whole but not in part, so long as neither CPI nor any of its Affiliates files any claims in a continuation-in-part Patent which require new matter for support for the primary purpose of avoiding, circumventing,
evading or minimizing its payment obligations to SVI hereunder or pursuant to the Development Agreement) priority to a Patent covered by the preceding clause (i) (e.g., claims in a continuation-in-part Patent which require new

	 	 
matter for support are not Billabong Patents, so long as neither CPI nor any of its Affiliates files any claims in a continuation-in-part Patent which require new matter for support for the
primary purpose of avoiding, circumventing, evading or minimizing its payment obligations to SVI hereunder or pursuant to the Development Agreement). 

  

	 	D.	 “Bionics” means Boston Scientific Neuromodulation Corporation (formerly known as Advanced Bionics Corporation), a wholly-owned
indirect subsidiary of Boston Scientific Corporation and an Affiliate of CPI. 

  

	 	E.	 “Bionics Agreements” means the following agreements: (i) the Bionics Lead Development Agreement, (ii) that certain
Amended and Restated Multiple Advance Secured Convertible Promissory Note dated as of June 30, 2007 made by SVI and payable to Bionics (as may be further amended, restated, supplemented or otherwise modified from time to time), (iii) the
Bionics License Agreement, and (iv) that certain Security Agreement dated as of December 30, 2005 by and between SVI and Bionics (as amended by that certain Omnibus Amendment dated as of June 30, 2007, and as may be further amended,
supplemented, or otherwise modified from time to time). 

  

	 	F.	 “Bionics Amendment” means that certain Omnibus Amendment No. 2 to the Bionics Lead Development Agreement and Bionics License
Agreement dated as of the date hereof by and between SVI and Bionics. 

  

	 	G.	 “Bionics Lead Development Agreement” means that certain System and Lead Development and Transfer Agreement dated as of
December 30, 2005, as amended by that certain Amendment No. 1 dated as of May 31, 2006, as further amended by that certain Omnibus Amendment dated June 30, 2007, as further amended by the Bionics Amendment (as may be further
amended, supplemented or otherwise modified from time to time). 

  

	 	H.	 “Bionics License Agreement” means that certain License Agreement dated as of December 30, 2005, as amended by that certain
Omnibus Amendment dated June 30, 2007, as further amended by the Bionics Amendment (as may be further amended, supplemented or otherwise modified from time to time). 

 

	 	I.	 “Brady Lead” has the meaning ascribed thereto in the Project Plan attached as Exhibit A to the Development Agreement.

  

	 	J.	 “BSC Controlled Surgi-Vision IP” means the Patents included in (i) the Surgi-Vision IP, (ii) the Existing Intellectual
Property under which Bionics holds a license under the Bionics Agreements, and (iii) any Future Intellectual Property and Joint Intellectual Property conceived and reduced to practice prior to the Effective Date and under which Bionics holds a

  

 2 

	 	 
license under the Bionics Agreements. For the avoidance of any doubt whatsoever, in no event shall BSC Controlled Surgi-Vision IP include any IPR in and to Intellectual Property owned by or
licensed to SVI that is not related to the Field. 

  

	 	K.	 “BSC Core Product Information” means that core product information proprietary to CPI which is listed on Exhibit C hereto (as may
be updated from time to time by CPI upon notice to SVI). 

  

	 	L.	 “Change in Control” means any transaction or series of transactions (whether or not related), including a merger, consolidation,
exchange, sale of equity securities, recapitalization, sale of assets, dissolution or liquidation, pursuant to which any Person or group of Persons (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended)
acquires (directly or indirectly) (i) equity securities possessing the voting power to elect a majority of a Party’s (or a successor’s) board of directors (or equivalent body) or a majority of the voting equity interests in a Party
(or a successor thereto) or (ii) all or substantially all of the assets of a Party. 

  

	 	M.	 “Claim” means any allegation, demand, investigation, suit, proceeding, claim, settlement or compromise.

  

	 	N.	 “Commercial Sale” means sale by CPI or any of its Affiliates of a Royalty Product to a Third Party (including, without limitation,
any of CPI’s or its Affiliates’ distributors), but specifically excludes (a) transfers to Third Parties for use during pre-clinical or clinical testing, or for physician preference testing, teaching or experimental purposes,
provided that neither CPI or its Affiliates receive monetary consideration therefore, and (b) transfers of Royalty Products among CPI and its Affiliates prior to sales to Third Parties. 

 

	 	O.	 “Confidential Information” means information which, prior to or during the Term (including pursuant to the Earlier Confidentiality
Agreement) is disclosed or shared by one Party to the other Party or generated or developed by one or both Parties, including information that was disclosed, shared, generated or developed under the Earlier Confidentiality Agreement, that the
non-owning Party has a reasonable basis to believe is confidential to the owning Party or has been marked or orally designated by the owning Party as confidential. 

 

	 	P.	 “CPR” has the meaning ascribed thereto in Section 4(E)(ii). 

 

	 	Q.	 “Cure Period” has the meaning ascribed thereto in Section 7(B)(i). 

 

	 	R.	 “Damages” has the meaning ascribed thereto in Section 13(A). 

 

 3 

	 	S.	 “Definitive Agreements” means this Agreement and the Development Agreement, collectively. 

 

	 	T.	 “Development IP” has the meaning ascribed thereto in the Development Agreement. 

 

	 	U.	 “Earlier Confidentiality Agreement” means that certain Mutual Nondisclosure Agreement entered into by the Parties on
August 20, 2006, as amended by the First Amendment to the Mutual Nondisclosure Agreement entered into by the Parties on September 5, 2007. 

  

	 	V.	 “Effective Date” is defined in the introductory paragraph. 

 

	 	W.	 “Existing Intellectual Property” has the meaning ascribed thereto in Section 4.8 of the Bionics Lead Development
Agreement. 

  

	 	X.	 “Field” means the Implantable Cardiac Field and the Neuro Field, collectively. 

 

	 	Y.	 “Future Intellectual Property” has the meaning ascribed thereto in Section 7.6 of the Bionics Lead Development
Agreement. 

  

	 	Z.	 “Governmental Authority” means any domestic or foreign, federal, national, state, multi-state, international, multinational or
municipal or other local government, any subdivision, agency, commission or authority thereof, or any quasi-governmental or private body exercising any regulatory or taxing authority thereunder or any court or other tribunal or judicial authority.

  

	 	AA.	 “Heart Failure Lead” has the meaning ascribed thereto in the Project Plan attached as Exhibit A to the Development
Agreement. 

  

	 	BB.	 “Indemnified Party” has the meaning ascribed thereto in Section 13(A).  

 

	 	CC.	 “Indemnifying Party” has the meaning ascribed thereto in Section 13(A). 

 

	 	DD.	 “Implantable Cardiac Field” means the field of implantable medical leads for all cardiac applications (including nerve stimulation
for intentionally affecting the heart), including implantable leads for cardiac rhythm management, heart failure and defibrillation, and all uses, applications, research, design, development, manufacturing, and marketing of such implantable leads
and all products related to such implantable leads, including but not limited to adaptors and components, for all cardiac applications. 

  

	 	EE.	 “Infringe” means (as applicable, depending on the context of the subject or object of the word Infringe) to infringe,
misappropriate, use or disclose without authorization or otherwise violate Intellectual Property Rights 

  

 4 

	 	 
(whether direct, indirect, contributory, inducement or otherwise). The words “Infringement” and “Infringing” have corresponding meanings.

  

	 	FF.	 “Intellectual Property” means intangible property that is legally protectable, including inventions, improvements, discoveries,
conceptions, algorithms, integrated circuits, ideas, techniques, processes, designs, products, developments, specifications, methods, drawings, diagrams, tooling, models, software programs (including object code, source code and commenting), data,
data analysis, data interpretation, written reports, Know-How, Trade Secrets, Confidential Information, documentation and copyrightable material whether patentable or non-patentable. 

 

	 	GG.	 “Intellectual Property Rights” or “IPRs” means all rights under or to Intellectual Property.

  

	 	HH.	 “JHU” means the Johns Hopkins University. 

 

	 	II.	 “JHU Agreements” means, collectively, (i) that certain License Agreement by and between SVI and JHU entered into on or around
June 20, 1998, as amended by that certain Amendment to License Agreement dated as of January 15, 2000, and as further amended by that certain Addendum to License Agreement entered into on or around December 7, 2004, as in effect as of
the Effective Date, (ii) that certain License Agreement by and between SVI and JHU entered into on or around December 7, 2006, as in effect as of the Effective Date; (iii) the consent letter dated December 27, 2005 signed by JHU,
(iv) the consent letter dated August 7, 2007 signed by JHU, (v) the letter dated August 7, 2007 signed by Bionics, SVI and JHU, and (vi) the consent letter dated March 19, 2008 signed by SVI and JHU.

  

	 	JJ.	 “Joint Intellectual Property” has the meaning ascribed thereto in Section 11.1(b) of the Bionics Lead Development
Agreement. 

  

	 	KK.	 “Know-How” means all factual knowledge and information that gives a Person the ability to produce or market something that it
otherwise would not have known how to produce or market with the same accuracy or precision, including all formulae, algorithms, processes, procedures, writings, data, protocols, techniques, proposals, designs, ideas, concepts, strategic, research
and development information and related documentation business and other plans, research, inventions, and invention disclosure and all records of the foregoing. 

 

	 	LL.	 “License” has the meaning ascribed thereto in Section 2(A).  

 

	 	MM.	 “License Fee” has the meaning ascribed thereto in Section 3(E). 

 

	 	NN.	 “Licensed Product” means any product in the Implantable Cardiac Field, including but not limited to Royalty Products.

  

 5 

	 	OO.	 “Net Sales” means the net sales from the Commercial Sale of Royalty Products recorded by CPI and its Affiliates in accordance with
United States generally accepted accounting principles, consistently applied by CPI and its Affiliates across all similar product lines, in connection with the preparation of CPI’s and its Affiliates’ financial statements, and shall be
determined in accordance with the procedure listed in Exhibit B hereto. For purposes of this definition, Royalty Products will be considered “sold” when and only when CPI or its Affiliate recognizes the revenue from sales to a Third
Party purchaser. 

  

	 	PP.	 “Neuro Field” means the neuromodulation field of the Bionics Lead Development Agreement. For purposes of clarity, the Neuro Field
does not encompass the Implantable Cardiac Field. 

  

	 	QQ.	 “Non-Billabong Royalty Product” means an implantable lead (alone or in combination with other devices) that if sold by CPI or one
of its Affiliates in the Implantable Cardiac Field would (absent the License) Infringe a valid and enforceable claim of an issued Royalty Patent but would not (absent the License) Infringe a valid and enforceable claim of an issued Billabong Patent.

  

	 	RR.	 “Opinion” has the meaning ascribed thereto in Section 4(D). 

 

	 	SS.	 “Patent” means all classes or types of patents, design patents, utility patents, including issued patents, published and
non-published patent applications (including inventors’ certificates and utility models) in any country or jurisdiction or under any treaty, including all originals, provisionals, substitutions, continuations, continuations-in-part,
divisionals, supplementary protection certificates, renewals, all letters patent granted thereon, and all reissues, reexaminations, extensions, confirmations, revalidations, registrations, patents of addition and foreign counterparts, as well as
industrial design registrations. 

  

	 	TT.	 “Person” means an individual, partnership, corporation, business trust, limited liability company, unincorporated association,
trust, joint venture or any other entity or Governmental Authority. 

  

	 	UU.	 “Prosecution” means prosecution of any proceeding in the United States Patent and Trademark Office or in any other registration
authority in any country, including regarding any application (whether ex parte or inter partes), including interference, reexamination and reissue. 

  

	 	VV.	 “Records” means written records sufficient in detail to enable the royalties and percentage of Sub-License Revenue payable under
this Agreement by CPI to be determined and verified by SVI or its independent auditors. 

  

	 	WW.	 “Reduced Royalty Component” means a component of an implantable lead that (a) is either (i) purchased from a Third Party,
or (ii) subject to a 

  

 6 

	 	 
royalty or other license payment (whether lump sum, periodic, percentage or otherwise) which CPI or one of its Affiliates pays to a Third Party, and (b) has a purpose related to MR safety.

  

	 	XX.	 “Reduced Royalty Product” means a Non-Billabong Royalty Product that includes one or more Reduced Royalty Components.

  

	 	YY.	 “Royalty Patent” means (i) a Patent to which SVI has and has granted to CPI exclusive commercial rights in the Implantable
Cardiac Field and which is listed on Exhibit D hereto, (ii) any claims of any future Patent for which SVI has and has granted to CPI exclusive commercial rights in the Implantable Cardiac Field, which claim and are entitled to claim (in
whole, but not in part) priority to a Patent covered by the preceding clause (i) (e.g., claims in a continuation-in-part Patent which require new matter for support are not Royalty Patents), and (iii) any of the Billabong Patents to which
SVI has and has granted to CPI exclusive commercial rights in the Implantable Cardiac Field. For the avoidance of any doubt, CPI acknowledges and agrees that the following shall not be considered in determining whether SVI has and has granted to CPI
exclusive commercial rights in the Implantable Cardiac Field with respect to any Patent: (a) any lien or security interest in such Patent; (b) any rights retained by JHU under the JHU Agreements; (c) to the extent the Patent was
supported by federal funding obtained by JHU, any rights, conditions and limitations imposed by U.S. law (including any royalty-free nonexclusive license granted to the U.S. government pursuant to U.S. law and any requirement that products used or
sold in the U.S. be manufactured substantially in the U.S.); and (d) any right to author, to publish and to retain or transfer copyright to scientific reports retained by SVI or SVI’s collaborators or granted by SVI to Third Parties.

  

	 	ZZ.	 “Royalty Product” means an implantable lead (alone or in combination with other devices) that if sold by CPI or one of its
Affiliates in the Implantable Cardiac Field would (absent the License) Infringe a valid and enforceable claim of an issued Royalty Patent. 

  

	 	AAA.	 “Royalty Product Dispute” has the meaning ascribed thereto in Section 4. 

 

	 	BBB.	 “Royalty Product Notice” means a notice from CPI to SVI stating that CPI has determined that a Licensed Product is (or is not) a
Royalty Product or will become (or will not become) a Royalty Product upon the issuance of any allowed claims of any pending application for a Royalty Patent. 

 

	 	CCC.	 “Short Form Registration Statement” means a short-form document suitable for recordation at a local patent office, sufficient to
put persons on notice of the license to Patent rights granted pursuant to the Definitive Agreements. 

  

 7 

	 	DDD.	 “Sub-License Revenue” means the cash revenue payments that CPI and its Affiliates actually receive from the license or sub-license
to Third Parties of the right to make, have made, import, use, promote, market, distribute, lease, sell, offer for sale or commercialize Royalty Products, recorded by CPI and such Affiliates in accordance with United States generally accepted
accounting principles, consistently applied by CPI and such Affiliates across all similar product lines, in connection with the preparation of CPI’s and its Affiliates’ financial statements. Sub-License Revenue does not include
non-monetary value that may be exchanged with any such Third Party (e.g., via a cross license) or sales from such Third Party to CPI or its Affiliates so long as CPI or such Affiliate did not structure the arrangement for the sole purpose of
avoiding, circumventing, evading or minimizing its payment obligations to SVI hereunder. 

  

	 	EEE.	 “Surgi-Vision IP” means all IPR in and to all Intellectual Property in the Implantable Cardiac Field now or hereinafter owned by or
exclusively licensed to SVI, including the Billabong Patents. 

  

	 	FFF.	 “Tachy Lead” has the meaning ascribed thereto in the Project Plan attached as Exhibit A to the Development Agreement.

  

	 	GGG.	 “Term” has the meaning ascribed thereto in Section 7(A). 

 

	 	HHH.	 “Termination Option” has the meaning ascribed thereto in Section 8. 

 

	 	III.	 “Third Party” and “Third Parties” mean one or more Persons other than SVI, CPI and their respective Affiliates.

  

	 	JJJ.	 “Third Party Licensor” means any Third Party that has granted a Party a license to Intellectual Property.

  

	 	KKK.	 “Trade Secret” means any Know-How or other information that generally facilitates the production, manufacturing, marketing, or sale
of products or services, increases revenues, or provides an advantage over the competition, is not generally known, and is the subject of reasonable efforts to maintain its confidentiality. 

2.  Grant of Rights. 
  

	 	A.	 License. Subject to the terms and conditions of this Agreement, SVI hereby grants to CPI an exclusive, sublicensable, worldwide license under
the Surgi-Vision IP, including but not limited to the Billabong Patents (the “License”), to make, have made, use, promote, market, import, distribute, lease, sell, offer for sale and commercialize the Licensed Products in the
Implantable Cardiac Field for the term of this Agreement. SVI further grants CPI the right to adapt the Surgi-Vision IP to a commercial form suitable for incorporation into CPI’s and its Affiliates’ product(s) in the Implantable Cardiac
Field. For the avoidance of doubt, the sole and 

  

 8 

	 	 
exclusive nature of the License herein granted being acknowledged, SVI, including any transferee, assignee or successor thereof or its Third Party Licensors, shall have no right to deal in any
way with (or exercise any right herein granted to CPI with respect to) the Surgi-Vision IP or any Licensed Product (including to manufacture, promote, market, distribute, sell, offer for sale and/or commercialize Licensed Products) within the
Implantable Cardiac Field, and any such purported right shall be null and void; provided, however, that the foregoing shall not apply with respect to: (a) any lien or security interest in the Surgi-Vision IP; (b) any rights
retained by JHU under the JHU Agreements; (c) to the extent a Patent was supported by federal funding obtained by JHU, any rights, conditions and limitations imposed by U.S. law (including any royalty-free non-exclusive license granted to the
U.S. government pursuant to U.S. law and any requirement that products used or sold in the U.S. be manufactured substantially in the U.S.); and (d) any right to author, to publish and to retain or transfer copyright to scientific reports
retained by SVI or SVI’s collaborators or granted by SVI to Third Parties. The Parties hereby further agree and confirm that the terms and conditions of the License granted herein, including the aforesaid exclusivity, shall survive any Change
in Control of SVI or the assignment, transfer or sale of all or substantially all of its assets, by operation of law or otherwise. 

  

	 	B.	 Publication Rights. Subject to Section 9 (“Confidentiality”) herein below, the License granted in
Section 2(A) includes the right to disclose or make public any and all information, including results, based on the work or activities carried out by CPI in connection with the development of Licensed Products or their use within the
Implantable Cardiac Field. 

  

	 	C.	 Recordation. SVI and CPI shall cooperate to prepare a Short Form Registration Statement and/or confirmatory assignment(s) and license(s) in
any countries as to which either Party so desires. Each Party may, at its own expense, record such Short Form Registration Statements and/or confirmatory assignment(s) and license(s). 

 

	 	D.	 Reserved Rights. All rights and interests not expressly granted to CPI are reserved by SVI for itself, its Affiliates and other licensees and
sublicensees (including Bionics), including, but not limited to, the rights to use and grant licenses under the Surgi-Vision IP to make, have made, import, use, promote, market, distribute, lease, sell, offer for sale or commercialize products
(other than in the Implantable Cardiac Field for so long as CPI has an exclusive license in the Implantable Cardiac Field under this Agreement). For the avoidance of any doubt, without limiting the generality of the foregoing sentence, SVI reserves
all rights to use and grant licenses under the Surgi-Vision IP to make, have made, import, use, promote, market, distribute, lease, sell, offer for sale or commercialize products in the non-chronically implanted, catheter-based cardiac

  

 9 

	 	
electrophysiology field; provided, that such products are not within the Field. 

3.  Compensation. 
  

	 	A.	 In consideration of the exclusive license in the Implantable Cardiac Field to the Surgi-Vision IP granted herein, CPI agrees to pay to SVI royalties
on Net Sales of Royalty Products as follows: either (i) one and a half (1.5%) percent of the aggregate worldwide Net Sales of all Reduced Royalty Products; or (ii) three and a half (3.5%) percent of the aggregate worldwide Net Sales of
Royalty Products which are not Reduced Royalty Products. After the aggregate royalty payments to SVI under this Agreement (which excludes the License Fee, as defined hereunder) reach one hundred million ($100,000,000.00) dollars, the royalty on Net
Sales of all Royalty Products which are not Reduced Royalty Products will be reduced from three and a half (3.5%) percent to two (2%) percent. 

  

	 	B.	 CPI will make royalty payments to SVI on a quarterly basis for the preceding quarter sixty (60) days following the issuance of the consolidated
financial statements of CPI and its Affiliates for such quarter, as publicly reported; provided, however, that (i) in no event shall CPI make such royalty payments to SVI later than one hundred twenty (120) days following the
end of the quarter, and (ii) in the event such financial statements are no longer publicly reported, CPI will make such royalty payments to SVI within ninety (90) days following the end of the quarter. 

 

	 	C.	 For each of the first three (3) years following the first Commercial Sale of a Royalty Product (commencing with the first fiscal quarter
following (but not including) the first Commercial Sale of a Royalty Product), CPI will pay SVI aggregate royalties (pursuant to Section 3(A) and Section 3(F), collectively) of no less than one hundred fifty thousand
($150,000.00) dollars, regardless of Net Sales of Royalty Products in such year. 

  

	 	D.	 For purposes of clarity, any Licensed Product that does not constitute a Royalty Product at the time of its Commercial Sale shall not be subject to
any retroactive royalty or other payment (except as provided in the Development Agreement) in the event such Licensed Product subsequently becomes a Royalty Product. 

 

	 	E.	 In further consideration of the exclusive license in the Implantable Cardiac Field to the Billabong Patents granted hereunder, CPI shall pay SVI a
one-time, non-refundable license fee of thirteen million ($13,000,000.00) dollars (the “License Fee”), paid in the following installments: (i) five million ($5,000,000.00) dollars paid upon execution of the Definitive Agreements; (ii)
three million ($3,000,000.00) dollars paid no later than three (3) months after execution of the Definitive Agreements; (iii) three million ($3,000,000.00) dollars paid no later than six (6) months after 

 

 10 

	 	
execution of the Definitive Agreements; and (iv) two million ($2,000,000.00) dollars paid no later than nine (9) months after execution of the Definitive Agreements. 

 

	 	F.	 CPI will pay SVI twenty-five (25%) percent of all Sub-License Revenue, which percentage will be paid on a quarterly basis for the preceding quarter
sixty (60) days following the issuance of the consolidated financial statements of CPI and its Affiliates for such quarter, as publicly reported; provided, however, that (i) in no event shall CPI make such Sub-License Revenue
payments to SVI later than one hundred twenty (120) days following the end of the quarter, and (ii) in the event such financial statements are no longer publicly reported, CPI will make such Sub-License Revenue payments to SVI within
ninety (90) days following the end of the quarter. Examples of what types of transactions do and do not implicate Sub-License Revenue payments are listed in Exhibit E hereto. In keeping with the spirit of this Agreement, CPI agrees that
it shall not (and it shall cause its Affiliates not to) structure any license or sub-license to Third Parties for the sole purpose of avoiding, circumvent, evading or minimizing its payment obligations to SVI hereunder. 

 

	 	G.	 Only one royalty will be paid hereunder for each Royalty Product whether such Royalty Product (i) constitutes more than one type of lead, or
(ii) is covered by more than one claim of a Royalty Patent, by the claims of more than one of the Royalty Patents, or by the claims of Royalty Patents of more than one country. CPI has no obligation to pay royalties (and, although SVI will not
be obligated to refund any royalties already paid, CPI will have the right to offset in future royalty payments the amounts of royalties already paid) on sales of Royalty Products that are later returned, rejected or recalled.

  

	 	H.	 Simultaneously with its quarterly payment of royalties and Sub-License Revenue percentage, CPI will provide SVI with a written report setting forth
in reasonable detail the amount of each type of Royalty Product sold during such quarter, the Net Sales for each such type of Royalty Product sold during such quarter, the Sub-License Revenue actually received by CPI and its Affiliates during such
quarter, and the amount of the royalties due for such quarter. 

  

	 	I.	 In the event that a product simultaneously falls within the definition of “Royalty Product” under this Agreement and the definition of
“Licensed Product” under the Bionics License Agreement: (a) SVI agrees that any sale of such product will only implicate the payment of fees under one of the two agreements, not both (e.g., SVI will not receive royalty payments both
under this Agreement and the Bionics License Agreement with respect to the same sale); (b) the Parties will determine which agreement will govern the fees to be paid to SVI primarily by reference to the product’s actual intended use, and
whether such use falls within the scope 

  

  

 11 

	 	 
of the neuromodulation field of the Bionics Lead Development Agreement or the Implantable Cardiac Field; and (c) if the Parties are unable to determine the governing agreement pursuant to
clause (b) above, the Parties shall settle such disagreement pursuant to substantially the same mediation and arbitration provisions set forth in Section 4(E) and (F) below with respect to a Royalty Product Dispute (it being
understood and agreed that scope of the arbitration will be limited to determining which agreement will govern the fees to be paid to SVI and that in no event will the Arbitrators have the power or authority to terminate this Agreement or the
Bionics License Agreement). 

 4.  Royalty Products Disputes. 

 

	 	A.	 Prior to the first Commercial Sale of any product which CPI reasonably believes constitutes a Licensed Product, CPI shall deliver to SVI a Royalty
Product Notice regarding such Licensed Product. Notwithstanding the foregoing, any failure by CPI to deliver a Royalty Product Notice will not constitute a breach of this Agreement (it being understood, however, that any failure by CPI to deliver a
timely Royalty Product Notice could result in SVI having additional time to assert that the Licensed Product is a Royalty Product in accordance with the procedures of this Section 4). 

 

	 	B.	 Within one hundred twenty (120) days of SVI’s Chief Executive Officer, President or Chief Financial Officer obtaining actual knowledge of
the first Commercial Sale of any product which SVI reasonably believes constitutes a Licensed Product and which was not previously the subject of a Royalty Product Notice, SVI shall deliver to CPI written notice requesting that CPI deliver a Royalty
Product Notice for such product. Within sixty (60) days following CPI’s receipt of such a request, CPI shall deliver to SVI a Royalty Product Notice regarding such Licensed Product. Notwithstanding the foregoing, any failure by SVI to
deliver a request for Royalty Product Notice will not constitute a breach of this Agreement (it being understood, however, that any failure by SVI to deliver a timely request for Royalty Product Notice could result in SVI losing the opportunity to
receive certain royalties or Sub-License Revenue payments otherwise payable hereunder). 

  

	 	C.	 To the extent there is any dispute between the Parties as to whether a Licensed Product constitutes (or will constitute) a Royalty Product (any such
dispute being referred to herein as a “Royalty Product Dispute”), such Royalty Product Dispute shall be exclusively resolved pursuant to the provisions of this Section 4. SVI may deliver to CPI written notice of its
intent to begin a Royalty Product Dispute within, and only within, the following timeframes. For the purposes of clarity, if SVI fails to deliver to CPI written notice of a Royalty Product Dispute within the applicable timeframes in subsections
(i) or (ii) below, SVI waives its rights to challenge CPI’s determination or to otherwise claim that the subject Licensed Product constitutes (or will constitute) a Royalty Product. 

 

 12 

(i)            If CPI has delivered a Royalty
Product Notice for a particular Licensed Product, SVI’s written notice of any Royalty Product Dispute regarding such Licensed Product must be delivered to CPI either (x) within thirty (30) days after receiving the applicable Royalty
Product Notice, or (y) within thirty (30) days after issuance of a Royalty Patent with a different allowed claim scope than existed at the time of such Royalty Product Notice (in the case of (y), however, the Royalty Product Dispute must
be limited to such different allowed claim scope). 

(ii)            If CPI failed to deliver a
Royalty Product Notice for a particular Licensed Product following a written request from SVI pursuant to Section 4(B), SVI’s written notice of any Royalty Product Dispute regarding such Licensed Product must be delivered to CPI
within ninety (90) days after such written request was delivered to CPI. 

(iii)          If CPI did not deliver a Royalty Product
Notice for a particular Licensed Product and SVI did not provide CPI with a written request for a Royalty Product Notice within the timeframe set forth in Section 4(B), then SVI waives its rights to receive royalties or Sub-License
Revenue payments otherwise payable to SVI pursuant to Section 3(A) and Section 3(F), respectively, for that Licensed Product with respect to the period of time preceding SVI’s actual delivery to CPI of written notice of
a Royalty Product Dispute. 
  

	 	D.	 In the event the Parties are unable to resolve a Royalty Product Dispute informally within forty-five (45) days after delivery of SVI’s
written notice of such Royalty Product Dispute, the Parties shall hire an experienced patent attorney who is knowledgeable in the field of intellectual property law relating to medical devices and who (and whose firm) shall have no current or prior
(within the preceding five year period) business relationships with the Parties or any of their respective Affiliates to offer an opinion, within a reasonable amount of time as mutually agreed upon by the Parties, as to whether the lead, product or
device subject to the Royalty Product Dispute constitutes a Royalty Product (the “Opinion”). If either Party challenges the Opinion, resolution of the Royalty Product Dispute will proceed as follows under this Section 4.
The cost of such patent attorney shall be shared equally between the Parties. 

  

	 	E.	 No Party hereto may invoke, demand, file or otherwise commence an arbitration pursuant to Section 4(F) until the Parties have completed
a good faith mediation of the applicable Royalty Product Dispute in accordance with the following provisions: 

(i)           Within thirty (30) days after a
Party receives notice from the other Party that such other Party challenges the Opinion, the Parties shall confer to jointly select a mediator. 

(ii)           If CPI and SVI cannot agree on a
mediator pursuant to Section 4(E)(i) above, such Parties shall request the International Institute for Conflict Prevention & Resolution (“CPR”) to provide, within ten (10) days of making such request, a
list of ten 
  

 13 

 
(10) neutral proposed mediators who are experienced patent attorneys or attorneys with substantial patent litigation experience, in each case who are knowledgeable in the field of intellectual
property law relating to the development of medical devices and who (and whose firms) shall have no current or prior (within the preceding five year period) business relationships with either of the Parties or any of their respective Affiliates.

 (iii)          CPI and SVI each shall have
fifteen (15) days to object to any proposed mediator due to a conflict of interest or other lack of qualifications, and any proposed mediator to which either CPI or SVI objects shall be removed from the list of proposed mediators provided by
CPR. Within a period of five (5) days following the end of such fifteen (15) day objection period, CPI and SVI will then separately rank the remaining mediators, and deliver such ranking to the other Party, and the highest combined ranked
mediator shall be selected. Any such mediation shall be completed within forty-five (45) days after the date on which the mediator is selected. 

(iv)          The cost of such mediator shall be shared
equally between the Parties. 
  

	 	F.	 In the event that no agreement is reached by CPI and SVI as to a Royalty Product Dispute following a good faith mediation in accordance with
Section 4(E) above, either CPI or SVI, acting alone, may deliver to the other Party written notice demanding arbitration within twenty (20) days following the completion of such mediation undertaken, in which case the following
provisions shall apply: 

(i)            CPI and SVI hereby agree to
use their reasonable best efforts to complete such arbitration within one hundred and eighty (180) days of receipt of notice demanding arbitration. 

(ii)            The arbitration shall be
conducted in accordance with the then current CPR Rules for Nonadministered Arbitration, as such rules are modified by this Section 4(F) or by agreement of CPI and SVI. 

(iii)          The arbitration shall be conducted in
Washington, D.C. by a panel of three (3) neutral arbitrators (the “Arbitrators”) who shall be experienced patent attorneys or attorneys with substantial patent litigation experience, in each case who are knowledgeable in the
field of intellectual property law relating to the development of medical devices and who (and whose firms) shall have no current or prior (within the preceding five year period) business relationships with either of the Parties or any of their
respective Affiliates. Within fifteen (15) days after receipt of notice demanding arbitration, CPI and SVI shall request CPR to provide, within ten (10) days of making such request, a list of fifteen (15) qualified neutral proposed
Arbitrators. 
 (iv)          CPI and SVI each
shall have fifteen (15) days to object to any proposed Arbitrator due to a conflict of interest or other lack of qualifications, and any proposed Arbitrator to which either CPI or SVI objects shall be removed from the list of proposed
Arbitrators provided by CPR. Within a period of five (5) days following the end of such fifteen (15) day objection period, CPI and SVI will then separately rank the remaining 

 

 14 

 
proposed Arbitrators, and deliver such ranking to the other Party, and the three (3) highest combined ranked proposed Arbitrators shall be selected to be the Arbitrators. 

(v)            The Arbitrators shall apply
the substantive laws of the Federal Circuit Court of Appeals as to any Patents involved in the Royalty Product Dispute. 

(vi)          Discovery shall be limited to document
requests, requests for admission and depositions. CPI and SVI each shall be entitled to present expert witness testimony regarding the issues of whether the lead, product or device at issue constitutes a Royalty Product pursuant to this Agreement.
CPI and SVI each shall, within sixty (60) days after receipt of a written request by the other Party, make a reasonable search for and provide to the other Party documents reasonably relevant to the issues raised by any claim or counterclaim.
CPI, on the one hand, and SVI, on the other hand, each shall be limited to twenty (20) hours of non-expert depositions and fourteen (14) hours of expert depositions. 

(vii)          CPI and SVI shall be entitled to a
hearing and a post-hearing briefing, the scheduling and length of which shall be determined by the Arbitrators. 

(viii)         The arbitration of any Royalty Product
Dispute pursuant to this Section 4(F) shall be final and binding upon the Parties and judgment upon the decision may be entered in any court of competent jurisdiction. The Arbitrators shall be entitled to render a determination of the
disputed items in any Royalty Product Dispute only and shall not be entitled to award damages or other relief unless the Arbitrators determine that a Party has acted in bad faith with respect to the Royalty Product Dispute. 

(ix)           The cost of any arbitration
pursuant to this Section 4(F), including the cost of the record or transcripts thereof, if any, administrative fees, and all other fees involved including reasonable attorneys’ fees incurred by the Party determined by the
Arbitrators to be the prevailing Party, shall be borne by the Party determined by the Arbitrators not to be the prevailing Party, or as otherwise determined by the Arbitrators. 

(x)            Any determinations made
pursuant to this Section 4(F) shall, in the absence of fraud or intentional misconduct, be conclusive for all purposes of this Agreement, and CPI, SVI and any Arbitrators appointed pursuant to Section 4(F) each shall be free
from any and all liability resultant from such. 
     5. Records; Audit. CPI will (and will cause
its Affiliates to) keep accurate Records and retain such Records for a particular quarter for a period of not less than three (3) years after the end of the applicable quarter. Upon reasonable notice and during regular business hours, CPI will
(and will cause its Affiliates to) make available from time to time (but no more frequently than once a year) the Records for audit at SVI’s expense by independent representatives selected by SVI to verify the accuracy of the reports provided
to SVI. Such representatives must execute a confidentiality agreement reasonably acceptable to CPI prior to conducting such audit. Such representatives may disclose to SVI only the results of their audit regarding the accuracy and completeness of
royalty payments, payments of Sub-License Revenue and records related thereto, and will not disclose CPI’s or its Affiliates’ confidential business information to SVI without the prior written consent of CPI. In the event that such audit

  

 15 

 
reveals an underpayment by CPI of the actual royalties and/or Sub-License Revenue owed SVI, (i) CPI shall pay SVI the amount of the underpayment plus interest thereon at the lesser of
(a) ten percent (10%) per annum or (b) the maximum rate allowed by law, accruing from the date such amounts should have been paid to SVI, and (ii) if such underpayment exceeds five percent (5%) of the actual royalties and/or
Sub-License Revenue owed SVI, CPI shall reimburse SVI for all reasonable costs incurred to perform the audit. In the event that such audit reveals an overpayment by CPI of the actual royalties and/or Sub-License Revenue owed SVI, SVI shall refund
the difference to CPI. 
 6.  Development and Commercialization of Licensed Products.

  

	 	A.	 Commercialization. Subject to Section 6(B) below, on and after the date hereof, CPI shall have full control, authority and
discretion over any and all commercialization of Licensed Products, including: (i) all activities relating to the manufacture and supply of the Licensed Products; (ii) all marketing, promotion, sales, distribution, import and export
activities relating to the Licensed Products; and (iii) all activities relating to any regulatory filings, registrations, applications and approvals relating to any of the foregoing; provided, that, as between the Parties, all such
activities shall be at the sole cost and expense of CPI. Except as set forth in the Development Agreement, as between the Parties, CPI shall own all data, results and all other information arising from any such activities under this Agreement,
including all regulatory filings, registrations, applications and approvals relating to Licensed Products, and all of the foregoing information, documentation and materials shall be considered Confidential Information owned solely by CPI.

  

	 	B.	 No Obligation to Commercialize. It is hereby acknowledged and agreed that notwithstanding any and all rights herein granted to CPI pursuant
to the License, CPI shall have no obligation whatsoever to exercise any such rights, and for greater certainty but without limiting the generality of the foregoing, CPI shall have no obligation to develop, commercialize, sell or otherwise deal with
any of the Surgi-Vision IP or any Licensed Products, or to generate or maximize payments to SVI for royalties or Sub-License Revenue, the whole without in any way affecting, limiting or jeopardizing any of the rights herein granted to CPI.

 7.  Term and Termination. 

 

	 	A.	 Term. Unless sooner terminated pursuant to this Section 7, the term of this Agreement will begin as of the Effective Date and
shall remain in full force and effect until, and shall expire upon, the expiry of the last to expire of the Royalty Patents (the “Term”). 

  

	 	B.	 Termination by Either Party. 

(i)        Termination for Breach. Either Party may
terminate this Agreement for cause on thirty (30) days’ written notice (the “Cure Period”) to the other Party in the 

 

 16 

 
event of a breach of any material provision of this Agreement by such other Party; provided that, during the Cure Period, the breaching Party fails to cure such breach. In the event the
noticed breach is incapable of cure, the non-breaching Party may terminate the Agreement immediately upon written notice to the other Party. 

 (ii)            Termination for
Insolvency. Either Party may terminate this Agreement without notice if the other Party becomes insolvent, makes or has made an assignment for the benefit of creditors, is the subject of proceedings in voluntary or involuntary bankruptcy
instituted on behalf of or against such Party (except for involuntary bankruptcies which are dismissed within sixty (60) days), or has a receiver or trustee appointed for substantially all of its property. 

 (iii)          No Prejudice. Any
termination by any Party under this Section 7(C) shall be without prejudice to any damages or remedies to which it may be entitled from the other Party. 
  

	 	C.	 Effect of Termination. 

 (i) Upon expiration of this Agreement or termination of this Agreement by either Party, all rights
and obligations under this Agreement shall terminate (except as provided in Section 7(D)) and all License rights arising out of this Agreement shall revert to SVI; provided that (x) with respect to any Licensed Product the
Commercial Sale of which occurred prior to such termination, any license which may have attached to such Licensed Product that is already sold (whether explicit or implied) shall survive termination, (y) for one (1) year after such
termination, CPI and its licensees may continue to manufacture Royalty Products that, at the time of such termination, were already in the production pipeline (provided that CPI shall bear the burden of establishing to SVI’s reasonable
satisfaction the type and quantity of Royalty Products that were in the production pipeline at the time of termination), and (z) for a period of two (2) years after such termination, CPI, its distributors and licensees may continue to sell
Royalty Products in its existing inventory; provided that any sales pursuant to clause (z) above shall be subject to CPI’s payment obligations in Section 3;  

 (ii)            Upon expiration of this
Agreement pursuant to Section 7(A), the License in the Implantable Cardiac Field will continue in effect with respect to the non-Patent portions of the Surgi-Vision IP; and 

 (iii)          Upon any termination of this
Agreement by either Party, each Party will comply with Section 9(F) (“Return of Information”). 
  

	 	D.	 Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or
termination. Without limiting the foregoing, the obligations pursuant to Sections 1, 3 (including, without limitation, any unpaid installments of the License Fee) (it is understood, however, that Section 3 will survive without
prejudice to any right that CPI may have to damages or offset), 5, 7(C), 7(D), 9, 10, 13, 14, 16 and 17 shall survive termination of this Agreement. 

 

 17 

 Notwithstanding the foregoing, no claim for breach of warranty or
representation under Section 10 may be brought unless it is either (i) brought no later than two years following the latter of the termination or expiration of this Agreement or the Development Agreement, or (ii) brought
anytime as a counterclaim or a defense. 
 8.  Termination Option Under the Development
Agreement. Under the Development Agreement, CPI has the option, within sixty (60) days after successful completion of the first of the lead feasibility studies identified therein, not to continue with further development under that
agreement and to terminate that agreement (the “Termination Option”). In the event CPI exercises the Termination Option pursuant to the Development Agreement: 

 

	 	A.	 The License to CPI will automatically become non-exclusive for Surgi-Vision IP (other than the Billabong Patents) in the Implantable Cardiac Field
existing as of the termination date of the Development Agreement, and CPI will not be obligated to make any Sub-License Revenue or royalty payments (including annual minimum royalty payments) based on sales of Licensed Products occurring thereafter.

  

	 	B.	 The Billabong Patents will automatically be removed from the scope of the License and, subject to Section 8(C) below, CPI’s rights
with respect to the Billabong Patents under this Agreement will terminate. In addition, any and all Surgi-Vision IP invented, acquired or licensed to SVI after the termination date of the Development Agreement will automatically be removed from the
scope of the License and CPI’s rights with respect to such Surgi-Vision IP under this Agreement will terminate. 

  

	 	C.	 Any sublicenses granted by CPI with respect to the Billabong Patents pursuant to this Agreement will automatically terminate, provided,
however, that with respect to any Licensed Product the Commercial Sale of which occurred prior to CPI’s exercise of the Termination Option, any license which may have attached to such Licensed Product that is already sold (whether
explicit or implied) shall survive such termination. 

  

	 	D.	 CPI’s rights and obligations regarding enforcement of the BSC Controlled Surgi-Vision IP pursuant to Section 11(B) shall terminate
(in which event Bionics will have the rights and obligations set forth in the Bionics Lead Development Agreement). 

  

	 	E.	 CPI’s rights and obligations regarding patent Prosecution of the BSC Controlled Surgi-Vision IP pursuant to Section 12 shall
terminate (in which event Bionics will have the rights and obligations set forth in the Bionics Lead Development Agreement). 

  

	 	F.	 CPI will be obligated to make any remaining installments of the License Fee, as scheduled, and such remaining installments (if any) will constitute

  

 18 

	 	 
a license fee for the non-exclusive license in the Implantable Cardiac Field described in Section 8(A) above. 

 

	 	G.	 CPI’s exercise of the Termination Option will have no effect on Bionics’ rights and obligations under the Bionics Lead Development
Agreement. 

 9.  Confidentiality. 

 

	 	A.	 Ownership of Confidential Information. The Parties agree that (i) all BSC Core Product Information generated or developed by CPI, its
Affiliates, or a Third Party on behalf of CPI or its Affiliates will be deemed to be Confidential Information owned by CPI, and (ii) the terms and existence of the Definitive Agreements are Confidential Information owned by both Parties. Except
as otherwise expressly provided in this Section 9, neither Party is subject to the obligations of a “non-owning Party” with respect to Confidential Information that is owned by both Parties. Except as otherwise expressly
provided in this Agreement, for all other Confidential Information, the “owning Party” is deemed to be the disclosing Party. Confidential Information shall remain the property of the owning Party, and the non-owning Party shall not be
deemed by virtue of this Agreement or any access to the owning Party’s Confidential Information to have acquired any right, title or interest in or to any Confidential Information, except the limited right to use such Confidential Information
in accordance with the terms of the Definitive Agreements or other agreements between the Parties or their Affiliates. 

  

	 	B.	 Non-Use and Non-Disclosure. Prior to the commencement of the Term, certain Confidential Information was exchanged between the Parties under
the terms of the Earlier Confidentiality Agreement. Likewise, from time to time during the Term, either Party may make available to the other Party or otherwise generate or develop Confidential Information. The non-owning Party will maintain the
owning Party’s Confidential Information in confidence and will not use such Confidential Information except as reasonably necessary to perform its obligations and exercise its rights under this Agreement or other agreements between the Parties
or their Affiliates. Notwithstanding any provision to the contrary contained in the Bionics Lead Development Agreement, SVI agrees and acknowledges that CPI and its Affiliates may share all of SVI’s Confidential Information with and among each
of their respective Affiliates for use solely within the Field, provided that (i) prior to any such sharing of SVI’s Confidential Information such Affiliates are bound by obligations of confidentiality, non-disclosure and non-use
substantially similar in scope to those in this Agreement and (ii) CPI shall be responsible for any breach of confidentiality, non-disclosure and non-use by any such Affiliate. Neither Party will disclose the other Party’s Confidential
Information without the prior written consent of the other Party, except as permissible in Section 9(D) below or in other agreements 

 

 19 

	 	 
between the Parties or their Affiliates. All Confidential Information will be treated by the non-owning Party with the same care as it would exercise in the handling of its own Confidential
Information, but not less than reasonable care. The limitations and undertakings specified in this Section 9 shall survive termination of this Agreement for a period of five (5) years. 

 

	 	C.	 Standard Exceptions. The obligations of Sections 9(B), (E) and (F) do not apply to any of the other Party’s
Confidential Information: (i) which, other than the Development IP, is already known by the non-owning Party at the time of the disclosure; (ii) following such information becoming publicly known without the wrongful act or breach of this
Agreement by the non- owning Party; (iii) following such information becoming rightfully received by the non-owning Party from a Third Party without breaching any confidentiality obligation owed by such Third Party to the owning Party;
(iv) following such information becoming approved for release by written authorization of the owning Party; or (v) other than the Development IP, following such information becoming subsequently and independently developed by employees or
representatives of the non- owning Party without knowledge or use of the owning Party’s Confidential Information. The burden of proving the existence of facts which would provide an exception under this Section 9(C) rests with the
non-owning Party. Notwithstanding any provision herein to the contrary, to the extent required under the JHU Agreements, SVI shall be permitted to disclose the terms of this Agreement to JHU. 

 

	 	D.	 Permitted Disclosures. Each Party may disclose the other Party’s Confidential Information: 

(i)            to the extent reasonably
necessary for a Party to prepare, file and Prosecute a Patent application under this Agreement or other agreements between the Parties or their Affiliates; 

(ii)           to the extent permissible under any
other agreements between the Parties or their Affiliates; 

(iii)          to the extent reasonably necessary for a
Party to develop or commercialize, directly or indirectly through one or more licensees, products related to or utilizing Intellectual Property within its allocated (or retained) field of rights pursuant to this Agreement or the Development
Agreement; provided that: (a) such disclosure may include the disclosure of this Agreement’s existence and the scope of any license granted hereunder; (b) prior to making any such disclosure pursuant to this subsection, such
Party will, if reasonably practical, take reasonable steps to limit the scope of such disclosure and its effect on confidentiality; and (c) this subsection will not apply to any BSC Core Product Information owned by CPI; 

(iv)          to the extent reasonably necessary for the
purposes of this Agreement or other agreements between the Parties, to its respective Affiliates, consultants, agents, 

 

 20 

 
advisors, attorneys, outside contractors and clinical investigators, but only if those Persons are bound by obligations of confidentiality, non-disclosure, and non-use substantially similar in
scope to those in this Agreement; provided, such Party shall be responsible for any breaches of confidentiality, non-disclosure and non-use by any such Affiliate, consultant, agent, advisor, attorney, outside contractor or clinical
investigator to whom disclosure is made; 

(v)          in connection with communications to such
Party’s stockholders and prospective investors; provided that, unless otherwise agreed between the Parties: (a) such stockholders and prospective investors are subject to obligations of confidentiality no less stringent than those
contained herein; and (b) such disclosure be expressly limited to the existence of this Agreement and the scope of any license granted hereunder; 

(vi)         to the extent reasonably necessary to enforce
this Agreement or other agreements between the Parties or their Affiliates; 

(vii)        to the extent reasonably necessary to comply with a
subpoena, court order, or administrative order. Before complying, the Party subject to such subpoena, court order or administrative order will notify the other Party, allow the other Party a reasonable time to oppose the disclosure, and reasonably
cooperate with the other Party’s efforts to do so; or 

(viii)       to the extent reasonably necessary to comply with an
applicable law, rule, regulation of any Governmental Authority or securities exchange, including the FDA, the Securities and Exchange Commission and the New York Stock Exchange. Before complying, the Party subject to such law, rule or regulation
will notify the other Party, allow the other Party a reasonable time to seek a protective order (if appropriate), and reasonably cooperate with the other Party’s efforts to do so. 

 

	 	E.	 Further Limitation on Use and Disclosure of Surgi-Vision IP. Notwithstanding the foregoing, while CPI recognizes SVI’s legitimate right
to commercialize the Surgi-Vision IP outside the Field, the Parties agree and acknowledge that, in order to give CPI the full benefit of the exclusive License granted herein, with respect to those portions of the Surgi-Vision IP that constitute
Confidential Information owned by SVI, SVI will, if reasonably practical, take reasonable steps to limit the scope of any disclosure of such Surgi-Vision IP; provided, however, that the foregoing obligation on SVI will not apply with
respect to disclosure of Surgi-Vision IP by SVI to Bionics. In the event CPI exercises its Termination Option under the Development Agreement and the License becomes non-exclusive, SVI’s obligations under this Section 9(E) shall
cease. 

  

	 	F.	 Return of Information. Upon termination or expiration of this Agreement for any reason, each Party will return or destroy (at the other
Party’s 

  

 21 

	 	 
choice) all Confidential Information owned by such other Party then in its possession and, if applicable, provide a certification of such destruction. 

 

	 	G.	 Publication and Authorship. Notwithstanding Section 9(E) above, SVI shall have the right to author, to publish and to retain or
transfer copyright to scientific reports describing the methods and results of any or all Surgi-Vision IP licensed to CPI hereunder; provided that, if the studies were conducted with the financial and/or technical support of CPI or any of its
Affiliates, such reports shall include an acknowledgment to that effect. Prior to publishing any reports or submitting any manuscripts wherein the publication could adversely affect patent rights for any Surgi-Vision IP (i.e., new inventions for
which patent applications have not been filed), (i) SVI shall make the manuscripts for such reports available to CPI, using reasonable efforts to provide CPI copies of such manuscripts at least thirty (30) days before submission to a
journal or other publisher so that CPI can take any steps it deems necessary to protect such Surgi-Vision IP disclosed in such manuscripts, (ii) CPI will promptly review such manuscripts, and (iii) SVI will delay its submission to such
journal or other publisher for up to one hundred eighty (180) days if CPI, in its reasonable discretion, determines that it needs additional time to protect such Surgi-Vision IP. 

 

	 	H.	 Injunctive Relief. Each Party acknowledges and agrees that the breach of this Section 9 would be likely to cause serious and
irreparable harm, the amount of which may be extremely difficult to estimate, thus making any remedy at law or in damages inadequate. Each Party therefore agrees that if the other Party breaches this Section 9 or if such Party has cause
to believe that the other Party intends to or is about to breach such provisions, then such Party will be entitled to seek injunctive relief enjoining the breach and will have the right to specifically enforce this Agreement and the terms and
provisions hereof in addition to any other remedy available at law or in equity. 

  

	 	I.	 Termination of Earlier Confidentiality Agreement. The Parties agree that the Earlier Confidentiality Agreement will terminate as of the
Effective Date, and that any and all Confidential Information exchanged or disclosed by the Parties pursuant to the Earlier Confidentiality Agreement will be subject solely to the terms of this Section 9 and Section 9 of the
Development Agreement. 

 10. Representations, Warranties and Covenants. 

 

	 	A.	 No Conflicting Agreements. SVI represents, warrants and covenants that, after giving effect to the Bionics Amendment, it has not and will not
enter into any agreement or commitment or obligation with any Third Party or Affiliate that conflicts in any way with its obligations under this Agreement. CPI represents, warrants and covenants that it has not and will

  

 22 

	 	 
not enter into any agreement or commitment or obligation with any Third Party or Affiliate that conflicts in any way with its obligations under this Agreement. 

 

	 	B.	 Authority. Each Party represents and warrants that, as of the Effective Date and after giving effect to the Bionics Amendment: (i) it
has the full right, power, and authority to execute and deliver this Agreement and to perform its terms; (ii) it has taken all required corporate actions to approve and adopt this Agreement; (iii) this Agreement is enforceable against it
according to its terms, subject to bankruptcy, insolvency, and other laws relating to or affecting creditors’ rights and to general equity principles; and (iv) the person or persons executing this Agreement on its behalf are duly
authorized and empowered to do so. Without limiting the generality of the foregoing, SVI represents and warrants as of the Effective Date that, subject to the terms of the JHU Agreements, it has the authority to Prosecute all Patents which are part
of the Surgi-Vision IP, including all Patents licensed to SVI under the JHU Agreements, and that SVI has the right to delegate or otherwise pass control of Prosecution to CPI and its Affiliates in the manner set forth in Section 12,

  

	 	C.	 JHU Agreements. SVI represents and warrants that it has provided CPI with true and complete copies of the JHU Agreements and all appendices,
addenda, amendments, waivers, consents or other agreements related thereto existing as of the Effective Date, and covenants that, subsequent to the Effective Date, it will not execute any appendices, addenda, amendments, waivers, consents or other
agreements related to the JHU Agreements that adversely affect CPI’s or its Affiliates’ rights hereunder, without first obtaining CPI’s prior written consent. SVI further represents and warrants that the JHU Agreements are the only
license agreements SVI has entered into with respect to Patents in the Implantable Cardiac Field. 

  

	 	D.	 Sufficiency. SVI represents and warrants that Exhibit A and Exhibit D collectively set forth a true and complete list, as of
the Effective Date, of all Patents related to the development of the Licensed Products pursuant to the Development Agreement which are (i) owned or co-owned by SVI, or (ii) licensed to SVI (complete with the name of the Third Party
Licensor of each licensed Patent) in the Implantable Cardiac Field. SVI represents and warrants that all items required to be disclosed pursuant to clause (ii) are licensed exclusively to SVI and constitute Surgi-Vision IP.

  

	 	E.	 Title. SVI represents, warrants and covenants that, except as provided in this Agreement, the Development Agreement, the Bionics Agreements
or the JHU Agreements: (i) SVI owns, and during the Term will continue to own, all legally enforceable right, title and interest to all of the Surgi-Vision IP it purports to own, and SVI has an exclusive license in the Implantable Cardiac Field
to all of the Surgi-Vision IP that it does not 

  

 23 

	 	
purport to own, in each case free and clear of all liens, mortgages, charges, security interests and other encumbrances without an obligation to pay any royalties, license fees or other amounts
to any Third Party; and (ii) SVI has and will retain all rights necessary to exclusively license the Surgi-Vision IP to CPI in the Implantable Cardiac Field. 

 

	 	F.	 Third-Party Infringement. SVI represents and warrants that, as of the Effective Date, to SVI’s actual knowledge, (i) there is no
Infringement by any Third Party (including any employee or former employee of SVI) of any Surgi-Vision IP, and (ii) there are no violations of any exclusive rights granted to SVI by its Third Party Licensors, except that SVI has filed a patent
application (application number [***]) attempting to invoke an interference. SVI further represents and warrants that, as of the Effective Date, no Claims have been made by SVI or, to SVI’s actual knowledge, by SVI’s Third Party Licensors
for any Infringement by others of any rights with respect to any Surgi-Vision IP, except that SVI has filed a patent application (application number [***]) attempting to invoke an interference. 

 

	 	G.	 Freedom-to-Operate. SVI represents and warrants that, as of the Effective Date, it has not received and has no knowledge of any Claim by a
Third Party containing any express or implied allegation that SVI, its Third Party Licensors or the Surgi-Vision IP is or may be Infringing any of such Third Party’s Intellectual Property Rights, except that (i) SVI knows of a Third
Party’s attempt to invoke an interference against U.S. 6,904,307, (ii) SVI has filed a re-issue with respect to U.S. 6,904,307, and (iii) SVI has filed a patent application (application number [***]) attempting to invoke an
interference. If, at any time during the Term or thereafter, SVI receives or becomes aware of any such Claim, SVI shall promptly notify CPI of such Claim in writing, describing the Claim in reasonable detail (but, provided CPI has not exercised its
Termination Option, performing and providing no written analysis regarding the Claim). Provided CPI has not exercised its Termination Option, upon such notice, CPI may, in its sole discretion, evaluate such Claim to determine whether a license of
the Third Party’s Intellectual Property is necessary or desirable, or whether such Third Party’s Intellectual Property may otherwise have a material effect on the Surgi-Vision IP in the Implantable Cardiac Field. SVI further represents and
warrants that, as of the Effective Date, it is not, and to SVI’s actual knowledge its Third Party Licensors are not, currently evaluating any Intellectual Property of any Third Party (and neither SVI nor, to SVI’s actual knowledge, its
Third Party Licensors has conducted any such evaluations in the past three (3) years) to determine whether a license thereof is necessary or desirable, or whether such Intellectual Property may otherwise have a material effect on the
Surgi-Vision IP in the Implantable Cardiac Field. 

 [***] Indicates portions of this exhibit
that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 
  

 24 

	 	H.	 Know-How and Trade Secrets. SVI represents, warrants and covenants that: (i) it has taken, and will continue to take, all actions that a
reasonably prudent person would take to maintain its Trade Secrets as confidential and proprietary, and to protect against the loss, theft or unauthorized use of such Trade Secrets; (ii) its Trade Secrets are not in the public domain and have
not been divulged or appropriated to the detriment of SVI; (iii) SVI, and to SVI’s actual knowledge, its Third Party Licensors, have disclosed no confidential Surgi-Vision IP to any Third Party that was not, at the time of disclosure,
under an obligation to maintain such Surgi-Vision IP in confidence, and, to SVI’s actual knowledge, there have been no breaches of any such confidentiality obligations; and (iv) SVI’s records do and will continue to include sufficient
documentation of the Know-How and Trade Secrets, such as manufacturing and engineering plans, blueprints, designs, process instructions, formulae, quality assurance protocols and procedures and the like, to enable persons who are reasonably skilled
and proficient in the relevant subject matter to continue the same in the ordinary course of business without unreasonable delay, expense, or reliance on the memory of any individual. 

 

	 	I.	 Licenses. SVI represents and warrants that, as of the Effective Date, it has not, and to its actual knowledge its Third Party Licensors have
not: (i) granted any licenses or other rights, and have no obligation to grant any licenses or other rights, with respect to any Surgi-Vision IP in the Implantable Cardiac Field, except for (a) any rights retained by JHU under the JHU
Agreements; and (b) to the extent a Patent was supported by federal funding obtained by JHU, any rights, conditions and limitations imposed by U.S. law (including any royalty-free non-exclusive license granted to the U.S. government pursuant to
U.S. law and any requirement that products used or sold in the U.S. be manufactured substantially in the U.S.); or (ii) entered into any covenant not to compete or contract limiting or purporting to limit the ability of SVI to grant any
licenses and assignments in fulfillment of its obligations herein. SVI further represents, warrants and covenants that none of the Surgi-Vision IP or Royalty Patents was or will be supported by federal funding obtained by SVI, and that there are and
will be no rights, conditions and limitations imposed by U.S. law (including any royalty-free non-exclusive license granted to the U.S. government pursuant to U.S. law) with respect to same. 

 

	 	J.	 Validity. SVI represents and warrants as of the Effective Date that, to SVI’s actual knowledge: (i) there have been no sales,
public disclosures, or other events that create a bar to patentability of any Billabong Patents; (ii) none of the Billabong Patents has been abandoned, suppressed, or concealed; (iii) to SVI’s actual knowledge, as of the Effective
Date there are no impediments to patenting any of the Surgi-Vision IP (other than due to certain Surgi-Vision IP being non-patentable subject matter or as otherwise disclosed in the following clause (iv)); (iv) there is no

  

 25 

	 	
interference, opposition, cancellation, reexamination or other contest, proceeding, action, suit, hearing, investigation, charge, complaint, demand, notice, claim, dispute threatened or pending
against SVI or its Third Party Licensors relating to the Surgi-Vision IP, except that (a) SVI knows of a Third Party’s attempt to invoke an interference against U.S. 6,904,307, (b) SVI has filed a re-issue with respect to U.S.
6,904,307, and (c) SVI has filed a patent application (application number [***]) attempting to invoke an interference; (v) all material statements and representations made by SVI in any pending applications, filings or registrations
relating to the Surgi-Vision IP were true in all material respects as of the time they were made, and are still believed to be true; and (vi) no Surgi-Vision IP consisting of Patents is subject to any injunction, judgment, order, decree, ruling
or charge or is subject to any pending or threatened oppositions, interferences or other proceedings before the United States Patent and Trademark Office or in any other registration authority in any country, except that (a) SVI knows of a
Thirs Party’s attempt to invoke an interference against U.S. 6,904,307, (b) SVI has filed a re-issue with respect to U.S. 6,904,304, and (c) SVI has filed a patent application (application number [***]) attempting to invoke an
interference. 

  

	 	K.	 Disclosure. SVI represents and warrants that in the course of diligence and negotiations leading up to the execution of this Agreement, SVI
has not misrepresented to CPI any material information regarding the Surgi-Vision IP and the technology related thereto. 

  

	 	L.	 No Existing Infringement by CPI or CPI’s Affiliates. SVI represents and warrants that, as of the Effective Date, it has no actual
knowledge that any CPI or CPI Affiliate lead existing as of the Effective Date does or would Infringe (i) a valid and enforceable claim of an issued Royalty Patent or (ii) any allowed claims of a pending patent application for a Royalty
Patent, upon the issuance of same. 

     11. Enforcement. 

 

	 	A.	 Notice of Infringement. If either Party learns of any actual, alleged or threatened Infringement of any BSC Controlled Surgi-Vision IP by a
Third Party, such Party shall promptly notify the other Party and shall provide such other Party with all available evidence of such Infringement. 

  

	 	B.	 Enforcement [***]. As between the Parties, [***] shall have the sole right (but not the obligation), each at its own expense and with legal
counsel of its own choice, to bring suit (or take other appropriate legal action) against any actual, alleged or threatened Infringement of the [***]; provided, however, that [***] shall have the right (but, subject to Section 11(D)
below, not the obligation) to participate in an advisory capacity only in the 

 [***]
Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 

 26 

	 	
institution and prosecution of any such Infringement suit, [***]. 

  

	 	C.	 Enforcement Following a Loss of Exclusive Rights. Notwithstanding Section 11(B) above to the contrary, in the event [***], as
between the Parties, [***] shall have the sole right (but not the obligation), at its own expense and with legal counsel of its own choice, to bring suit (or take other appropriate legal action) against any actual, alleged or threatened Infringement
of [***]. 

  

	 	D.	 Join in Action. If a Party brings any such action or proceeding hereunder, the other Party agrees to be joined as party plaintiff if
necessary to prosecute such action or proceeding, and to give the Party bringing such action or proceeding reasonable assistance and authority to file and prosecute the suit; provided, however, that neither Party shall be required to transfer
any right, title or interest in or to any property to the other Party or any Third Party to confer standing on a Party hereunder. 

  

	 	E.	 Costs. [***] will pay all costs, fees, and expenses associated with an Infringement action initiated and prosecuted solely by [***].
[***] will pay all costs, fees, and expenses associated with (i) an Infringement action initiated and prosecuted solely by [***], and (ii) [***] participation in an advisory capacity under Section 11(B). 

 

	 	F.	 Recovery. Any recovery obtained in an action initiated and prosecuted solely by [***], and in which [***] does not participate in an advisory
capacity, shall belong to [***]. Any recovery obtained in an action initiated and prosecuted solely by [***] shall belong to [***]. Any recovery obtained in an action initiated and prosecuted by [***], and in which [***] participates in an advisory
capacity, shall be allocated in a fair and equitable manner mutually determined by the Parties. For purposes of clarity, any recovery pursuant to this section will be net of litigation costs as provided in Section 11(E) above.

  

	 	G.	 Cooperation. Each Party agrees to fully cooperate with the other in the prosecution of any such suit at no additional expense to that
cooperating Party. 

 [***] Indicates portions of this exhibit that have been omitted and
filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 
  

 27 

 12. Patent Prosecution. 

 

	 	A.	 Costs. CPI and its Affiliates will pay all Patent Prosecution costs and expenses for all Patents subject to their sole control, as set forth
in Section 12(B) below (“Prosecution Costs”). 

  

	 	B.	 Intellectual Property Protection. With respect to any BSC Controlled Surgi-Vision IP, CPI and its Affiliates will jointly control the
Prosecution of all Patents, each at its own expense and with legal counsel of its own choice, and will take such other legal steps as CPI and its Affiliates will determine in their sole discretion to be necessary to protect their rights for all BSC
Controlled Surgi-Vision IP. For the avoidance of doubt, neither CPI nor its Affiliates will be obligated to pay any Prosecution Costs to protect any Intellectual Property if they determine, in their sole discretion, that those Prosecution Costs
outweigh the likely benefits to CPI or such Affiliate. 

  

	 	C.	 SVI Cooperation. SVI will cooperate with CPI and its Affiliates in filing, Prosecuting and maintaining Patents and taking such other legal
steps as set forth in this Section 12 and will execute and deliver any documents and instruments in connection therewith which CPI or its Affiliates may request at no additional cost or expense to CPI or such Affiliate.

  

	 	D.	 SVI Inspection and Intervention. SVI will have the right upon reasonable notice and reasonable request to inspect, at SVI’s sole expense
and discretion, the Prosecution documents and strategy of CPI and its Affiliates with respect to the BSC Controlled Surgi-Vision IP. The Parties agree that such information constitutes Confidential Information of CPI and its Affiliates, and that the
disclosure of such information is not intended to constitute a waiver of any privilege, including attorney-client privilege. In addition, CPI (or its applicable Affiliate) will provide written notice to SVI prior to abandoning any patent application
or issued Patent that is part of the BSC Controlled Surgi-Vision IP. If SVI desires to file and Prosecute any such patent application, or to pay maintenance fees or annuities to maintain any such issued Patent, in any country that CPI or its
Affiliates determined was not worthwhile to protect CPI’s or such Affiliates’ rights, SVI may provide CPI with a reasonable written request to file and Prosecute or maintain such Patent (“Prosecution Request”). CPI will
have 30 days to fulfill the Prosecution Request. If CPI or one of its Affiliates fails to complete the Prosecution Request within 30 days of receiving the Prosecution Request, SVI may independently file and Prosecute the patent application or
maintain the issued Patent that was the subject of the Prosecution Request, and SVI will bear all Prosecution Costs and will control the remainder of the Prosecution for such patent application or the maintenance of such issued Patent.

  

 28 

 13. Indemnification. 

 

	 	A.	 General Indemnification. Each Party (the “Indemnifying Party”) will defend, indemnify and hold harmless the other Party (the
“Indemnified Party”) and all of such Party’s Affiliates from and against any and all liabilities, losses, obligations, claims, damages, penalties, causes of action, costs and expenses (including reasonable attorneys’ fees)
(collectively “Damages”), to the extent such Damages arise out of any Third Party claim based on allegations that, if true as alleged, would constitute (i) a breach of the representations and warranties made by it in this
Agreement, or (ii) a material breach of its obligations pursuant to this Agreement. 

  

	 	B.	 Indemnification Procedures. An Indemnifying Party’s duty to indemnify pursuant to Section 13(A) is subject to the
Indemnified Party giving prompt written notice to such Indemnifying Party of any claim against the Indemnified Party covered by the Indemnifying Party’s indemnification obligations hereunder; provided, however, that a delay in
such notice to the Indemnifying Party shall not terminate indemnification obligations hereunder, unless such delay shall have materially impaired the defense of such claim. The Indemnifying Party shall have sole and exclusive control of the defense
of any such claim, including the choice and direction of any legal counsel. The Indemnified Party may not settle or compromise any such claim without the written consent of the Indemnifying Party. 

14. Disclaimer of Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, NEITHER PARTY MAKES ANY
REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY, INCLUDING ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

15. Intentionally Omitted. 

16. Conflicts with Bionics Lead Development Agreement. The Parties agree that, in the event of any conflict
between the terms or conditions of this Agreement and the Bionics Lead Development Agreement, this Agreement will control. 

17. Miscellaneous. 
  

	 	A.	 Notices. Any notice or other communication in connection with this Agreement must be in writing, must be addressed as provided below and will
be deemed delivered when (a) actually delivered in person or by facsimile, provided that delivery is made during normal business hours, (b) three business days have elapsed after deposit in the United States mail, postage prepaid
and registered or certified, return receipt requested, or (c) two business days after sent by nationally recognized overnight receipted courier: 

  

 29 

 To CPI: 

Cardiac Pacemakers, Inc. c/o 

Boston Scientific Corporation 

One Boston Scientific Place 

Natick, MA 01760-1537 

Attention: Chief Financial Officer 

Phone: 508.650.8000 

Fax: 508.650.8956 

with copies to: 

Boston Scientific Corporation 

One Boston Scientific Place 

Natick, MA 01760-1537 

Attention: General Counsel 

Phone: 508.650.8000 

Fax: 508.650.8960 

and 

Cardiac Pacemakers, 

Inc. 4100 Hamline Avenue North 

St. Paul, MN 55112 

Attention: Chief Patent Counsel 

Phone: 651.582.7196 

Fax: 651.582.2926 

To SVI: 

Kimble L. Jenkins 

Surgi-Vision, Inc. 

50 North Front Street 

19th
 Floor 
 Memphis, TN 38103 

Phone: 901.531.3236 

Fax: 901.579.4979 

with copies to: 

John C. Thomas, Jr. 

Surgi-Vision, Inc. 

200 N. Cobb Parkway 

Suite 140 

Marietta, GA 30062-3585 

Phone: 770.514.0077 

Fax: 770.424.8236 
  

 30 

 and 

Oscar L. Thomas 

Bass, Berry & Sims PLC 

100 Peabody Place 

Suite 900 

Memphis, TN 38103 

Phone: 901.543.5905 

Fax: 901.543.5999 

and in any case at such other address as a Party may specify by written notice in accordance with this Section. All
periods of notice will be measured from the date of deemed delivery as provided in this Section. 
  

	 	B.	 Assignment. This Agreement shall be binding upon and inure to the benefit of the Parties, their successors and permitted assigns. Neither
this Agreement nor any right or obligation hereunder will be assignable by a Party without the prior written consent of the other Party and any purported assignment without such consent will be void; provided that, subject to CPI’s
exercise of its rights pursuant to Section 5(C)(iii) of the Development Agreement, either Party may, without such prior written consent, assign this Agreement to an Affiliate or in connection with a merger or consolidation (or other
similar transaction) or the sale of all or substantially all of its assets in the realm of its respective field under this Agreement; provided, further, that such Party must give the other Party thirty (30) days prior written
notice of such assignment. Any permitted assignee will assume all obligations of its assignor under this Agreement. No assignment will relieve any Party of responsibility for the performance of any accrued obligation that such Party then has
hereunder. 

  

	 	C.	 Affiliates. To the extent that CPI allows its Affiliates to exercise rights pursuant to this Agreement (including under a sublicense from
CPI), CPI agrees (i) to bind such Affiliates to the confidentiality, use restriction, records/audit, intellectual property enforcement and patent Prosecution provisions of this Agreement and (ii) to be responsible for any breaches by its
Affiliates of such provisions. Notwithstanding anything to the contrary, but subject to the previous sentence, if and when CPI allows its Affiliates to exercise rights pursuant to this Agreement (including under a sublicense from CPI), CPI may do so
under any form of permission or arrangement, whether written, oral or course of conduct, and if done pursuant to a written document irrespective of whether that particular written document contains within its four corners all of the restrictions and
requirements set forth in this Agreement. 

  

 31 

	 	D.	 Force Majeure. If the performance of this Agreement or any obligations under this Agreement, except the making of required payments, is
prevented, restricted, or interfered with by reason of fire, flood, earthquakes, explosion, or other casualty, accident, or act of God; strikes or labor disturbances; war, whether declared or not, or other violence; sabotage; any law, order,
proclamation, regulation, ordinance, demand, or requirement of any government agency; or any other event beyond the reasonable control of the Parties, the affected Party, upon giving prompt notice to the other Party, will be excused from such
performance to the extent of such prevention, restriction, or interference. The affected Party will use its reasonable efforts to avoid or remove such cause of non-performance or to limit the impact of the event on such Party’s performance and
will continue performance with the utmost dispatch whenever such causes are removed. 

  

	 	E.	 Export Controls. A recipient of technical data or products agrees to comply with all United States Department of Commerce and other United
States export controls. Each Party agrees that, unless prior authorization is obtained from the Office of Export Administration, it will not knowingly ship or transfer technical data covered by this Agreement or any direct product of such technical
data, directly or indirectly, to any country in contravention of any Office of Export Administration requirement. 

  

	 	F.	 Entire Agreement. This Agreement and its Exhibits, together with the Development Agreement, set forth the entire agreement between the
Parties and supersede all previous agreements and understandings, whether oral or written, between the Parties with respect to the subject matter of this Agreement. 

 

	 	G.	 Amendment. This Agreement may not be modified, amended or discharged except as expressly stated in this Agreement or by a written agreement
signed in ink by an authorized representative of each Party. 

  

	 	H.	 Separability. The provisions of this Agreement will be deemed separable. If any provision in this Agreement will be found or be held to be
invalid or unenforceable in any jurisdiction in which this Agreement is performed, then the meaning of that provision will be construed, to the extent feasible, to render the provision enforceable, and if no feasible interpretation would save such
provision, it will be severed from the remainder of this Agreement that will remain in full force and effect unless the provisions that are invalid or unenforceable substantially impair the value of the entire Agreement to either Party. In such
event, the Parties will use their respective reasonable efforts to negotiate a substitute, valid and enforceable provision that most nearly reflects the Parties’ intent in entering into this Agreement. 

 

 32 

	 	I.	 Waiver. No waiver of any term, provision or condition of this Agreement whether by conduct or otherwise in any one or more instances will be
deemed to be or construed as a further or continuing waiver of any such term, provision or condition or of any other term, provision or condition of this Agreement. 

 

	 	J.	 Relationship of Parties. Each of the Parties hereto is an independent contractor and nothing herein will be deemed to constitute the
relationship of partners, joint venturers, nor of principal and agent between the Parties hereto. 

  

	 	K.	 Counsel/Interpretation. The Parties and their respective counsel have negotiated this Agreement or have had an opportunity to review this
Agreement. The Parties hereto acknowledge and agree that: (a) the rule of construction to the effect that any ambiguities are resolved against the drafting Party will not be employed in the interpretation of this Agreement; and (b) the
terms and provisions of this Agreement will be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement. When used in this
Agreement, the words “including” or “includes” are deemed to be followed by the words “without limitation.” 

  

	 	L.	 Governing Law. The construction, validity and performance of this Agreement will be governed exclusively by the laws of the State of
Minnesota, U.S.A., without regard to the principles of conflicts of law. Each Party hereby submits itself for the sole purpose of this Agreement and any controversy arising hereunder to the non-exclusive jurisdiction of the federal and state courts
located in the State of Minnesota, and any courts of appeal therefrom, and waives any objection (on the grounds of lack of jurisdiction, venue or forum non conveniens or otherwise) to the exercise of such non-exclusive jurisdiction over it by any
such courts. With the exception of an arbitration pursuant to Section 4 above, any action brought by SVI against CPI in connection with this Agreement, must be instituted in the federal or state courts located in the State of Minnesota.
A Party shall be entitled to seek within such jurisdiction whatever equitable relief it may be entitled to under applicable law. 

  

	 	M.	 Headings. The article and section headings in this Agreement are inserted for convenience only and will not constitute a part hereof.

  

	 	N.	 No Third-Party Beneficiary Rights. Except with respect to CPI’s Affiliates and to Persons receiving indemnification under
Section 13, no person not a Party to this Agreement is an intended beneficiary of this Agreement, and no person not a Party to this Agreement will have any right to enforce any term of this Agreement. 

 

 33 

	 	O.	 Compliance with Laws. Each Party will comply in all material respects with all applicable U.S. and foreign statutes, laws, ordinances, rules,
orders and regulations in all actions relating to this Agreement and its performance hereunder. 

  

	 	P.	 Counterparts. This Agreement may be executed in any number of counterparts each of which will be deemed to be an original but all of which
together will constitute one and the same instrument, and all signatures need not appear on any one counterpart. 

  

	 	Q.	 Effect of Bankruptcy. No proceeding, or result or adjudication of a proceeding, in which either of the Parties is a debtor, defendant or
party seeking an order for its own relief or reorganization, under any foreign, United States or state bankruptcy or insolvency law will (in and of itself) cause a termination of this Agreement or any of the licenses granted under this Agreement.

  

	 	R.	 U.S. Dollars. All payments to SVI contemplated in this Agreement, including payments of the License Fee, all royalty payments and payments of
Sub-License Revenue, shall be made in U.S. Dollars. 

 IN WITNESS WHEREOF, the Parties hereto
have executed this Agreement as of the Effective Date. 
  

									
	 SURGI-VISION, INC.
	 		 	CARDIAC PACEMAKERS, INC.
					
	   BY
	 	 :  /s/  Kim Jenkins
	 		 	    BY
	 	 :  /s/  Fred A.
Colen

									
				
	   NAME:
	 	   Kim Jenkins
	 		 	   NAME: Fred A. Colen

				
	   TITLE:
	 	   PRES
	 		 	  TITLE: Executive Vice President,
		 		 		 	  Operations and Technology CRM

ACKNOWLEDGEMENT BY BIONICS 

Boston Scientific Neuromodulation Corporation (formerly known as Advanced Bionics Corporation) acknowledges that even though it is not a
party to this Agreement, it hereby agrees that Section 16 of this Agreement shall be binding upon it. 
  

			
	   BY:
	 	 /s/ Michael
Onuscheck

			
	   NAME:
	 	 Michael Onuscheck

	   TITLE:
	 	 President

  

 34 

 EXHIBIT A 

Billabong Patents 

[***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment. 
  

 35 

 EXHIBIT B 

NET SALES 

Cardiac Rhythm Management (“CRM”) lead revenue, for purposes of determining a royalty payment for a given period is calculated
by the product of: 
 The number of Royalty Product units sold in a given period, net of returns of Royalty
Products made in that period, and 
 The weighted average selling price of Royalty Products sold in that period.

 If a sale of a Royalty Product does not include an explicit sales price because the transaction included multiple products, a
sale price for the Royalty Product will be calculated consistent with the methods used for management reporting of average selling prices for CRM leads. 

In general, discounts exist when leads are bundled with other CRM components, such as pulse generators, and sold as a system, or when
multiple products are sold in bulk quantities. For management reporting, these discounts are applied on a pro rata basis to all of the components in the system or bulk sale. 

 

 36 

 EXHIBIT C 

BSC CORE PRODUCT INFORMATION 

BSC Core Product Information is related to the design, development, manufacture, and commercialization of implantable medical leads for
all cardiac applications. This includes but is not limited to: 
  

	 	1.	 Design and development documents, methods, and data 

	 	a.	 Device specifications 

	 	b.	 Assembly drawings, including tolerances 

	 	c.	 Material and component specifications, including tolerances 

	 	d.	 Material and component supplier capability requirements 

	 	e.	 Computational design evaluation methods and results, including FEA methods and results 

	 	f.	 Biomechanics parameters used in design evaluation 

	 	g.	 Biocompatibility requirements and data 

	 	h.	 Design verification and validation methods and results, including fatigue testing and biocompatibility testing 

	 	i.	 Pre-clinical and pre-market human clinical trial methods and results 

	 	j.	 MRI performance-related testing methods and results 

 

	 	2.	 Process development, manufacturing, and process control documents, methods, and data 

	 	a.	 Manufacturing instructions and production methods, including connection methodologies and parameters, materials preparation and assembly techniques

	 	b.	 Supplier selection process, CPI’s or its Affiliates’ supplier identity and status of supplier relationship 

	 	c.	 Supplier material and component qualification methods and results 

	 	d.	 Process validation methods and results 

	 	e.	 Process control methods and results including sampling plans, test and inspection methods and criteria 

 

	 	3.	 Regulatory submission documents, methods and data 

	 	a.	 Any non-public information relating to regulatory approval strategy, and communications with regulatory agencies 

 

 37 

 EXHIBIT D 

ROYALTY PATENTS 

[***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 
  

 38 

 EXHIBIT E 

SUB-LICENSE REVENUE EXAMPLES 

Transactions subject to Sub-License Revenue: 
  

	 	•	 	 A license or sublicense to a Third Party, granting such Third Party the right to make, have made, import, use or sell a Royalty Product

  

	 	o	e.g., If CPI or its Affiliate(s) sells leads to a Third Party and also grants that Third Party a license/sublicense to make and sell devices which constitute Royalty
Products, then CPI (for itself and/or on behalf of its Affiliate(s)) would make royalty payments for the sale of leads to that Third Party and will also make payments on the license/sublicense revenue CPI and/or its Affiliate(s) receives

 Transactions not subject to Sub-License Revenue: 

 

	 	•	 	 Grant of an implied license accompanying a sale of a Royalty Product (e.g., pursuant to first sale doctrine) 

 

	 	•	 	 Grant of an explicit license accompanying a sale of a Royalty Product to use the product 

6687551.6 

fb.us.2472577.53 
  

 39

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]